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ABSTRACT 
To date, no single, ideal strategy of vaccination has been identified that can 
provide complete protection against every form of viral, bacterial and parasitic 
disease encountered currently by man. This is because every pathogen requires 
activation of a unique immunological response to ensure effective clearance from 
the body. Thus, one of the main challenges of modem vaccine development is to 
devise strategies of vaccination that can be tailored to ensure the rapid and effective 
removal of a pathogen before it is able to initiate infection. In addition, the concept 
of therapeutic vaccines to treat established disease has recently been introduced for 
the treatment of chronic infections such as Hepatitis B virus (HBV). 
This thesis describes work undertaken to consider how strategies of 
vaccination can be manipulated to generate specific types and magnitude of immune 
response to prevent infection or treat established infection. In particular, the 
project considered the combined use of naked DNA vaccination with a second 
form of vaccination to maximise the specific immune response generated. 
The vaccination strategies employed were based on the initial delivery of 
DNA vaccine through intramuscular injection or ballistic delivery using a gene gun, 
followed by heterologous boosts, based on the same antigen delivered using an 
alternative route. These boost strategies included a) intramuscular delivery of 
purified recombinant HBcAg, b) mucosal delivery of HBcAg expressed by an 
attenuated strain of Salmonella typhimurium, and c) intranasal delivery of the protein 
accompanied by a mucosal adjuvant. 
Following each vaccination regime tested a number of specific immune 
responses, including serum and mucosal antibody production, CD4+ T helper 
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proliferation in spleens and lymph nodes, CD8+ T cell activation and killing were 
measured. These experiments revealed that the character of the immune responses 
primed in response to DNA vaccination differed according to route of 
immunisation, with intramuscular vaccination inducing a rapid CTL response. 
CD4+ T cells generated appeared to be of the Thl phenotype and showed the 
strongest localisation in the spleen. In contrast, following vaccination with the gene 
gun, CD4+ cells of a Th2 phenotype were generated with responses being found to 
be stronger in the local draining lymph nodes than the spleen. 
Combining DNA delivered using the intramuscular route with recombinant 
purified protein delivered by the same route was effective at boosting systemic 
antibody titres, as was boosting using attenuated Salmonella expressing the same 
antigen when delivered to the mucosal surface of the gut. In contrast, boosting of 
DNA primed animals with purified protein, even in the presence of an appropriate 
mucosal adjuvant, was not successful at increasing titres of systemic antibodies. 
Interestingly, specific mucosal immune responses were absent when either of the 
heterologous vaccination strategies used a mucosal boosting approach. The 
implications of the characterisation of the immune responses to the various 
prime/boost protocols employed are discussed and their potential use for the 
development of new prophylactic and therapeutic vaccine design considered. 
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1 INTRODUCTION 
1.1 Aims of vaccination 
The aim of vaccination is to provide a human or animal with immunity to a 
specific disease. Traditionally this has been achieved by exposing the immune 
system to non-pathogenic components (antigens) of a disease-causing organism, or 
to an avirulent form of the entire pathogen. This exploits the immune system's 
capacity to effect a more rapid and potent memory response to foreign antigens on 
subsequent re-exposure to the antigens during an actual infection. An effective 
vaccine should provide long lasting, protective immunity against the disease and 
where possible reduce the capacity of the organism to spread to other susceptible 
hosts. 
1.2 History of Vaccination 
1.2.1 Development of Vaccination 
The idea of deliberate exposure of an individual to a relatively harmless 
form of disease in order to protect against the full virulence of a natural infection is 
not new. The process of variolation, a term given to the practice of scoring the skin 
and deliberately exposing it to material from the pustules on the skin of a smallpox 
victim, was reported to have been used as far back as the 17th century (Bazin 2003). 
Variolation provoked a very mild form of the smallpox and protected the recipient 
when exposed to the fully virulent form of the disease. In 1796 Edward Jenner 
took the process a step further, by testing the commonly held idea that infection 
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with cowpox provided protection from smallpox. This was confirmed when he 
deliberately inoculated a young boy with material from the pustules on the skin of 
an infected cow. In order to confirm the protective effects of the treatment the boy 
was later exposed to an attenuated strain of smallpox. The boy did not display any 
disease symptoms, and the process of vaccination (from Vaccinia, the virus that 
causes cowpox) was born (Baxby 2002; Bazin 2003). Jenner's vaccination had the 
great advantage of providing lasting protection without risk of the vaccine recipient 
becoming the source of a smallpox outbreak. 
1.2.2 The Requirement for New Vaccines 
As a result of this early work, vaccine development against a variety of 
diseases has continued for more than 200 years. Over this period of time there has 
been a dramatic increase in the level of understanding of both pathogenesis and the 
nature of the immune system as well as improvements in public hygiene and 
successful treatment of disease by chemotherapy. Despite these advances, there 
remain many infections for which there are no effective vaccines. These include 
malaria, HIV, hepatitis C virus, anthrax, and many others. 
In many older vaccine formulations, protection is mediated largely by the 
induction of strong antibody (humoral) responses. Without denying the undoubted 
success of such vaccines, humoral responses alone are not always sufficient to offer 
protection. Observations in human patients and animal models of disease show 
that other processes including responses mediated by specific cells of the body are 
also required. Thus much current vaccine research focuses on the generation of 
broad and effective immune responses (Plotkin 2003). 
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In addition to diseases that have been present in human populations for a 
long period of time, there are also newly emerging infections such as HIV and 
SARS, which provide an ongoing challenge to vaccinologists. These pathogens are 
often highly virulent and reinforce the need for continued research to identify 
vaccine strategies that provide wider application. 
Immunity to a disease often involves the activation of a combination of 
different effector mechanisms. The protective mechanisms required may be largely 
dependent on the pathogen in question and the causes of its pathogenesis and its 
lifestyle. The way in which these mechanisms are activated and how they function 
to protect against disease are described below. 
1.3 Innate Immunity 
The immune system can be split into two separate but linked entities; the 
innate and the specific (or adaptive) immune systems. Innate immunity is based 
upon activation of responses following tissue damage or recognition of types of 
molecules particularly associated with pathogens. The defence mechanisms that 
make up innate immunity are able to act immediately, because unlike specific 
immunity they do not rely on the clonal expansion of cells. 
The innate defence mechanisms include mechanical systems, the action of 
cells such as phagocytes and the complement system. The innate immune system 
has no memory mechanism of its own, however, it can still have relevance in 
vaccine development. Although the innate and specific systems are in many ways 
separate and are induced by different mechanisms, each can enhance the other to 
provide maximum effectiveness (Medzhitov and Janeway Jr. 1998). For example, 
cytokines secreted by innate cells (e. g. macrophages) and specific cells (such as 
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lymphocytes) can increase the efficacy of both cell types (Biron 1998). Also, 
molecules found associated with the invading pathogen itself can have a significant 
impact on non-specific activation of the immune system. A number of these 
pathogen-associated molecular patterns, or PAMPs have been recently identified 
and play an important role in the activation of naive lymphocytes (see section 1.4.1, 
Antigen Processing and Lymphocyte Activation). 
Physically, the body is protected from infection by the epithelial barriers of 
the skin and mucosal surfaces of the intestines, lungs and urogenital tracts. 
Pathogens can initiate an infection only when these surfaces are colonised or 
crossed. In particular, the normal fauna of the skin and mucosal surfaces can 
provide a considerable defence by competing for space and nutrients with potential 
pathogens. Secretion of mucus is also important, coating micro-organisms and 
preventing them from adhering to the surface and when combined with the co- 
ordinated beating of cilia on the surface of epithelial cells in the lungs, allows 
expulsion of microbes from these surfaces. 
In addition to mechanical barriers at the epithelia, there are also chemical 
products and degradative proteins that can kill or inhibit the growth of bacteria. 
These include lysozyme, present in saliva and tears, which can cause the lysis of 
bacteria, acid pH in the stomach and digestive enzymes that destroy the majority of 
pathogens prior to their arrival in the gut. 
1.3.1 Non-specific Activation of Immune Cells 
A range of phagocytic cells that are able to recognise, ingest and kill many 
pathogens that do penetrate the epithelia include macrophages, which are found in 
many tissues of the body and are highly efficient phagocytes, and neutrophils that 
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are present in the blood. These can quickly penetrate tissues hosting an incipient 
infection and phagocytose the organisms present. 
A number of these cells have been shown to be activated by PAMPs, which 
stimulate Toll-like receptors (TLRs) found on the surface of some immune system 
cells. This leads to the activation of signalling pathways that result in the 
production of antimicrobial products and inflammatory cytokines by these cells. In 
addition, stimulation of TLRs triggers dendritic cell (DC) maturation and results in 
the induction of co-stimulatory molecules and increased antigen-presenting capacity 
(Krug et al. 2001). Thus, microbial recognition by TLRs helps to directly activate 
innate immune responses for immediate killing of pathogens and indirectly stimulate 
adaptive responses Qaneway and Medzhitov 2002). 
Stimulation of TLRs via PAMPs provides an early warning signal to the 
immune system that pathogens are present, thus allowing the rapid deployment of 
innate defence mechanisms based on a general molecular pattern, rather than 
specific antigen recognition Qaneway and Medzhitov 2002). 
To date, several PAMPS have been identified. Two of these; bacterial 
lipopolysaccharide (LPS) and unmethylated Cytidine-phosphate-guanisine 
dinucleotides (CpG motifs) in DNA (Brown and Corral 2002; Janeway and 
Medzhitov 2002; Royle et al. 2003), have direct relevance to this project. 
Gram negative bacteria such as E. coli and Salmonella carry endotoxin, or LPS 
as an integral part of their outer membrane. The structure of LPS, as shown in 
Figure 1-1, consists of highly conserved lipid A, which anchors the structure into 
the cell wall, the core polysaccharide and the hyper-variable 0-polysaccharide. This 
antigen is highly immunogenic and is readily recognised by antibodies. It is the 
variation in the recognition of this region by antibodies that results in the many 
different serotypes of Salmonella (Ewing 1972). It can also have a significant effect 
18 
on the biology of the organism; Salmonella can alter the nature of the LPS molecule 
it expresses under different conditions. This ability allows the bacteria to change its 
surface characteristics to suit the environment of gut epithelial cells or protect itself 
against the intracellular killing mechanisms within the phagosomes of macrophages 
(Ernst et ah 1999; Freudenberg et al. 2001). 
However, LPS can also interact with the innate immune system, directly 
through 'MR -4 found on the surface of DCs and macrophages (Royle et al. 2003). 
Stimulation through TLR-4 signalling by LPS causes upregulation of macrophage 
killing mechanisms, increased cytokine production and higher levels of co- 
stimulatory molecules on the surface of APCs. The presence of these molecules, 
along with the microbial antigens presented by macrophages and DCs, helps 
activate CD4+ Th cells leading to a co-ordinated adaptive immune response (Ernst 
et aL 2001; Royle et aL 2003). 
The CpG motifs found in bacterial DNA are another example of a PAMP. 
These unmethylated CpG motifs found in a particular nucleotide context in 
bacterial but not eukaryotic DNA activate the immune system via TLR-9. They are 
discussed in more detail in the section on DNA vaccination below (section 1.5.4.3). 
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Figure 1-1: Composition of bacterial LPS 
Lipid A, the mitogenic region of the LPS molecule, is made up of a variable number 
and chain lengths of fatty acid. These are linked to the core region of LPS by 
phosphorylated diglucosamine (G1uN) and 2-keto-3-deoxymanno-octonic acid 
(KDO). The O-side chain polysaccharide or O-antigen consists of repeating 
oligosaccharide units. These also vary between strains and species; the 086 antigen 
of E. coli is shown here. This variation can have a large impact on phenotype and 
pathogenicity, for example bacteria with complete 0 antigen form smooth colonies 
whereas bacteria which cannot synthesise the antigen form rough colonies. Figure 
adapted from `Immunological aspects of bacterial virulence' (Patrick and Larkin 
1995). 
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1.3.2 Chemokines and Inflammation 
Once activated via the TLRs, cells such as macrophages are stimulated to 
secrete several cytokines including inflammatory mediators. These include two sub- 
families of chemokines, a and (3, which can cause an influx of cells. The a- 
chemokines, such as interleukin-8 (IL-8), attract neutrophils, whereas the (3- 
chemokines attract macrophages (Herbert et aL 1995). These molecules help target 
neutrophils and macrophages to the site of infection by up-regulating expression of 
leukocyte adhesion molecules in the endothelial cells of nearby blood vessels. As 
well as monocytes and neutrophils, specific immune cells such as lymphocytes 
migrate to the site of inflammation. The inflammatory response can therefore 
speed the genesis of a specific immune response (Biron 1998). 
1.3.3 Complement 
Complement is another molecular component of the innate immune system. 
This system is made up of a large number of proteins present in the plasma that 
respond to the presence of microbes by the binding of certain proteins to the 
pathogen surface. Following activation, they can function in a number of ways, 
including opsonisation of pathogens which enhances the efficiency with which 
phagocytes such as macrophages are able to internalise them. Complement is 
regarded as part of the innate immune system, however, the ability to induce an 
inflammatory response is also an example of how the innate and specific immune 
systems can communicate. Complement can also act as an effector arm of specific 
immunity, as it can additionally be activated by the formation of antibody-antigen 
complexes (Barrington et a1.2001). 
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1.4 Antigen-Specific Immunity 
1.4.1 Antigen Processing and Lymphocyte Activation 
Specific or adaptive immunity is based on the precise recognition by 
lymphocytes of antigen-fragments containing specific epitopes. The antigens of a 
micro-organism are processed by cells and the resulting peptide fragments are 
presented on the cell surface in the context of Major Histocompatibility (MHC) 
molecules. These peptides are subject to surveillance by T lymphocytes. If the T 
cell receptor (TCR) specifically recognises the epitope contained in the fragments 
displayed on the surface of antigen presenting cells (APCs), along with an 
appropriate secondary signal, the T cells are activated. They then proliferate and 
differentiate into effector cells with a range of functions including the enhancement 
of antibody production by B cells, phagocytosis by macrophages and activation of 
cytotoxicity. 
1.4.1.1 Endogenous Antigen Processing and CD8` T cell activation 
Antigens expressed within most body cells can be processed through the 
endogenous pathway, illustrated in Figure 1-2. Although this pathway is utilised by 
both professional and non-professional APCs, it can be modulated in professional 
APCs (such as DCs) by an increased expression of co-stimulatory molecules. The 
antigens processed through this pathway are largely drawn from defective ribosomal 
products (Lehner and Cresswell 2004). The pathway is therefore open to any 
protein expressed in the cytosol, including self-antigen, virus antigen and DNA 
vaccine antigens. However, proteins from sources other than the cytosol are also 
able to enter the pathway, as discussed below in section 1.4.1.3, Cross Presentation. 
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Figure 1-2: The endogenous antigen presentation pathway 
Recently synthesised ribosomal products are degraded by proteasomes (1) and 
peptidases. The resulting peptidases are transported into the ER by TAP molecules 
(2). In the ER peptides are able to bind to MHC class I molecules. The MHC- 
peptide complex is then able to migrate to the cell surface (3). 
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The antigens are broken down by proteasomes into 8- 10 amino acid 
peptide fragments, which enter the endoplasmic reticulum (ER) via the transporter 
associated with antigen-processing (TAP) molecule. Associated with TAP are MHC 
class I molecules to which some of the peptides will be able to bind. On binding, 
the three-dimensional structure of MHC I is altered resulting in the release of the 
peptide-MHC complex from associated ER proteins. The complex then migrates to 
the cell surface via the Golgi apparatus where it is exposed to CD8 T cell 
surveillance (Heemels and Ploegh 1995; Williams et aL 1996; Lehner and Cresswell 
2004). 
The process of activation of CD8+ T cells is shown in Figure 1-3. Naive 
lymphocytes, whether CD4+ T cells, CD8+ T cells or B cells, require similar signals 
for activation. In T cells, the first signal comes from an antigen-specific interaction 
between the cell surface TCR and the MHC class I-peptide complex. This requires 
specific recognition of the peptide by the TCR. The specificity of the TCR is 
conferred by somatic recombination of the genes encoding the TCR proteins during 
development of the T cell in the thymus. The vast array of different possible 
recombinations that can occur by chance (approximately 1018 variations) mean that 
every T cell effectively has a unique specificity (Goldrath and Bevan 1999; Nemazee 
2000). This variation is key to the T cell population and provides the capacity to 
respond specifically to a huge range of different antigens (Correia-Neves et aL 2001). 
Such wide variety ensures that some cells will be generated bearing TCRs that are 
specific for self-antigens. Usually, cells that bind to self-antigens during 
development undergo apoptosis, preventing autoimmunity (Davis and Bjorkman 
1988; Oltz 2001). As well as direct TCR-peptide interactions between the T cell and 
the APC, the CD8+ molecule binds to invariant regions of MHC I in an antigen- 
independent fashion (Garboczi et aL 1996). 
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The TCR-peptide specific interaction along with CD8+-MHC binding is 
sufficient to trigger previously activated CD8+ T cells. However, naive lymphocytes 
require an additional, secondary, signal in order to initiate proliferation and 
differentiation into effector cells. This is provided by a second cognate interaction 
between a co-stimulatory molecule on the APC and its co-receptor on the naive T 
cell. The level of expression of APC co-stimulatory molecules varies depending on 
the activation status of these cells and whether the APC is a `professional' presenter. 
For example, a DC is a professional APC and is characterised by constitutive 
expression of co-stimulatory molecules such as the B7 family members CD80 and 
CD86 (which bind to CD28 on the T cell), or CD40 (which binds to CD40 ligand). 
Expression is increased even further on activation of the cell. However, many other 
cells expressing MHC class I need to upregulate the surface expression of these 
molecules whilst processing exogenous antigens. Expression of co-stimulatory 
molecules is tightly regulated by signalling events associated with the recognition of 
molecules associated with tissue damage or with certain pathogens (PAMPs) by 
receptors including the TLRs (Harding et al. 1992; Gonzalo et al. 2001; Shedlock and 
Shen 2003). 
The co-stimulatory requirement for activation of naive CD8+ T cells are 
higher than that required for naive CD4' cells. This ensures that the potentially 
devastating cytotoxic response is not induced inappropriately. To activate a naive 
CD8+ cell requires either antigen presentation by a DC, which naturally express high 
level of co-stimulatory molecules, or the action of Ih cells with the same antigen- 
specificity, that can upregulate co-stimulatory molecule expression in other types of 
APC. 
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Figure 1-3: CD8+ T cell antigen recognition and activation 
Peptides in the context of MHC I are specifically recognised by the TCR and CD8+ 
binds to MHC I. This is sufficient for activation of effector CD8+ T cells. An 
additional signal is required for activation of naive cells, to initiate proliferation and 
differentiation. This comes from co-stimulatory molecules expressed by the APCs 
such as B7, which binds to CD28 on the T cell, providing the secondary signal. 
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The requirement for a secondary signal provides an additional level of 
regulation in the development of a primary immune response, and helps to ensure 
that responses only develop against pathogens or antigens associated with tissue 
pathology, what is referred to as a `danger' signal. A successful vaccine therefore 
needs to include the specific antigens for lymphocytes to recognise, and must also 
provide the secondary signal necessary for activation, differentiation and 
proliferation of the lymphocytes. 
1.4.1.2 Exogenous Antigen Processing and CD 4' T Cell Activation 
Although APCs can process antigen through the endogenous pathway and 
present peptides in the context of MHC class I, as described above, internalised or 
exogenous proteins are present in a separate cellular compartment and are 
processed and presented by a distinct pathway (with some exceptions; see Cross 
Presentation below). They are bound to MHC class II molecules, unique to 
professional APCs, and are presented to CD4+ T helper cells. 
Following internalisation, exogenous antigen is processed in vesicles that 
become increasingly acidic with time. As the pH lowers, proteases within the 
endosome are activated, breaking down proteins into peptides (Brodsky and 
Guagliardi 1991; Watts 2004). 
MHC class II molecules are present in the ER, but are prevented from 
binding protein from the cytosol that has been taken up by TAP (as MHC class I 
molecules do), by an associated molecule; the invariant chain. This molecule 
physically blocks the peptide-binding site of MHC class II and targets it to migrate 
to endosomes. When the invariant chain-MHC class II complex reaches a late-stage 
endosome, limited proteolysis of the invariant chain occurs, leaving a smaller 
peptide called CLIP. This molecule is then exchanged for antigenic peptides. The 
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MHC class II-peptide complex then migrates to the cell surface where the antigen is 
presented to CD4+ T cell surveillance (Brodsky and Guagliardi 1991; Pieters 1997). 
This process is illustrated in Figures 1-4 (Processing of exogenous antigen) and 1-5 
(MHC class II presentation). 
Activation of CD4+ cells is a similar process to the activation of CD8+ cells 
described above. The TCR specifically recognises the peptide in the context of the 
MHC class II molecule and CD4+ binds to invariant regions of MHC class II. Co- 
stimulatory signals are also required to activate naive CD4+ cells; these are the same 
as the secondary signals involved in CD8+ activation. 
It has been suggested that antigen is initially presented to naive CD4+ T cells 
exclusively by DCs within the T cell areas of secondary lymphoid tissues (lymph 
nodes, spleen and the Peyer's Patches in the intestinal wall) (Jenkins et al. 2001; 
Bajenoff and Guerder 2003). Other potential APCs such as macrophages and B 
cells are not found in the T cell areas of this tissue, and free antigen does not easily 
enter the IN. However, B cells are able to interact with T cells at the interface of 
the B and T cell compartments of the lymphoid tissues following encounter with 
specifically recognised antigen, and may be important in presenting blood-borne 
antigen to CD4+ T cells (Baumgarth 2000; Mills and Cambier 2003). DCs are 
thought to acquire antigen by pinocytosis at the site where it entered the body or 
was expressed, rather than in the lymphoid tissue itself. Danger signals such as 
PAMP recognition and inflammation enhance CD4+ T cell activation by stimulating 
DCs to migrate to T cell areas and upregulate their expression of MHC and co- 
stimulatory molecules. 
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Figure 1-4: Processing of exogenous antigen 
MHC II - antigen 
complex 
Although MHC class II molecules are present in the ER, they cannot bind to 
peptides in the ER due to the presence of the invariant chain (1). Extracellular 
material (exogenous antigen) is internalised and degraded by proteases and the 
progressively acidic conditions in endosomes (2). MHC class II molecules migrate 
to endosomes, where the invariant chain is partially cleaved by proteases. This 
allows binding of the degraded exogenous antigen. The MHC II - peptide complex 
is transported to the cell surface (3). 
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Figure 1-5: CD4+ T cell antigen recognition and activation 
This process is similar in many ways to the presentation of antigen and activation of 
CD8+ T cells, the main differences being the peptide is presented by MHC class II 
molecules and the TCR is associated with CD4+ on the T cell. 
30 
1.4.1.3 Cross Presentation - Crossover Between the Endogenous and 
Exogenous Pathways 
It is worth noting that there are exceptions to the two main processing 
pathways outlined above: endogenous antigen can be presented in the context of 
the MHC class II molecule and exogenous antigen in that of MHC class I. 
Although molecules found in the cytosol are rarely processed and presented 
in complex with MHC class II in professional APCs, other cellular proteins can be 
processed in this way. Fragments of proteins associated with cell membrane, ER 
and Golgi apparatus proteins can be presented in this manner (Robinson and Delvig 
2002). Thus endogenous antigen can still trigger CD4+ T helper responses. 
Conversely, exogenous antigen can be presented by MHC class I molecules, 
by at least one of several mechanisms. In macrophages and DCs fusion of ER and 
phagosome membranes has been shown to occur. This could allow interaction 
between antigen internalised by phagocytosis and MHC class I molecules 
(Ackerman and Cresswell 2004); (Kumaraguru et ah 2000; Maecker et ah 2001). 
Another mechanism that has been described is peptide exchange. In this model 
MHC class I- endogenous peptide complexes are already present on the surface of 
a phagocytic cell, as in normal endogenous antigen presentation. As exogenous 
material is phagocytosed, MHC class I- peptide complexes on the cell surface may 
be simultaneously internalised. The conditions in the lysosome degrade the 
exogenous antigen to peptides able to bind to MHC class I molecule, which can 
then be exchanged for the already bound endogenous peptides. This second 
mechanism is considered as being less likely to occur in vivo, since the proteolytic 
environment of the endocytic pathway is unlikely to reproducibly generate the same 
peptides as produced by the proteasomes that normally produce MHC class I 
epitopes (Lehner and Cresswell 2004). 
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While the mechanism(s) behind cross-priming are not fully understood, it is 
a phenomenon that has been observed repeatedly. One example particularly 
relevant to this project is the processing of particulate exogenous antigen by DCs 
and subsequent efficient presentation to CD8+ T cells (Stober et at 2002). It is 
therefore possible for exogenous antigen to stimulate activation of CTLs. 
1.4.1.4 B Lymphocyte Antigen Recognition and Activation 
B cell specificity is defined by a process of somatic recombination (similar to 
that of T cells) within the genes of immunoglobulin, which code for the B cell 
receptor (BCR). This occurs during development of the lymphocyte in the bone 
marrow, and is limited only to exclude specificities for self-antigens. Previously 
activated memory B cells can be triggered by antigen specific recognition alone 
(Hebeis et al. 2004), in the same way as memory T lymphocytes. 
However, recognition of antigen alone is usually insufficient for activation 
of naive B cells. As with T cells, a secondary signal is required, often in the form of 
antigen-specific interactions between an activated Th cell and the naive B cell which 
is presenting the antigen. This standard model of B lymphocyte activation was first 
proposed over 30 years ago (Bretscher and Cohn 1970). According to the current 
version of this model, B cells internalise and process antigen through the BCR, 
providing the first activation signal necessary. However, as with T lymphocytes, 
signal one is not sufficient to initiate clonal expansion and differentiation of naive B 
cells. 
Segregation of B and lb cells in secondary lymph nodes is maintained by 
chemokine gradients to which the naive lymphocytes respond differentially. Within 
hours of encountering antigen, B cells increase chemokine receptor CCR7 
expression, enhancing responsiveness to T cell chemokines. Likewise, activated T 
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cells express receptors for follicular zone chemokines. Thus B cells that have 
encountered antigen and activated T cells are able to migrate to the boundaries of 
cortical T and follicular B cell zones (Mills and Cambier 2003). When these cells 
come into contact, then antigen specific TCR/MHC-peptide interaction can induce 
the expression of secondary signal molecules in the B cell. These include CD40 
ligand and IL-4, -5 and -6, initiating proliferation of the B cell and differentiation 
into an antibody secreting plasma cell (Baumgarth 2000; Mills and Cambier 2003). 
However, T cell-independent B cell activation mechanisms also exist. These 
require T cell-independent antigens, or antigens plus secondary signals from a 
source other than Th cells, and can induce a full B cell response. These alternative 
means of activation potentially provide a more rapid humoral response, since they 
can be initiated without the prior clonal amplification of Th cells, a process that 
takes several days (Baumgarth 2000). Some multivalent, polymeric antigens, such as 
the hepatitis B core antigen (see below), are able to simultaneously bind 
simultaneously to several BCR molecules. This extensive cross-linking of the 
receptor molecules can be sufficient to initiate activation of the B cell without T cell 
help (Milich and McLachlan 1986). B cell mitogens, for example LPS, can also 
activate B cells regardless of their antigen specificity. 
1.4.2 T Cell Effector Functions 
All T cell functions are dependent on interaction between an activated T cell 
and a target antigen-specific presenting cell. The functions performed by T cells 
depend upon the array of effector molecules that they secrete in response to being 
triggered. These include tightly regulated cytotoxins, such as those released by 
CTLs to kill virally infected cells, and cytokines that can act locally or at a distance 
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by binding to cell receptors. This results in a change in the behaviour or properties 
of the target cell. 
1.4.2.1 C'''S' T Cell Eiiector Responses 
While humoral responses, supported by CD4+ T cell help, provide 
protection in the extracellular spaces in the body, activated CD8+ T cells, or CTLs, 
combat intracellular pathogens by effector cytokine secretion and killing of cells 
presenting foreign antigens. 
An activated CTL that encounters a recognised peptide-MHC class I 
molecule will be triggered to kill the presenting cell. The principal way in which this 
occurs is through the calcium dependent release of specialised lysosomes following 
recognition. These contain perform, a molecule that enters the membrane of the 
target cell and polymerises to form a transmembrane pore. The presence of this 
pore disrupts the integrity of the membrane and allows free flow of water and salts 
in and out of the cell. In addition, proteases known as granzymes are released from 
the same lysosomes as perform. On formation of the transmembrane pore, the 
granzymes are able to enter the target cell. Granzymes activate caspase enzymes, 
triggering a chain of events that ends with degradation of DNA and the induction 
of apoptosis (Barry and Bleackley 2002). CTLs also express Fas ligand. When the 
T cell and target cell bound together in an antigen-specific reaction, Fas ligand can 
bind to Fas receptors (`death receptors) in the target cell membrane. Ligation of 
Fas also activates caspase molecules. Fas activated apoptosis is believed to be an 
important mechanism in regulating peripheral immune responses; once antigen is no 
longer present, the majority of antigen-specific lymphocytes are killed via this 
mechanism (Seid et aL 2002; Dockrell 2003). 
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Apoptosis is an induced form of cell death, regulated by carefully controlled 
cellular pathways. Unlike necrosis, it results in the release of fragments of cellular 
material in vesicles or `blebs', which are taken up by phagocytic cells. Chromosomal 
and cytosolic DNA are degraded into small fragments, and proteases are activated. 
These mechanisms ensure the destruction of intracellular pathogens and uptake of 
dying cell by macrophages but importantly does not encourage an inflammatory 
response. In contrast, necrotic cell death allows the escape of intracellular 
pathogens and the release of molecules that induce an inflammatory response. The 
two forms of cell death therefore have very different immunological outcomes, and 
apoptosis results in significantly less immunopathology than necrosis. 
As well as directly killing cells, activated CI Ls secrete cytokines such as 
tumour necrosis factors (TNF) -a and -ß and IFN-y. These molecules act non- 
specifically and do not cause cell death. Instead they contribute to host defence in 
various different ways. TNFs and IFNs upregulate Natural Killer cell activity and 
IFN-y directly inhibits viral replication and increases expression of proteins 
involved in the expression of antigen, such as MHC class I, in infected cells. IFN-'y 
also activates macrophages in conjunction with another signal such as the presence 
of LPS. It reduces intracellular tryptophan concentrations, which can inhibit the 
growth of intracellular pathogens by effectively starving them, and increases the 
efficacy of Fas-and perforin-mediated cytotoxicity by CTLs (Roth and Pitcher 
2004). TNF-cc and TNF-ß also activate macrophages, acting synergistically with 
IFN-y, and can induce killing in some target cells through TNF receptor I. 
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1.4.2.2 CD4` T Cell Responses 
CD4+ Ih cells aid in the activation, enhance the activity and encourage 
proliferation of other immune cells. They can activate macrophages to kill 
intracellular bacteria, induce proliferation and class switching in B cells and help 
activate naive CD8+ T cells (see above). Like CD8 T cells, their effects are 
mediated by direct cellular interactions and cytokine secretion following antigen 
specific recognition. 
Physical detection of antigen-specific CD4+ T cells has revealed features of 
the in vivo immune response that were not appreciated from previous in vitro studies. 
In vivo, antigen is initially presented to naive CD4+ T cells mainly by DCs within the 
T cell areas of secondary lymphoid tissues. Anatomical constraints make it likely 
that these DCs acquire the antigen at the site where it enters the body. 
Inflammation enhances T cell activation by stimulating DCs to migrate to the T cell 
areas and upregulate MHC and co-stimulatory molecule expression. Inflammatory 
signals induce chemokine receptors on activated T cells that direct their migration 
toward B cell follicles to interact with antigen-specific B cells (Jenkins et aL 2001). 
T helper cells have been shown to be important in the development of a 
strong memory response. Proliferation of memory CD8+ T lymphocytes and the 
level of cytokine production they display are dependent on the presence of CD4+ T 
cells during an initial recognition of antigen (Shedlock and Shen 2003; Sun and 
Bevan 2003). 
The cytokine environment generated at the time of priming is also 
important in the differentiation of the T cell. This can come from previously 
activated helper cells or from the APC itself and directs the T helper bias of the 
ensuing clonal population. CD4+ Th cells fall into two main categories; Ill cells 
and 112 cells, depending on the pattern of cytokines they generate following 
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activation. Broadly speaking, Thl cells promote inflammatory responses and 
activate macrophages by the production of IL-2, IFN-y, IL-6 and IL-12, and Th2 
cells support the expansion of activated B cells through the generation of IL-4, IL-5 
and IL-10 (Mosmann and Sad 1996). 
Successful protection against some diseases, such as tuberculosis, can be 
significantly affected by the expansion of particular subsets of Th cells (Tanghe, 
D'Souza et al 2001). 
Th1 CD4+ Responses 
Thl cells co-ordinate the immune response against intracellular 
microorganisms. Central to this is the antigen-specific activation of macrophages. 
Some bacteria such as Salmonella and mycobacteria are able to survive and grow in 
the phagolysosomes of macrophages after phagocytosis. In this environment they 
are protected from CTLs and antibodies. They survive by specifically inhibiting the 
normal killing process of acidification of the phagosome, proteolysis and fusion 
with lysosomes used by macrophages. However, activation of macrophage by a 
Thl cell following antigen recognition can eliminate such intracellular pathogens by 
enhancing the killing mechanisms within the cell. Two signals are required for 
macrophage Activation: IFN-y and one of several other potential signals, such as 
CD40L, TNF-a or TNF-ß binding. These signals can be simultaneously be 
provided by an activated CD4+ Th1 cell secreting appropriate inflammatory 
cytokines. 
The Thl cytokine IFN-y also induces B cells to switch the class of 
immunoglobulin subtype they produce, usually in mice from IgM to IgG2a. This 
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subtype of antibodies has been correlated with strong opsonisation activity (see 
section 1.4.3 Humoral Immune Responses). 
Th2 CD4+ Responses 
Th2 cells on the other hand activate naive B cells to proliferate and produce 
IgM. The cytokines they secrete also drive class-switching to production and 
secretion of other types of antibody, including IgG1, IgA and IRE. These 
antibodies are more important in the control of extracellular pathogens, and are 
efficient at neutralisation and opsonisation of pathogens. Also IgA in its secretory 
form has the capacity to translocate the mucosal epithelium, neutralising microbes 
at the mucosal surfaces. Details of the effector functions of antibodies are given 
below (section 1.4.3) 
Factors Affecting the Development of a Th1 or Th2 Outcome 
The differentiation of a naive CD4+ T into a Th1 or Th2 type of cell appears 
to be heavily dependent upon the microenvironment surrounding the cell when it is 
activated. There are several factors that appear to influence this environment, 
including the local production of cytokines. These can have a major influence on 
Th1/Th2 outcome and their presence is largely dependent on the type of cells that 
are present and activated. Macrophages and NK cells secrete pro-Thi cytokines 
such as TNF-CL and IL-12. Mast cells and B cells secrete the pro-Th2 cytokines IL- 
4 and IL-10. As well as the cytokines present, the concentration of activating 
antigen can affect the outcome, with higher concentration of antigen resulting in a 
tendency toward Thi cell development. In addition, in mice there appears to be a 
balance between these types of responses. IFN-y inhibits Th2 cell growth and IL- 
10 inhibits Thl cell growth. This action can lead to strong polarisation of response. 
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1.4.3 Humoral Immune Responses 
B cells develop in the bone marrow and in their naive state traffic through 
the B cell follicles of secondary lymphoid tissues. On activation, they proliferate in 
germinal centres, begin to secrete antibody and undergo somatic hypermutation (to 
generate increased diversity of antibody specificity). During this stage of 
differentiation, the B cell population undergoes affinity maturation; cells compete to 
bind antigen and those with poor affinity are selected out. Class switching of 
antibody production can be influenced by cytoltines secreted by T helper cells, for 
example, in order to produce antibody with different effector functions. 
Antibodies protect extracellular spaces within the body and mucosal 
surfaces at the interface between the body and the external environment. They 
function by binding to molecules or microbes in an antigen-specific manner. They 
are structurally similar to the BCR and their specificity is determined by the same 
somatically recombined genes, therefore the antibody produced by a plasma cell will 
bind to the same antigen that was initially bound by the BCR. Figure 1-6 shows a 
schematic diagram of an antibody showing the variable antigen-binding and the 
constant regions. 
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Figure 1-6: Schematic IgG antibody molecule 
This diagram shows the functional and structural domains of immunoglobulin G. 
The molecule is made up of light (, ) and heavy (}) chains with variable (V) and 
constant (C) domains. The molecule is bivalent, with a pair of light and heavy 
variable domains making up each antigen binding site. The entire antibody can be 
divided into two fragments: an antigen-binding fragment (Fab) and a crystallisable 
fragment (Fc) the latter of which can bind to Fc receptors on the surface of B cells 
and other APCs. 
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1.4.3.1 Antibody Classes and Subtypes 
Different classes of antibody are produced by different plasma cells and 
each has the capacity to induce the mechanisms outlined above to a different degree 
(Corbeil 2002). 
The different classes of antibody are determined by the gene from which the 
heavy chain is transcribed. The different classes of antibody include 
Immunoglobulin (Ig) M and IgD (expressed by naive B cells), IgG (the main class 
found in serum during infection) and IgA (a form of which can cross mucosal 
surfaces). The class produced by aB cell depends on the cytokines present in the 
microenvironment, often due to T cell help. For example, a Th cell might secrete 
IFN-y during activation of aB cell, which can induce the production of IgG2a. 
Alternatively, the main cytokine secreted might be IL-4, which would cause IgGl 
production (Stavnezer 1996; Nambu et al. 2003). Table 1-1 shows the influence of 
different cytokines on immunoglobulin class and subtype expression. 
1.4.3.2 Antibody Functions 
Antibodies have several main protective functions. First is the neutralisation 
of pathogens and their toxins. Antibodies can physically block the active sites of 
toxin molecules, for example, inhibiting their enzymatic function or attach 
themselves to ligands on the bacterial surface, prevent them from binding to 
receptors on host cells. Any functionally important molecule that is exposed to 
antibody binding can thus be a target of neutralisation. 
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IgM IgGi IgG2a IgG2b IgA 
IL-4 Inhibits Induces Inhibits -- 
IL-5 ---- Augments 
IFN-y Inhibits Inhibits Induces -- 
TGF-ß Inhibits -- Induces Induces 
Table 1-1: Role of cytokines in regulating immunoglobulin expression 
Adapted from Qaneway et al. 2001), (Tokuyama and Tokuyama 1999) and 
(Michaelsen et al. 2004). 
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The second function is opsonisation; the promotion of phagocytosis. 
Certain immune effector cells such as macrophages are able to bind to antibodies 
via the Fc region (see Figure 1-6) once the antibody is bound to its target, facilitating 
phagocytosis. 
Antibodies can trigger the complement cascade, which is itself able to 
enhance opsonisation and induce lysis of some bacteria (see section 1.3, Innate 
Immunity; (Ehrenstein et ah 1998). 
Antibodies can also bind to viral proteins expressed on the surface of 
infected self-cells and allow the binding of NK cells that can kill the infected cell. 
This process is known as antibody-dependent cell-mediated cytotoxicity (Moretta et 
aL 2003). 
The constant region of the immunoglobulin molecule determines its 
antibody class and influences the functional activity of the molecule. The Fc region 
of different immunoglobulin classes are recognised by Fc receptors on the surfaces 
of different immune effector cells, allowing each antibody class to interact with 
distinct subsets of immune cells. For example IgGl Fc is recognised by 
macrophage and neutrophil receptors, enhancing the phagocytosis of pathogens 
coated with this immunoglobulin subtype (Barrington et aL 2001). 
The Fc portion of an antibody-antigen complex can bind to the Clq 
molecule of complement, enhancing the uptake of immune complexes by 
phagocytes and activating the complement cascade (Brekke et at 1995). 
IgM can strongly activate complement, thus providing an alternative 
protective mechanism early in infection, when high levels of IgNI are present but 
specific cellular responses have not reached their maximum. IgM is also believed to 
have a role in the development of a strong IgG response (Ehrenstein et al. 1998). 
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The Fc region enables the active transport of antibody to areas where it 
would not otherwise be present, for example the mucosal surfaces. This is 
accomplished by binding of the Fc to receptors allowing the translocation of the 
molecule through epithelial barriers. This is an important protective measure, 
bringing the protective mechanisms of antibodies to these areas. Most types of 
antibody cannot cross the epithelia, but secretory IgA (sIgA) is able to do so, as is 
IgM to a lesser extent. SIgA is produced by plasma cells residing in the lamina 
propria, adjacent to the basal membrane of the epithelial surfaces. The sIgA 
molecule is a dimer consisting of two individual IgA molecules joined by aJ chain. 
Poly-immunoglobulin receptors on the basal surface of epithelial cells bind sIgA. 
Binding is followed by internalisation, active transport across the cell and release 
into e. g. the bronchial or intestinal lumen (Rojas and Apodaca 2002). This form of 
IgA is able to neutralise pathogens and toxins at the epithelial surfaces. Thus sIgA 
provides antigen-specific defence at the mucosal surfaces in addition to innate 
mechanisms. 
In contrast, IgG acts to protect the extracellular spaces of the internal 
tissues. It has a relatively long half-life and like IgA can neutralise pathogens and 
toxins. In addition it can activate complement and opsonise pathogens. t It is the 
main class of immunoglobulin found in the serum during infection. IgG2a is 
effective at opsonising material for phagocytosis and activating complement (Clark 
1997; Michaelsen et al. 2004). The main functions of 1gM are efficient neutralisation 
(due to its pentameric structure) and activation of complement. 
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1.4.4 Lymphocyte Migration 
Lymphocyte action and immune responses as a whole can be restricted to 
certain body compartments. This provides an immune response where necessary, 
enabling the efficient clearance of pathogens whilst limiting the potential for 
widespread immunopathogenesis. The tropism of lymphocytes is regulated by the 
expression of surface adhesion molecules, such as integrins. Naive lymphocytes 
display a lymph node-specific tropism, causing them to reside in areas where they 
are likely to encounter APCs. Expression of different adhesion molecules might, 
for example, direct activated cells to migrate to a site of inflammation (Sallusto et al. 
1999). A consequence of this is that different routes of vaccination may or may not 
synergise to provide stronger overall response, depending on which immunological 
compartment the individual responses occur in, and the flow of antigen, APCs and 
lymphocytes between the compartments. 
1.4.5 Generation of Memory T and B Lymphocytes 
Immunologic memory gives the immune system the ability to respond more 
rapidly and effectively to pathogens that have been previously encountered. 
Activated lymphocytes develop either into the effector cells that provide the 
functions described above, or into memory cells. Whilst effector cells are 
responsible for conferring immediate defence against pathogens, memory cells are 
important for providing immunity against re-infection, or in the case of a response 
stimulated by vaccination, long-term defence against a natural infection. 
When an infection has been cleared, or vaccine antigen is removed by the 
immune system, the ongoing signals that stimulate an effector response are 
removed. In the absence of these signals, the majority of effector cells die through 
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apoptosis (Masopust et al. 2001). Memory T and B cells are a distinct subset of the 
clonally expanded lymphocyte population that has undergone affinity selection for 
the antigens presented during immunisation. Unlike effector cells, they can persist 
without residual antigen. The generation of such a population is believed to be 
proportionate to the number of effector cells activated, thus measurement of strong 
immune responses based on the initial effector population is predictive of the 
development of strong secondary responses on subsequent challenge. Th cells are 
important in the development of the memory response. Proliferation of memory 
lymphocytes is dependent on the presence of CD4+ T cells during an initial 
vaccination (Sun and Bevan 2003). 
A secondary or subsequent humoral response to a pathogen is characterised 
by a much higher level of IgG production. IgM is still present in the secondary 
response, at similar levels to those measured during the primary response. IgA and 
IgE are also present to a greater degree during memory responses. Individual 
antibody molecules exhibit a higher affinity for antigen, due to somatic 
hypermutation in the V regions of immunoglobulin genes and antigen-binding 
dependent selection in the lymph nodes. The affinity continues to increase during 
secondary and subsequent immune responses, therefore it can be advantageous to 
deliver multiple doses of a vaccine over a period of time. The increased affinity of 
surface antibody as well as greater expression of MHC class II molecules facilitate 
antigen uptake and presentation, giving a greater sensitivity to low antigen 
concentrations. Memory B cells persist in the germinal centres of the secondary 
lymphoid organs (Ochsenbein et al. 2000). 
Memory T cells, on the other hand, can traffic to various tissues depending 
on which surface adhesion molecules are expressed, by which they can be 
distinguished from effector T cells. Like memory B cells, such T cells are long lived 
46 
and can be observed at elevated numbers following the resolution of an infection. 
There are two subsets of memory T cells: effector memory T cells and central 
memory T cells. The effector cells circulate in the periphery and can be activated 
much more rapidly than central memory cells, which persist in the lymphoid tissues 
and may possess greater longevity. The two populations of memory cells are 
thought to provide two different functions in the event of re-exposure to antigen. 
The peripheral cells are able to provide a rapid effector response whilst the central 
cells promote secondary proliferative responses (Masopust et al. 2001; Sallusto et ah 
2004). 
1.5 Types of Vaccine 
The goal of a vaccine is to stimulate the immune cells described above to 
confer protection against a particular pathogen and to maintain this protection over 
a long period of time. Outlined below are some conventional types of vaccines 
including those examined in this thesis. 
1.5.1 Killed Whole-Cell Vaccines 
Killed whole cell vaccines are composed of entire pathogen preparations, 
whose viability has been destroyed by chemical and/or heat treatment. These types 
of vaccine are considered safer than live, attenuated vaccines as there is no danger 
of reversion to a virulent phenotype. However, they are generally less immunogenic 
and often require multiple doses to be effective. Examples of chemically inactivated 
vaccines are those protecting against rabies virus, Bordetella pertusrir (the causative 
agent of whooping cough, although an acellular vaccine has recently been 
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introduced in the UK), and the Salk polio vaccine. 'T'his vaccine, in which wild-type 
virus is inactivated by treatment with formalin, is more expensive to produce than 
the attenuated vaccine, and is less immunogenic, but its improved safety may render 
it a more appropriate choice in regions were there are few natural cases of polio 
(Imam 1981). Despite the high efficacy of killed vaccines, side effects are not 
uncommon, and such vaccines are used in humans only when safer alternatives are 
not available. In animals, however, safety concerns are often less stringent, and 
whole-cell killed vaccines are in common use (Cobo et aL 2002; Armijos et aL 2004). 
1.5.2 Subunit Vaccines 
Acellular or subunit vaccines consist of the purified components of 
pathogens. They are believed to be safer than either killed whole-organism or live, 
attenuated vaccines, since a vaccine based on a whole organism can contain toxic 
components, even if the microbe itself is non-viable. Subunit vaccines contain a 
few or even a single purified antigen from the original pathogen. Recombinant 
subunit vaccines are precisely defined and are usually safe and well tolerated. 
Examples of successful subunit vaccines include Hepatitis B surface antigen and the 
acellular Bordetella pertuscis vaccine. The drawback to producing such vaccines is that 
many purified antigens do not elicit a strong immune response. This can be because 
too few antigens are included in the formulation or the removal of inflammatory 
molecules and PAMPs from the whole cell formulation reduces the potential to 
activate the immune system. Without these triggers, many antigens are not 
immunogenic and must be administered with an adjuvant -a substance that 
increases the immune response to co-administered molecules. To date the type of 
adjuvants that have been licensed for use in humans remain limited to aluminium 
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salts (alum), which has been in use for decades, or, more recently, detoxified 
bacterial molecules (e. g. monophosphoryl lipid A (Baldrick et aL 2002)). A 
consequence of using alum is that subsequent immunity tends to be biased strongly 
towards a Th2 response; high antibody production but little cell-mediated immunity, 
whereas bacterial derivatives can induce Thl responses (Lodmell et aL 2000). 
1.5.3 Live-Attenuated Vaccines 
Live, attenuated vaccines are generally powerful vaccines, reproducing many 
of the features of a natural infection including some degree of replication and 
survival of the organism in the body. This characteristic makes attenuated vaccines 
potentially more likely to generate protective immunity than killed organisms or 
subunit vaccines. However, attenuated vaccine strains can potentially revert to a 
virulent state resulting in disease. This has been observed with the Sabin oral polio 
vaccine, where reversion to virulence occurs in about one vaccinee per million and 
can result in poliomyelitis (Wood and Thorley 2003). Therefore the utility of this 
vaccine depends on the conditions in which it is employed. As a cheap, easily 
administered and highly effective vaccine, for treatment in endemic regions, this 
type of vaccine is invaluable. However, in a population from which the virus has 
been largely eliminated, the use of this vaccine can be the cause of the majority of 
cases of poliomyelitis (Plotkin 2003; Yang et al. 2003). In these circumstances it may 
become appropriate to use an inactivated vaccine that is less immunogenic but 
shows a greater safety profile (Wood and Thorley 2003). 
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1.5.3.1 Mucosal Vaccination and Inununology 
The single greatest advantage of mucosal vaccination is its potential to 
invoke immunity at the mucosal surface as well as systemically. Since the majority 
of pathogens invade the body through the mucosal surfaces, the mucosal immune 
response can prevent the initial entry of the organism into the host and thus prevent 
systemic disease. This effectively provides an earlier line of defence against 
infection and can additionally protect against infectious organisms that cause 
damage to these surfaces by the production of toxins. Protection is partially 
mediated by secretory IgA, which is not induced by parenteral vaccination (Johnson 
et al. 1995). Similarly, systemic vaccination fails to induce cell-mediated immunity at 
mucosal membranes, whilst delivery of a vaccine directly to the mucosal surfaces 
can induce such responses (Gallichan and Rosenthal 1996; Kanellos et aL 2000). In 
addition, it is believed that trafficking of lymphocytes between mucosal surfaces is 
linked and that a vaccine delivered to one part of the mucosal immune system can 
induce immunity at some distal mucosal sites. For example, oral immunisation can 
confer an immune response in the upper respiratory tract as well as in the intestinal 
mucosa. This is generally known as the common mucosal immune response and 
makes mucosal immunisation particularly attractive (Chen 2000). 
Mucosal immunisation also offers practical advantages for vaccine delivery. 
Since there is no hypodermic administration of the vaccine, blood-borne diseases 
such as HIV and hepatitis cannot be passed from one recipient to another by re-use 
of contaminated needles. Not are medical staff at risk of infection due to accidental 
needlestick injuries, currently a frequent occurrence (Elmiyeh et aL 2004). Painless, 
simple and non-invasive, mucosal administration can also lead to increased uptake 
in a population. 
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A potential problem with mucosal vaccination is the difficulty of generating 
mucosal immune responses. The normal response to mucosal antigens is anergy or 
tolerance, since an inappropriate response against innocuous airborne molecules or 
proteins in food, for example, could be harmful (Dougan et al. 2000). Secondary 
signals must be provided for the activation of naive lymphocytes. These signals can 
be triggered by bacterial toxins such as E. codi LT or Cholera toxin (Rappuoli et ah 
1999), which can be detoxified and yet remain effective as mucosal adjuvants (Pizza 
et al. 2001). 
1.5.3.2 Use ofAttenuated Vectors 
Despite the advantages outlined above, there are few mucosal vaccines in 
use. This is mainly because of the difficulty of generating mucosal responses. 
However, live organisms, even though attenuated, can overcome mucosal tolerance 
through the activation of innate immunity (Dougan et al. 2000; Huang et ah 2001; 
Woo et ah 2001). 
The ability to replicate, even at a reduced rate, confers increased longevity of 
antigen expression and stimulation of the immune system (compared to a non-living 
vaccination system). Also, immunisation with attenuated vectors can generate 
immune responses to the vector, which can induce protective responses against 
related pathogens, as has been shown with Salmonella (Salerno-Goncalves et aL 
2003), as well as to any heterologous antigens that are expressed by this organism. 
This can be achieved by genetic manipulation of the attenuated vaccine to allow 
expression of a heterologous antigen (Medina and Guzman 2001). Therefore this 
strategy has the potential to simultaneously vaccinate against more than one 
pathogen. 
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One problem associated with the use of attenuated vector vaccines is pre- 
existing immunity to the vaccine organism in geographical regions where the wild- 
type organism is endemic. This might result in early clearance of the vector and 
reduced exposure to the vaccine antigens, giving dramatically reduced immune 
responses (Medina and Guzman 2001). To overcome this, higher doses of bacteria 
can be used, but not without introducing the danger of giving too high a dose to 
non-immune individuals. Conversely, the calculated dose might be too high in non- 
endemic areas if vaccine is originally tested in endemic infection area (Attridge et al. 
1997). However, this theoretical risk may not be important, since it has been shown 
that prior immunologic experience of a Salmonella vaccine carrier strain (or similar 
strains of Salmonella) can potentiate a stronger humoral immune response than is 
seen without prior exposure (Bao and Clements 1991). 
A wide range of different bacteria and attenuation mutants are being 
evaluated for vaccine delivery, but Salmonella is one of the most studied genera, with 
several examples of human clinical trials (Medina and Guzman 2001). Such studies 
have considered their use in human typhoid fever vaccines (Salerno-Goncalves et al. 
2003), for use as carriers to deliver DNA vaccines to host cells (Woo et al. 2001), or 
to deliver vaccine antigens of other pathogens in humans (Bumann et aL 2000) and 
mice (Foynes et al. 2003). 
1.5.3.3 Use of Salmonella typhimurlum as a live attenuated delivery strain 
Salmonella enterica, serovar tyßhimurium, is referred to as S. typbimurium 
throughout this thesis. It is a Gram negative bacterium which when used to infect 
mice causes a systemic disease with many of the features associated with human 
typhoid fever. 
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Salmonella can enter the body through gut epithelial cells or M cells, specialist 
antigen sampling cells on the surface of the Peyer's patches in the intestinal 
epithelium. From here they are able to invade macrophages and DCs and can 
survive in the phagolysosomes of these cells. This is despite the intracellular killing 
mechanisms that exist within macrophages to eliminate intracellular pathogens 
(Carrol et al 1979). Migration of such infected cells can lead to systemic infection, 
with dissemination to the spleen, liver and lymph nodes. The presence of the 
bacteria at different sites enables the activation of responses both systemically and at 
mucosal surfaces (Medina and Guzman 2000). 
The presence of highly immunogenic components of the bacteria including 
LPS and flagellin and the invasion of immune cells such macrophages activate 
mechanisms which can enhance specific immune responses. This is mediated 
through the release of pro-inflammatory cytokines, such as IL-1 and TNF-a, 
resulting in an influx of neutrophils, DCs and T lymphocytes to regions with 
bacteria-carrying cells and upregulating APC co-stimulatory signals via TLRs 
(Takeda and Akira 2001). 
Control of infection is mainly by acquired T cell responses: including 
enhancement of macrophage killing mechanisms by Thl cells and direct killing of 
infected cells by CTLs (Mastroeni and Sheppard 2004). This occurs more rapidly 
with attenuated vaccine strains, but does not prevent the presentation of antigens 
encoded by the bacteria, or the dissemination of the bacteria around the body. 
1.5.3.4 Attenuation of S. typhimurium B. RD 509 
Live bacteria used to deliver vaccines must be attenuated to the extent that 
they cannot cause disease in the vaccine recipient. Salmonella is a much studied 
organism, and its virulence factors have been well characterised (Hensel et aL 1995; 
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Marcus et aL 2000). This has facilitated the creation of mutants lacking various 
virulence factors (O'Callaghan et a! 1988). One effective vaccine candidate is S. 
typhimw um BRD509. The strain is attenuated by deletion of two genes; arvA and 
aroD, encoding enzymes in the biosynthetic pathways involved in the generation of 
the aromatic amino acids (Strugnell et al. 1992). The bacteria are therefore 
auxotrophic, ie. dependent on external supply of these amino acids. The am genes 
were selected for mutation because aromatic metabolites are not usually present in 
human tissues, therefore mutants should be unable to replicate at these sites. Their 
diminished ability to replicate in vivo results in a self-limiting, sub-clinical infection, 
but they remain able to express and present vaccine antigen (Chatfield et a! 1993). 
Administration of this strain expressing antigens from other pathogens has been 
shown to result in mucosal responses offering partial protection against a mucosal 
pathogen (Strugnell et al. 1992). Systemic antibody production against the antigens 
of the secondary vaccine candidate has also been observed (Roberts et al. 2000), 
although T helper cell responses were limited to Salmonella antigens (Londono et a! 
1996). 
1.5.3.5 Antigen Expression 
The production and presence of a heterologous antigen lays a considerable 
metabolic burden on recombinant bacteria. This can result in reduced growth and 
decreased plasmid stability. Attempts to reduce the impact of antigen expression on 
plasmid stability have included the use of inducible promoters as an alternative to 
constitutive antigen expression. One commonly described promoter is nirB, which 
is activated under anaerobic conditions such as the interior of eukaryotic cells (Bell 
et aL 1990). This allows growth in vitro where oxygenation of the culture is high, 
whilst allowing antigen expression on vaccination in the tissue when the oxygen 
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tension is low. There have been several comparisons between strains expressing 
antigens under the control of different promoters. Two groups have demonstrated 
greater plasmid stability both in vitro and in vivo with the use of nirB than equivalent 
plasmids from which an antigen is constitutively expressed (Oxer et aL 1991; 
Chatfield et al. 1992). The nirB promoter has also been shown to drive higher levels 
of expression in S. typhimurium amA mutants than pagC under conditions in which 
both promoters were induced. In this case, plasmids expressing the same antigen 
under the control of these promoters were shown to have similar levels of stability 
in vitro. However, stability of both plasmids was reduced in vivo, although nirB was 
maintained at a higher level (Foynes et aL 2003). Other work has shown that the 
copy number of the plasmid carried by an S. yphimurium am mutant is inversely 
proportional to the ability of the bacteria to colonise mice, presumably due to the 
metabolic burden of maintaining a high copy number plasmid (Bell et aL 1990). 
1.5.4 DNA Vaccines 
1.5.4.1 Background and Development 
A relatively novel approach to inducing immune responses involves the 
administration of naked DNA that encodes the vaccine antigens of interest, rather 
than of the antigens themselves. This system relies on the use of a eukaryotic 
promoter to drive expression of the DNA encoded antigen within the transfected 
host cell. First described in 1990 (Wolff et al. 1990), its application to vaccine design 
resulted from the observation that specific antibodies could be generated to the 
antigen encoded by the DNA following intramuscular administration (Tang et al. 
1992). These findings were mirrored by later work (Williams et al. 1992), which 
used an alternative method of vaccination; ballistic delivery of DNA into the dermis 
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using a gene gun (see below). These initial studies have led to a massive expansion 
of research in this area. Work to date has investigated the possibilities of using 
DNA to act as a vaccine in humans and animals against a variety of diseases. Many 
approaches have been considered and a number of human clinical trials have been 
completed. However, these have demonstrated that DNA vaccines need to be used 
in combination with other vaccine strategies to generate immunity. Examples 
include vaccines for malaria (Epstein et al. 2004; Moorthy et ah 2004), HIV-1 (Mwau 
et ah 2004), and various cancers (Tagawa et ah 2003). 
DNA vaccines require a similar investment, in terms of development of the 
technology, to other forms of vaccines. However, production of the vaccine itself is 
much simpler and therefore potentially cheaper; there is no requirement for a 
complex purification of recombinant protein from bacteria (thus ensuring there is 
no potential for residual toxicity due to co-purified contaminants). DNA is easily 
isolated in a highly pure form, and can be dried out for storage. Transport of 
lyophilised DNA is simple; it requires no refrigeration and is stable for long periods 
of time, unlike protein vaccines, which commonly require refrigeration. 
1.5.4.2 Generation oflmmune Responses to DNA Vaccines 
A summary of the generation of immune responses following DNA 
vaccination is shown in Figure 1-7. DNA vaccination has been shown to elicit 
CD4+ T cell, CD8+ T cell and B cell responses. However, the precise mechanisms 
by which these responses are generated are not clear, probably depending on which 
transfected cells are involved in the expression of antigen and acting as professional 
APCs to CD4+ T helper cells. 
Initially, DNA is taken up into the cells of the vaccine recipient and 
translocated into the nucleus by as yet undefined mechanisms. From there, the 
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DNA is transcribed into mRNA and translated into protein by exactly the same 
process that cellular proteins are manufactured. Translation is followed by protein 
modification. Such proteins can then be processed and presented on the surface of 
the cell in the context of MHC class I molecules. This can lead to the activation of 
CD8+ T cells. In addition, specialist APCs can present vaccine antigen (either 
following direct transfection of the APC, or internalisation of antigen expressed and 
released following death of by other transfected cells). Antigen presentation by 
APCs can be in the context of MHC class I as above, or class II, potentiating the 
activation, of CD4+ T cells. Finally, B cells can also be activated following an 
encounter with vaccine antigen, although given the typically low humoral responses 
to DNA vaccines administered alone, this is thought to occur at a low level. 
Currently the precise mechanism by which professional APCs could acquire 
DNA-expressed antigens is unknown. It is possible that transfected muscle cells or 
keratinocytes could produce antigen that is picked-up by APCs. Alternatively, cells 
at the site of vaccination (e. g., Langerhans cells - LCs - in the dermis) could 
undergo direct transfection, or be transfected by DNA that moved from the target 
site through the blood vessels or lymphatics. Since neither muscle cells nor 
keratinocytes constitutively express MHC class II or the co-stimulatory molecules 
required to activate T-helper (ii) cells, their role in antigen processing and 
presentation may not be as APCs, but they may still have a significant role in the 
expression of the encoded antigen. 
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Figure 1-7: The development of immune responses following DNA 
vaccination 
Following vaccination, DNA is taken up into the nucleus (1). DNA is translated 
into mRNA and the encoded antigens are then expressed in the cytoplasm by the 
normal cellular mechanism (2). Following expression, the antigens will be processed 
and presented on the cell surface in the context of MHC class I molecule , 
(endogenous pathway). The MHC-antigen complex may then be recognised by 
specific CD8+ T cell (3), which is then activated and matures, resulting in 
proliferation and cytokine secretion (4). Activated CTLs will initiate apoptosis in 
any cells subsequently encountered presenting MHC-I-antigen complexes, which 
bind to the TCR in conjunction with a secondary signal. Antigens from a DNA 
vaccine may be encountered by professional APCs (5). These can be taken up into 
the cell by endocytosis and processed through the exogenous pathway, whereby 
epitopes are presented on the cell surface bound to MHC class II molecules. 
Subsequent interactions with naive CD4+ Th cells will then result in their activation, 
characterised by proliferation and secretion of cytokines in order to co-ordinate the 
cellular and humoral immune responses (6). If aB cell encounters an antigen to 
which its receptors can bind, it will begin to secrete antibody. AT helper cell with 
the same specificity can induce aB cell to mature into a plasma cell, whilst 
proliferating and undergoing class switch from IgM production to other classes 
including IgG (7). 
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It is known that myocytes can express vaccine antigen following transfection 
in vivo, and that they constitutively express MHC class I. Therefore it was initially 
thought that these cells were capable of driving the CD8+ activation observed 
(Hohlfeld and Engel 1994). Furthermore, soluble proteins, secreted by myocytes or 
released following cell death, could stimulate B cells and CD4+ T cells. However, 
the importance of myocytes in any of these processes is currently unclear. They 
lack co-stimulatory molecules, such as B7, that are necessary for activating naive 
CD8+ T cells, and therefore they are unlikely to directly initiate a CD8+ T cell 
response. Nevertheless, they may be a major source of expressed antigen. CTL 
activation is thought to be more-likely driven by professional APCs that may be 
directly transfected following immunisation. On trafficking to regional lymphoid 
tissues, these cells would be able to prime naive B cells, CD4' T cells and CD8+ T 
cells. This poses no theoretical problem when considering intradermal vaccination 
(see below), given the numbers of professional APCs such as LCs present in the 
dermis. However, muscle tissue is not well supplied with professional APCs. An 
alternative possibility is that the tissue damage caused by im. vaccination results in 
the recruitment of APCs to the muscle. These cells could then internalise DNA and 
express and present antigen themselves, or provide secondary signals for antigen 
presenting muscle cells; it is thought that antigen presentation and co-stimulation do 
not have to be provided by the same cell (Kundig et al. 1995). 
Some of the mechanisms that may be responsible for this process are 
outlined above in section 1.4.1.3, Cross Presentation. It is still uncertain precisely 
which cell types are involved in the generation of the activated T cells, but there is 
some evidence to suggest that the immune response may be modulated by altering 
the cellular localisation of expressed protein and the immunisation route (Morel et 
al. 2004). 
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Low antibody responses seen in response to some DNA vaccines suggest 
that DNA vaccines drive limited B cell activation. This is probably due to the low 
levels of antigen expressed by transfected cells in comparison to the quantity 
delivered by e. g. recombinant protein vaccination (Davis and McCluskie 1999). 
After administration, it has been demonstrated that antigen expression can 
continue for a significant time period (Wolff et aL 1990). This low but ongoing 
expression of antigen continuously augments the immune response and it has been 
conjectured that this similarity to natural infection enhances the response (Donnelly 
et a1.1997). 
L5.4.3 Factors Al ecting the Nature of the Immune Response Generated 
Level of Antigen Expression 
There is a direct correlation between the expression level of secreted 
proteins encoded by DNA vaccines and humoral responses, although there is no 
such correlation for intracellular proteins (Barry and Johnston 1997). The level of 
expression is also thought to have an effect on the induction of CTLs. However 
whilst increases up to a certain level gave an increased response, high doses actually 
resulted in a decreased CTL response (Barry and Johnston 1997). It maybe that 
higher levels of expression resulted in more rapid killing of transfected cells, 
curtailing the activation of CTLs. 
Nature of the Antigen 
The post-transcriptional localisation of antigen expressed following DNA 
vaccination has a major impact on the subsequent immune response. The effect of 
localisation was dissected by immunisation using DNA expressing cytoplasmic, 
secreted or transmembrane ovalbumin. Gene gun immunisation with cytoplasmic 
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or transmembrane protein led to strong ovalbumin-specific CTL responses, but not 
following immunisation with secretory protein. In contrast, im. immunisation with 
DNA expressing the secretory or transmembrane protein led to potent CTL whilst 
vaccination with the cytoplasmic form was ineffective. OVA-specific antibodies 
were detected following gene gun immunisation with all three constructs, whereas 
only the secretory construct induced antibody production following i. m. 
immunisation (Morel et al. 2004). These results demonstrate that the localisation of 
the protein is central to the nature of the response generated and indeed whether 
any response is elicited and that CTL and antibody responses are induced by 
different mechanisms. 
Vector and Promoter Selection 
The plasmid vector is responsible for directing transcription of the encoded 
antigen within cells transfected during vaccination. The backbone of the vector can 
be important due to the presence of immunostimulatory CpG motifs (see below). 
The other main significant feature is the promoter. The human cytomegalovirus 
(CMV) immediate early promoter is the most commonly used as it has been shown 
to drive high levels of antigen expression in murine skeletal muscle in vivo, following 
either gene gun or im. vaccination (Cheng et al. 1993; Manthorpe et aL 1993). 
Immunostimulatory CpG Motifs 
Bacterial plasmids used in DNA vaccination differ from eukaryotic DNA in 
several subtle but important characteristics. Firstly, bacterial CpG motifs (cytidine - 
phosphate - guanidine dinucleotides) are unmethylated, unlike those found in 
eukaryotic DNA. Secondly, these motifs are present at the frequency predicted by 
chance (1 in 16 dinucleotides) in bacterial DNA, whereas they are far less common 
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in eukaryotic DNA. These differences have no biological effect on the function of 
the DNA to store, replicate and transcribe genetic information, but can be exploited 
by the immune system to differentiate between mammalian DNA and bacterial 
DNA (Krieg 2002). In particular these differences are recognised by TLR-9 found 
on the surface of immune cells (Brown and Corral 2002). The stimulatory activity 
of the DNA motifs depends on the precise nucleotide sequence surrounding each 
motif (Krieg et aL 1999). 
Recognition of unmethylated CpGs is mainly mediated by DCs, since they 
express high levels of TLR-9. However, the activity of B cells, macrophages and 
NK cells are all directly affected to some degree. In B cells, recognition strongly 
enhances antigen-specific activation by upregulating co-stimulatory molecule 
expression, and can drive T cell-independent class switching. Secretion of IL-6, IL- 
10 and immunoglobulin are all upregulated. Innate effector mechanisms are 
enhanced, such as phagocytosis and the release of antimicrobial reactive oxygen 
species in macrophages, and NK cytotoxicity and IFN-y secretion are increased. T 
cells are not-directly affected, but can be more readily activated due to the changes 
in APCs (Cowdery et al. 1996; Krieg et aL 1999; Brown and Corral 2002). 
Recently, synthetic oligodeoxynuleotides, containing immunostimulatory 
CpG motifs, have been used as adjuvants in various vaccine strategies. They drive 
Thl responses in mice and primates, probably due to the induction of IL-12 and 
IFN-y (Krieg et al. 1999). In DNA and protein vaccines, CpGs have been shown to 
be effective at increasing antibody production, both systemically and at mucosal 
surfaces (McCluskie et al. 2001; McCluskie et aL 2002; Klinman 2003). 
62 
Delivery Route - Ballistic versus Intramuscular Vaccination 
DNA vaccination offers a degree of flexibility in terms of the quality of 
immune response generated, depending on the means of administration of the 
vaccine. It has been shown in many instances that immunisation by im. vaccination 
can result in an immune response dominated by CD4+ cells of the Thl phenotype. 
However, ballistic delivery of DNA into the dermis can elicit a Th2 dominated 
response. Ballistic delivery involves attaching plasmid DNA to microscopic gold 
particles, which are fired into the skin under pneumatic pressure, using a device 
known as a `gene gun'. The different immune responses generated to im. and gene 
gun DNA vaccination have been noted in several studies (Zlei 2002; Zhu et al. 
2004). 
Induction of Th1 responses following i. m. vaccination has been partly 
explained by the presence of immunostimulatory CpG motifs on plasmid DNA. In 
fact, although gene gun vaccination has been shown to preferentially induce Th2 
immunity this bias can be overcome by co-administering the vaccine DNA with 
large quantities of CpG motifs (Schirmbeck and Reimann 2001; Zhou et at 2003). 
This potential to overcome Th2 bias could be exploited in the therapeutic 
vaccination of chronic diseases where an ineffective Th2 immune response 
dominates. 
The inhibitory feedback between Thi and Th2 cytokines can make 
immunomodulation of existing responses difficult, since an existing Th2 cytokine 
milieu around naive CD4+ T cells will hinder their development into Thl cells. 
Thus vaccination strategies that induce strong Thi responses and specifically prime 
CD8+ T cell responses, such as im. DNA vaccines, may be necessary for effective 
therapeutic vaccination (Zajac et al. 1998). Immunomodulation is not only 
important in infectious disease, it can also be used to treat cancers and 
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autoimmunity (Prud'homme et al. 2001). However, this potential may not be as 
apparent as in mouse models. Although human memory T cells restimulated in the 
appropriate cytokine milieu may be able to switch Ih phenotype, mouse memory 
cells do not share this ability (Sallusto et al. 2004). 
1.5.5 Prime-Boost Strategies 
Conventional vaccines are often successful at generating effective antibody 
responses that can control or prevent a wide range of infections. However, as 
discussed above (see section 1.2.2, The Requirement for New Vaccines), there 
remain many diseases for which such a response is not sufficiently protective. 
These include tuberculosis, HIV and malaria, currently the three infectious diseases 
responsible for the greatest numbers of deaths world-wide. All three are 
intracellular pathogens, and cannot be cleared by an immune response lacking a 
potent cell mediated component. Homologous boosting (delivering multiple doses 
of the same vaccine formulation) can often increase humoral responses to the level 
where they are protective, such as with the recombinant HBsAg of the HBV 
vaccine. However, the strategy of repeatedly delivering the same vaccine is not 
effective at increasing the magnitude of CD8+ T cell responses. 
The advent of DNA vaccination was treated with enthusiasm as the ability 
to induce strong cell-mediated immune responses offered the tantalising prospect of 
effective vaccination against such intransigent diseases. In reality, DNA vaccination 
has not yet lived up to initial expectations. A logical progression was therefore to 
combine different vaccination strategies in heterologous prime-boost regimes. 
Sequential vaccination with the same antigen employing different strategies of 
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delivery has been shown to improve immunity by the two vaccines working 
synergistically together (McShane 2002). 
One of the aims of this project is to examine the effects of boosting a DNA 
prime vaccination with different heterologous boosts and determine the extent to 
which responses are enhanced. Whilst many strategies are able to prime cell 
mediated immunity, few have been shown to boost cellular responses effectively. 
The response after a primary vaccination generally focuses on a few 
immunodominant epitopes of an antigen. It is thought that boosting the response 
with the same antigen allows a preferential expansion of pre-existing memory T 
cells to these epitopes. When a different vector is employed, the further 
development of responses against the first vector is avoided. This may prevent a 
`dilution' of the response, instead allowing the immune system to focus on the 
vaccine antigen itself (Woodland 2004). 
The successful use of prime-boost vaccination strategies is dependent on the 
ability of the boost vaccine to enhance the primed immune response. For this to be 
achieved the boost needs to be given proximally to that of the prime to ensure that 
memory T and B cells residing in local draining lymph nodes are stimulated. In the 
case of attenuated vectors, an association with immune cells (such as the uptake by 
macrophages of Salmonella) may be an advantage since this could direct antigen 
more efficiently to lymphoid tissues and memory lymphocytes (Ramshaw and 
Ramsay 2000). 
There are various examples of prime-boost vaccination displaying 
synergistically improved responses (Kanellos et al. 2000; Estcourt et aL 2002; 
McCluskie et al. 2002). One in particular is the increased efficacy of BCG 
vaccination against tuberculosis when vaccination with the bacteria was enhanced by 
prior administration of a DNA vaccine. The DNA vaccine alone had little effect. 
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However, DNA prime followed by a BCG boost offered improved efficacy over 
BCG alone in an aerosol challenge model Protection was mediated in part by CTL 
activity (McShane 2002). 
Application of effective prime boost strategies has not only been suggested 
for the development of new prophylactic vaccines but also in the development of 
therapeutic vaccines. This type of vaccine would be used in the treatment of a 
chronic infection such as Hepatitis B in which activation of a specific arm of the 
immune system may serve to clear the disease. 
1.6 Hepatitis B Virus 
HBV is an enveloped virus with an icosahedral core and double-stranded 
circular DNA genome. The virus invades and replicates within the liver cells of the 
human host. Following replication, assembled virus particles bud from the cell 
surface (Ganemn and Schneider 2001). 
The virus can be passed on through sexual contact and body fluids such as 
blood, including untreated blood products. The high viral load in the blood of 
those infected renders it highly infectious through contaminated needles. Acutely 
infected adults can normally clear the virus. However, chronic infection is a 
problem with recent estimates of 350 million people infected world-wide (WHO 
1996). As about 25% of chronic carriers (1 million people each year) will die of 
chronic active hepatitis, cirrhosis or primary liver cancer there is an obvious need 
for new treatments to be developed. 
Although, a useful prophylactic vaccine exists, based on parenteral delivery 
of recombinant surface antigen expressed in yeast, it is not effective as a therapeutic 
vaccine in chronically infected patients (WHO 1996). 
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1.6.1 Host-Pathogen Interactions 
One area of much interest over the last 5 years is the potential to modulate 
the immune response to HBV to encourage clearance of the virus as persistence is 
believed to be due, at least in part, to modulation of the immune response by viral 
antigens. Patients who suffer from a self limiting disease usually display evidence of 
a strong, broad Thl response (Chisari and Ferrari 1995; Guidotti et al. 1996). In 
contrast, chronically infected patients display a strong humoral response to the virus 
but usually have weak CTL activity against only a few viral epitopes. This does not 
imply that the T12 response is ineffectual as there is clinical evidence that significant 
levels of circulating antibody are also necessary for clearance and to protect against 
re-infection (Milich and McLachlan 1986; Milich et at 1995). However, these 
humoral responses alone are not sufficient for clearance of an established infection. 
Interestingly, there is evidence that the virus itself plays a role in modulating 
the immune response to prevent effective clearance through the core antigen. The 
gene for this protein contains two in-phase start codons, one of which leads to the 
transcription of HBcAg, the other a protein that is processed in the ER and secreted 
from the cell as the HBeAg. This antigen, although largely identical to core in 
sequence, is a soluble protein, which unlike the HBcAg does not self assemble to 
form particles. It has been demonstrated that this non-particulate form of the 
antigen, is effective at stimulating a Th2 response which is less effective at clearing 
the virus than the Thl response induced by the particulate antigen (Nilich et aL 
1997). The high level of the HBeAg observed in the blood stream of chronic 
patients effectively swamps the immune system with antigen (Milich et aL 1998). 
This may result in the lack of a broad CTL response, which has been proposed as 
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the reason why the virus is ineffectively cleared, and thus represents a sophisticated 
evolutionary strategy, on the part of the virus, to enable chronic carriage and 
therefore increase the likelihood of dissemination to other hosts. 
1.6.2 Therapeutic Vaccination and HBV Infection 
A possible hypothesis for the successful clearance of HBV infection is that 
hepatocytes infected with the virus present viral antigens to CrL which then trigger 
apoptosis in these cells. On activation, however, the CIL begin to secrete Thi 
cytokines such as IL-12 and IFN-y (Rossol et at 1997). The latter cytokine induces 
an antiviral state in hepatocytes, resulting in degradation of viral RNA, abrogation 
of virus assembly and preventing future infection of cells (Guidotti et al. 1999). As 
the Th1 response brings the population of infected hepatocytes under control, B 
cells produce neutralising antibody that mops up circulating virus, preventing re- 
infection. Conversely, it may be that the poor activation of CTLs and 'M-like 
immune response in chronic carriers prevents them from clearing the virus (Chisari 
and Ferrari 1995; Guidotti et aL 1996). 
If this hypothesis is correct, it seems plausible that efforts aimed at curing 
chronically infected patients should induce a Th1 response. Indeed, current 
moderately effective treatments, such as interferon (IFN) and ribavirin therapy, are 
effective at raising Thl responses (Hultgren et al. 1998; Michel et al. 2001). 
Attempts have been made to use DNA vaccination in human patients to 
modulate immune responses to chronic HBV infection. They have been partially 
effective; inducing CTL responses and reducing viral replication (Michel et al.. 2001), 
but not leading to full clearance. It is possible that these results could be improved 
using combined vaccination/antiviral therapy or by employing a heterologous 
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prime-boost vaccination strategy. One difficulty with attempting to induce Thl 
immunity through vaccination has been the historical lack of safe, effective Th1 
adjuvants (Moingeon et aL 2001). However, DNA vaccines contain 
immunostimulatory CpG motifs (described above) that strongly drive Thl 
responses. It is therefore possible that DNA vaccination will become central to 
therapeutic vaccination strategies. 
1.6.3 Structure and Immunogenicity of the Core Antigen 
The model antigen used for the purposes of this project was the hepatitis B 
core antigen (HBcAg), the capsid protein of the hepatitis B virus. This monomeric 
protein of approximately 21kDa in size (as shown in Figure 1-8) is capable of self- 
assembly into large particles when present in sufficient concentrations. The 
assembled particle is shown in Figure 1-9. The antigen was selected as a model 
because it is highly immunogenic and it provides a unique opportunity to consider 
the impact of prime boost strategies on particulate rather than soluble antigens, as 
described previously in this laboratory (Zlei 2002). The reason for this comparison 
is the different nature of particulate and soluble antigen processing (see section 
1.4.1). Particulate antigens are presented with an efficiency three to four orders 
magnitude greater than that of soluble antigen (Kovacsovics-Bankowski et aL 1993; 
Harding and Song 1994). 
The particle itself is made up of many dimers of the core protein. During 
natural infection, it forms the capsid in which viral DNA and a DNA polymerase 
enzyme are packaged. Although the protein consists of 183 amino acids, only the 
N-terminal 140 amino acids are required for generation of the particulate structure, 
although particle stability is increased by inclusion of a cysteine at position 183 
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which forms an internal disulphide bridge. The remaining 43 amino acids provide 
the nucleic acid binding region required for encapsulation of the viral genome. The 
capsid particles can consist of either 180 or 240 subunits, forming particles of 320 
and 360 Angstrom in width, respectively (Wynne et aL 1999). 
The polymers are made up of many pairs of individual polypeptides. These 
dimers are highly stable and resistant to full denaturation. This is believed to be due 
to interactions between the a-helices of the cl loop (see below) (Bottcher et al. 
1997), and the extensive hydrophobic core of the protein. A cysteine-cysteine 
disulphide bridge is formed between the cc-helices in dimers, but is not necessary for 
dimer or capsid formation (Wynne et ah 1999). 
The major structural and immunological feature of the capsid is a surface 
spike. In the monomer, two consecutive cc-helices, from amino acid 50-73 and 79- 
110, form a hairpin structure known as the cl loop (Wynne et al.. 1999). These 
associate in the dimer to form a 4-helix bundle, which protrudes from the surface of 
the capsid by about 25 Angstrom (Conway et ah 1997). 
HBcAg contains several highly immunogenic T and B cell epitopes against 
which strong immune responses can be raised (Milich et al. 1995). It can function as 
aT cell-independent antigen, because of its ability to activate naive B cells directly 
by the cross linking of multiple BCRs, resulting in the induction of B7 co- 
stimulatory molecules (Milich et aL 1997). This does not, however, prevent the 
HBcAg from promoting T helper responses, therefore it is both aT cell-dependent 
and T cell-independent antigen (Milich and McLachlan 1986). The principle 
antigenic site of the protein is found at amino acids 78 to 82 and coincides with the 
tip of the surface spike (Bottcher et al. 1997) (see Figure 1-8). 
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Figure 1-8: Three-dimensional layout of the truncated core protein monomer 
The numbers represent the amino acid positions of principles features, i. e. (: and N 
terminal residues, start and end of a helix regions and cysteine residues (Bottcher ei 
al. 1997). 
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Figure 1-9: Assembled HBcAg polymer 
The assembled H Bci\g particle, determined at a resolution of 9 Angstroms from 
cryo-electron micrographs (Conway et al. 1997). 
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PROTECT AIMS 
This project was designed to fulfil two main objectives. 
" The first was to characterise and compare the immune responses 
developed following intra-muscular (i. m) and gene gun delivery of a 
DNA vaccine consisting of a plasmid expressing HBcAg. 
" The second was to determine the effect of boosting the primary 
response to DNA vaccination through the use of heterologous boost 
strategies. 
The boosting strategies examined included im. administration of the 
recombinant purified HBcAg alone, infra-nasal (i. n. ) administration of the purified 
antigen in combination with mucosal adjuvant LT and intra-gastric (i. g. ) 
administration of an attenuated bacterial vector (S. typhimurium BRD 509) that 
expresses the HBcAg in vivo. 
In order to complete this work, a plasmid capable of expressing the HBcAg 
in eukaryotic cells, pcDNA3.1/core, was constructed and the Salmonella strain was 
transformed with a plasmid that would express HBcAg following invasion of 
mammalian cells. 
To characterise the humoral and cell-mediated immune responses induced 
by the different vaccination strategies, assays were developed which allowed 
measurement of HBcAg specific serum and mucosal antibody production, CD4+ T 
cell proliferation and CD8+ T cell activation and killing capacity. 
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2 MATERIALS AND METHODS 
2.1 Microbiology 
2.1.1 Bacterial Stocks 
Master stocks of bacteria were maintained on microbank beads at -80°C. 
Working stocks were kept in 50% glycerol/Luria Bertani (LB) broth at -80°C. 
Bacteria were streaked out onto LB agar plates containing the appropriate 
antibiotics and grown at 37°C to confirm resistance and colony morphology before 
use. 
2.1.2 Transformation of Competent Escherichia coil by Heat 
Shock 
E. coli XL10 Gold® competent bacteria (Stratagene) were taken from 
storage at -80°C and thawed on ice. 4p1 of 1.42M (3-mercapto-ethanol was added to 
bacteria, which were incubated on ice with occasional gentle mixing for 10 minutes. 
To transform the bacteria, between 0.1 and 50ng of experimental DNA was added, 
mixed gently and incubated on ice for 30 minutes. The bacteria were heat pulsed 
for thirty seconds in a water bath at 42°C, then incubated on ice for two minutes. 
0.9m1 of preheated (37°C) LB broth was added to each tube and the tubes 
incubated for 1 hour at 37°C in a rotary shaker (-200rpm). The bacteria were then 
plated onto agar plates in the presence or absence of the appropriate antibiotics and 
incubated overnight at 37°C. 
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The ratio of colonies on antibiotic and antibiotic free plates gave an estimate 
of transformation efficiency. Colonies were screened by PCR or by restriction 
analysis (see below) to determine if the transformation was successful. 
2.1.3 Making Competent Salmonella typhimurium 
A 5m1 overnight starter culture of S. tphimurium LB5010 (galE) was used to 
inoculate a 500m1 flask of media. The culture was grown to mid logarithmic phase 
(OD6, O of -0.5) and then the bacteria concentrated by centrifugation at 4°C, at 
10,000g. The resultant pellet was resuspended in 200m1 TFB1 (30mM sodium 
acetate, 100mM RbCl, 10mM CaCl2,50mM MnCI2,15% glycerol in distilled water) 
and incubated on ice for 5 minutes. The bacteria were then pelleted as described 
previously and finally resuspended in 20m1 of TFB2 (10mM RbCl, 75mM CaCl2, 
10mM MES, 15% glycerol in distilled water). The competent cells were then 
aliquoted into microfuge tubes and stored at -80°C. When required, these bacteria 
were transformed with plasmid as described above. 
2.1.4 Creation of Recombinant Bacteriophage P22/pGA-1 
D-galactose was added, at a final concentration of 0.04%, to an overnight 
culture of S. 1yphimurium LB5010, which had been previously transformed with the 
plasmid pGA-1 using the method described above. The culture was then incubated 
for a further 45 minutes to allow uptake of D-galactose and synthesis of smooth 
LPS, making the bacteria susceptible to bacteriophage P22 infection. 
During this time, buffer T2 (66mM KH2PH4,69mM NaCl, 29mM K2SO4, 
17mM Na2HPO4,1mM MgSO4,55µM CaC1.6H2O, 0.01% gelatin in 1L distilled H20) 
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was used to dilute the P22 stock into 10-fold serial dilutions. 100µl of bacterial 
culture was added to tubes containing 10µl of virus for each dilution. The tubes 
were incubated for 1 hour statically at 37°C to allow the phage to infect the bacteria. 
Following infection, previously melted top agar (lg tryptone, 0.8g agar, 
140mM NaCl in 100m1 distilled H20) was cooled to 48°C and 3.5m1 was added to 
each bijou. The contents were poured evenly over an agar plate. Plates were 
incubated for 5-6 hours at 37°C until plaques were visible. A sterile microscope 
slide was used to scrape off the top agar layer. The virus was then recovered from 
this top agar by addition of 3m1 T2 buffer and 200µ1 chloroform to the agar (to kill 
any remaining live bacteria) to the agar. The tubes were incubated for 30 minutes at 
37°C to release the bacteriophage and then centrifuged for 5 minutes at 1000g. The 
supernatant, containing the recombinant phages, was recovered and stored in a glass 
bijou, with 5O1i1 fresh chloroform, at 4°C. 
2.1.5 Transduction of S. typhimurium BRD509 with 
Bacteriophage P22 
The recombinant virus was then used to transform the vaccine strain (S. 
tyßhimurium BRD509, attenuated by deletion of two Am genes (Strugnell et al. 1992), 
see Introduction section 1.5.3.4. Overnight cultures of this strain were aliquoted 
into microfuge tubes to which different volumes of the supernatant containing the 
phage were added. These were incubated at 37°C for 30 minutes to allow infection 
and then spread onto LB plates containing ampicillin/5mM EGTA. The presence 
of EGTA in the media prevents the virus completing its life cycle, so the infected 
bacteria are not lysed by replicating phage. 
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The bacteria were re-streaked onto LB plates containing ampicillin and 
EGTA after overnight growth, to ensure only those bacteria into which the 
bacteriophage had successfully passed the plasmid of interest would survive. 
2.1.6 Salmonella Viable Counts 
Viable counts of Salmonella were made to accurately determine the 
relationship between OD and concentration of bacteria for the purposes of 
vaccination and also to determine the numbers of bacteria recovered from tissue of 
previously inoculated mice. These were performed by making 10-fold serial 
dilutions of the bacterial suspension and plating 10ul volumes, in triplicate, onto 
quadrants of agar plates. The plates were incubated overnight at 37°C. The plates 
containing the highest concentration of colonies that could be distinguished 
separately were counted and the colony numbers recorded. 
2.2 DNA Manipulation and Preparation 
2.2.1 Plasmids 
22.1.1 pGA-1 
This plasmid, kindly provided by Medevapharma PLC, was created from 
pPV404. The plasmid encodes the HBcAg, under the control of the tac promoter. 
In pGA-1 the tac promoter is replaced by the anaerobically activated nirB promoter, 
which induces translation under low oxygen concentration. 
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2.2.1.2 ptr%ore 
The plasmid ptrc/core was also received from Medevapharma PLC. The 
core sequence was cloned from pGA-1 into a new plasmid, pKK233-2, in which 
expression is controlled by the trc promoter which is activated by addition of 1mM 
Isopropyl ß-D-1-thiogalactopyranoside (IPTG) to the media. 
221.3 pcDNA3.1+ 
This plasmid was obtained from Invitrogen. It has a eukaryotic (CMV) 
promoter and carries an ampicillin resistance gene. The plasmid is shown in Figure 
2-1. 
2.2.2 Small-Scale Preparation of Plasmid DNA 
Small scale preparation of plasmid DNA from bacteria was carried out using 
the Qiagen miniprep kit. The protocol for this kit can be found at 
http: //wwwl . giagen. com/literature/protocols/QIAprepMiniprep. aspx. 
The DNA was eluted in distilled H2O (pre-heated to 60°C to increase 
elution efficiency). DNA was stored at -20°C for subsequent analysis and reactions. 
2.2.3 Polymerase Chain Reaction 
The reagents for use in the polymerase chain reaction (PCR) were combined 
as described in Table 2-1 - PCR master mix. 
Template was acquired from plasmid DNA from a small-scale preparation 
of purified DNA (miniprep) or from bacterial lysates, prepared as follows. A 
freshly grown colony was picked from an agar plate using a sterile toothpick and the 
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bacteria added to 100µ1 of MB grade H20. The suspension was heated at 90°C for 
10 minutes and then centrifuged for one minute to pellet the lysed bacteria. 10µ1 of 
the supernatant was added to the PCR mix for each reaction. 
The PCR mix was aliquoted into individual sterile 2O0µ1 PCR tubes and the 
reaction was carried out using a Hybaid Genesprint PCR machine under the 
conditions described in Table 2-2 - PCR reaction parameters. 
2.2.4 PCR Primers 
The primers used in this project are outline in Table 2-3: Cloning and 
sequencing primers. All primers were synthesised by Invitrogen. 
2.2.5 Nucleic Acid Endonuclease Restriction Digestion 
The DNA to be digested was added to the reaction mix as described in 
Table 2-4. The total volume of the reaction mixture was then made to a final 
volume of 2O11 with distilled HZO. The reaction mixture was incubated for 1 hour 
at 37°C in a water bath and then the enzymes were inactivated by raising the 
temperature to 55°C for 5 minutes. 
2.2.6 DNA Purification 
Cleaning of DNA (isolating DNA from enzyme reaction mixtures and 
resuspending in H2O) was carried out using the Qiagen PCR purification protocol. 
The method for this protocol can be found at: http: //wwwl. qiagen. com/literature/ 
protocols/QlAquickSpin. aspx 
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Figure 2-1: Schematic representation of the plasmid pcDNA3.1` 
This diagram, obtained from www. inxVitrogcn. com, shows the main features of the 
plasmid including promoter (P(,, ), antibiotic resistance markers (: 1mpicillin and 
Neomycin) origin of replication (ori) and the restriction sites in the multiple cloning 
site. 
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Reagent Final concentration 
lOx DNA polymerase buffer (Promega) lx 
MgC12 1.5mM 
dNTPs 200µM 
primers (Invitrogen) 400nM 
Tag DNA polymerase (Promega) 2 units 
Table 2-1 - PCR master mix 
These reagents were made up to a total volume of 25µl distilled H2O per reaction, 
including the template DNA. 
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Stage Cycles Temperature Duration 
(°C) 
11 94 60s 
2 15-30 94 20s 
55 * 30s 
72 60s 
31 72 5min 
4-4 hold 
Table 2-2 - PCR reaction parameters 
*- the annealing step was modified depending on the predicted annealing 
temperatures of the primers. 
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Name Function Sense Restriction 
sites 
Sequence 
underlined 
(start/stop 
) 
codons 
BJS 1 cloning sense Hind III TTG GGT GGA AGC TTA CCA TGG 
ACA TTG ACC C 
BJS 2 cloning anti BamH I GCT TGG GGA TCC CTA ACA TTG 
sense AGA TTC CCT AG 
BJS 4 sequencing sense - GCC TTC TGA CTT CTT TCC TTC 
(internal core) C 
BJS 5 sequencing anti - TCG GTC CCG TCG TCT AA 
('internal core) sense 
BJS 11 sequencing sense - CGC AAA TGG GCG GTA GGC GTG 
(CMV 
promoter) 
BJS 22 sequencing anti - TCT AGC AT TAG GTG ACA CTA 
(pcDNA3.1 sense TAG 
post MCS) 
Table 2-3: Cloning and sequencing primers 
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2.2.7 Agarose Gel Electrophoresis 
Molecular biology-certified agarose (Bio-Rad) was mixed with TBE (9On M 
tris, 90mM borate, 2.5mM EDTA) at 2% (w/v) for separation of PCR products or 
digestion fragments <1000bp in size, or 1% for plasmids/fragments >1000bp. The 
agarose was melted, allowed to cool and then poured into a gel cast with l0µl of 
1mg/ml ethidium bromide. Once the gel was set, DNA was mixed with DNA 
loading buffer (Sambrook et aL 1989) to give between 50 and 500ng DNA per well, 
in a volume of up to 25µl. 1Kb DNA ladder (Gibco) was run alongside the DNA 
samples at 1µg per lane, providing individual marker bands for accurate sizing of 
approximately 100ng. Gels were then run at 80V for at least 80 minutes (depending 
on the size of the fragments) and finally visualised under UV light. 
2.2.8 Ethanol Precipitation of DNA 
To precipitate DNA samples, two volumes of MB grade ethanol were added 
to an aqueous sample of DNA in a microfuge tube. 0.1 volumes of 3M pH5.2 
sodium acetate was added. The mixture was frozen at -80°C for 30 minutes and 
then centrifuged at 10,000g for 30 minutes at 4°C. The tube was washed with 1ml 
70% v/v ethanol, frozen and centrifuged again. The DNA could then be 
resuspended in the appropriate volume and medium. 
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Reaction component Final concentration 
DNA 200ng - 1µg per reaction 
lOx enzyme buffer lx (composition varies with 
enzyme and manufacturer) 
Acetylated BSA 2µg 
Enzyme 1µl (10units) 
Table 2-4: Restriction digest reaction mixture composition 
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2.2.9 Ligation of DNA Fragments 
Pre-digested DNA fragments to be ligated together were added to the same 
microfuge tube, at the desired ratio (usually 3: 1, insert : vector). The DNA was 
then ethanol precipitated and resuspended in the ligation mix (O. 51i1 T4 DNA ligase, 
O. 5µ1 lOx ligase buffer, 4µl distilled H2O) and incubated overnight at 4°C. The 
ligated DNA was transformed into competent bacteria, which were screened for the 
recombined DNA by PCR. 
2.2.10 DNA Quantification by UV Spectrophotometry 
DNA was diluted in molecular biology grade water and measured in a 
spectrophotometer (Amersham Pharmacia biotech Genequant Pro RNA/DNA 
calculator) at wavelengths of 260 and 280nm. The concentration of double 
stranded DNA was calculated as fifty times the OD2,0. OD280gives a measure of the 
purity of the sample (Sambrook et al. 1989). 
2.2.11 Large Scale Preparation of DNA for Vaccination 
Large scale (-1mg) preparation of plasmid DNA from bacteria was carried 
out using the Qiagen megaprep kit. The protocol for use of this kit can be found at 
http: //wwwl. qiagen. com/literature/protocols/QIAGENPlasmidPurification. aspx. 
The DNA was resuspended in LPS-free Phosphate-buffered saline (PBS, 
0.15M NaCI, 2.5mM KCI, 0.15M KH2PO4,10mM Na2HPO4, pH7.3) for 
quantification and use in vaccinations. 
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2.2.12 Preparation of Gene Gun Cartridges for DNA Vaccination 
22.12.1 Precipitation ofDNA onto Gold Particles 
Gene gun DNA cartridges were made with 2µg DNA and 500µg of 1µm 
diameter gold particles per cartridge. Due to losses during washing and binding the 
DNA, the final concentration is approximately 1µg DNA per cartridge. 100µg of 
DNA and 25mg of gold particles were added to 200µ1 0.05M spermidine solution. 
100µl of 1M calcium chloride was added slowly. The mixture was allowed to 
precipitate at room temperature for 10 minutes and then centrifuged briefly to pellet 
the gold. The supernatant was discarded and the pellet washed three times in lml 
MB grade 100% ethanoL 
After the final wash, the pellet was resuspended in 3.3m1 0.05mg/ml poly 
vinyl pyrrolidone (PVP)/ethanol solution. 
22.12.2 Loading DNA-Gold Suspension onto Gene Gun Cartridge Tubing 
A 30 inch section of gene gun tubing was connected to the tubing prep 
station, and nitrogen allowed to flow through in order to clear the tubing. The 
DNA/gold suspension was vortexed thoroughly and aspirated into the tubing. The 
gold was allowed to settle out and the ethanol withdrawn slowly to give the tube an 
even coating of DNA/gold. 
The tubing was then left to rotate whilst drying in nitrogen (0.4L per 
minute) for 30 minutes. The tube was then removed from the station and sectioned 
into cartridges of 0.5 inches. 
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22.12.3 Assessment ofDNA Loaded onto Cartridges 
To quantify the amount of DNA on each cartridge, every 10th cartridge 
down the tube length was removed and the following analysis completed. 
Using a sharp, large bore hypodermic needle, holes were punched in the 
base of O. 5µ1 microfuge tubes. These were then placed inside 1.5 ml microfuge 
tubes. One cartridge was placed into each of the small tubes. 50µ1 of 10mM tris 
HCl pH8.5 was slowly pipetted into the cartridge. The cartridges were left at room 
temperature for -3 hours and then vortexed, the liquid spun out and collected, and 
the procedure repeated overnight at 4°C. 
The two samples for each cartridge were pooled and the DNA quantified by 
UV spectrophotometry (see above). 
2.2.13 Quantification of Lipopolysaccharide in DNA 
The limulus amaebocyte lysate (LAL) assay allows the quantification of LPS 
in a sample in a kinetic assay by comparison against a standard curve. Reagents are 
from the QCL endotoxin kit (BioWhittiker, Cambrex). LPS-free pipette tips and 
tubes were used throughout. 
The LPS standard was reconstituted in LPS-free water and vortexed for 10 
minutes. Four tenfold, lml serial dilutions were made from this stock, from 
50IU/ml to 0.05IU/ml, vortexing each sample thoroughly between dilutions. 
Appropriate serial dilutions of samples were made in the same way. Standards were 
added in duplicate to a 96 well plate (Costar 3590). Samples were added to four 
wells for each dilution to be tested. Two wells of each sample were then inoculated 
with spikes of 51U from the standard samples. This ensures that no contamination 
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in the sample could interfere with the assay. Blanks were added to two wells and 
the plate incubated at 37°C for ten minutes. 
When the samples were up to temperature, l00µ1 of alkaline phosphatase 
conjugated limulus lysate was added to each well of the assay plate and the OD, a5 
measured every 2.5 minutes over a period of 90 minutes. The results were analysed 
using the program Kineticalc 4 (Bio-tek instruments). 
2.3 Protein Analysis 
2.3.1 Antigen and Peptides 
HBcAg expressed by Picbia pactoris was purchased from AMS biotec (Cat. 
No. R3B601). 
All peptides were synthesised by Sigma Genosys, to a purity of >95%, based 
on epitopes identified by the references described in Table 2-5, and modified to 
reflect the sequence of the HBcAg used in this thesis. 
2.3.2 Polyacrylamide Gel Electrophoresis (PAGE) 
23.21 Preparation and Running ofPolyacrylarnide Gels 
All gels were prepared using the Bio-Rad miniprotein II PAGE apparatus. 
The lower 12.5% resolving gel was prepared as described in Table 2-6. 
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Peptide Epitope Sequence Reference 
HBcAg H-2b/H-2 VSFGVWIRTPPAYRPPNAP (Milich et aL 
p120-140 CD4+ IL 1987) 
HBcAg H-2b CD8+ MGLKIRQL (Kuhrober et ah 
93-100 1997) 
HBcAg H-2d CD8+ SYVNTNMGL (Kuhroher et ah 
87-95 1997) 
Table 2-5: HBcAg oligopeptide sequences 
The sequences of oligopeptides synthesised by Sigma-Genosis and used in ex vivo 
restimulation assays. 
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Component Composition Volume added 
(sufficient for 10ml total 
or 2 gels) 
Distilled water - 3.35m1 
Separating buffer 1.5M Tris, 0.014M SDS, pH 2.4m1 
8.8 with HC1 
30% Acrylamide Acrylamide/bis acrylamide 4.15m1 
29: 1 
10% ammonium persulphate 0.44M 60µ1 
(APS) 
Tetra methyl ethylene - 5t diamine (IEMED 
Table 2-6: Composition of separating gel for PAGE 
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After polymerisation, a 4.5% stacking gel was added and combs inserted 
prior to polymerisation to create appropriately sized wells (Table 2-7). 
After polymerisation of this layer, the comb was removed and the gel, still 
between the glass plates, removed from the casting rig and placed in the PAGE gel 
running apparatus. The gel was submerged in PAGE running buffer (25µM tris, 
192µM glycine, 3.5µM SDS) and the wells washed out by pipetting. 
Samples were prepared by mixing with equal volume of 2x protein sample 
buffer (0.125M Tris, 10% ß-mercaptoethanol, 20% glycerol, 4% SDS, 0.1% 
bromophenol blue) and boiled for 5-10 minutes. They were centrifuged for 
approximately 5 seconds to remove insoluble protein/particulate debris and then 
loaded into the wells. 10µl Seeblue ladder (Invitrogen) was added to one well to 
provide size markers. Electrophoresis of the samples was then carried out at 200V 
for 50 minutes. 
23.22 Staining ofPolyacrylamide Gels 
Once full protein separation had been completed, gels were carefully 
removed from glass plates and immersed in - 50ml Coomassie blue stain (1% 
Coomassie brilliant blue, 45% methanol, 10% glacial acetic acid) and left shaking 
gently overnight at room temperature. To remove the stain, the gel was washed 
several times in destain solution (45% methanol, 10% glacial acetic acid) until the 
background was colourless. For long term storage, gels were dried between 
cellophane layers using Gel-Dri solution (Novex). 
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Component Composition Volume added 
(sufficient for 4m1/2 gels) 
Distilled water - 2.4m1 
Stacking buffer 0.5M Tris, 0.014M SDS, lml 
pH 6.8 with HCl 
30% Acrylamide Acrylamide/bis acrylamide 0.6ml 
29: 1 
10% APS 0.44M 24µl 
TEMED - gµi 
Table 2-7: Composition of stacking gel for PAGE 
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2.3.3 Western Blotting 
23.3.1 Transfer of Protein from Polyacrylamide Gel onto Nitrocellulose 
Membrane 
To transfer proteins from SDS PAGE gels onto the surface of nitrocellulose 
membranes for analysis by Western blotting, the following materials were pre- 
soaked in transfer buffer (25mM tris, 192mM glycine, 20% methanol). These were 
placed in order, in a gel holder cassette: a fibre pad, 2 pieces of blotting paper, the 
polyacrylamide gel, a 4x9cm piece of Amersham Hybond C nitrocellulose, two more 
filter papers and the second fibre pad. 
The cassette was placed in a miniprotein II Western blot apparatus (Bio- 
Rad), which was filled with transfer buffer. Transfer was then carried out at 95V for 
75 minutes or overnight at 30V. 
23.3.2 Detection of Protein with Antibodies 
After the transfer, the nitrocellulose membrane was washed for 5 minutes in 
PBS containing 0.05% Tween 20 (polyoxyethylene sorbitan monolaurate Sigma P- 
5927). Non-specific binding on the filter was prevented by addition of 3% Marvel 
skimmed milk in PBST for at least 30 minutes. The filter was then washed twice in 
PBST for 5 minutes before incubation with the primary antibody, diluted typically 
to 1: 1000 concentration, in 3% skimmed milk in PBST for 45 minutes. The 
nitrocellulose was again washed twice in PBST then incubated with an appropriate 
secondary antibody, typically at 1: 5000, for 45 minutes. Two more PBST washes 
were followed by a final 5 minute wash in PBS without tween. Substrate solution 
(30mg 4-chloro-l-napthol tablet (Sigma), 10m1 methanol + 3Oµ1 H202, in 50 ml 
PBS, mixed together immediately before use) was added and incubated at RT until 
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bands had developed to sufficient brightness. The reaction was then stopped by 
removal of the substrate by washing the nitrocellulose in distilled water. 
2.3.4 Detection of Low Concentration Proteins by Chemi- 
Luminescent Signalling 
When attempting to detect protein expression in eukaryotic cells driven by 
the DNA constructs, it proved necessary to add the solution containing the protein 
sample directly onto the nitrocellulose membrane in a volume of no more than 1Oµ1 
per sample. This allowed production of a concentrated spot of sample. Once the 
samples had dried, the membrane was blocked in a solution of 1% bovine serum 
albumin (BSA) in PBS for 60 minutes at RT. Antibodies were added and incubated 
and washes were carried out as described for the normal Western blotting technique 
except that lower concentrations of antibodies were used, 6 washes were carried out 
at each stage and 3% milk PBST was replaced in all cases with 1% BSA PBST. 
To enhance the signal generated a chemiluminescent substrate was added to 
the blot. This substrate was prepared by combining equal volumes of the 
luminol/enhancer solution and the stable peroxide solution (Pierce), and was added 
to the membrane in a plastic cover for 5 minutes. To detect the released light, the 
developed blot was then placed against a piece of photographic film (Amersham) 
and exposed for 60 seconds before developing as normal. 
2.3.5 Electron Microscopy of HBcAg Samples 
Samples of commercial HBcAg (Biodesign International, R3B601) at a 
concentration of 1µg/ml were negatively stained and examined by transmission 
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electron microscopy with the technical assistance of the University of Glasgow 
Integrated Microscopy Facility. 
2.4 Tissue Culture Protocols 
All centrifugation steps carried out with eukaryotic cells were at 450g for 5 
minutes unless otherwise stated. All incubations were at 37°C with 5%CO2 in a 
humidified incubator. 
2.4.1 Passage of COS-7 Cell Line 
COS-7 cells are an African green monkey kidney epithelial cell line. This cell 
line expresses large quantities of recombinant antigens from transfected plasmid 
DNA. 
Adherent cells were grown in complete DMEM media (cDMEM: DMEM; 
Gibco 41965-039,10% FCS Harlan Serolabs 10108-165, L-glutamine Gibco 25030- 
032, penicillin-streptomycin Gibco 15070-022), in 25 or 75cm2 vented tissue culture 
flasks (Costar). Cells were split when -80% confluent, as follows. The media was 
poured off and discarded. The cells were washed in Hanks balanced salt solution 
(Sigma H9394) to remove any residual media or dead cells and then treated with 
5m1 of IN trypsin EDTA solution (Gibco) made up in Hanks solution. The flask 
was incubated at 37°C for no more than 5 minutes after which the cells could be 
dislodged. The trypsin was inactivated by adding 45m1 cDMEM and mixing gently. 
The cell suspension was then centrifuged and the cell pellet resuspended in 
cDMEM. To maintain the cell line, typically, 10% of this volume was added to a 
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new 75cm2 flask, the final volume of which was made up to 20m1 cDMEM and then 
re-incubated at 37°C, 5%C02. 
2.4.2 Passage of Non-Adherent Cell Lines 
P815/c and RBL5/c cells were used in CIL assays. Both cell lines were 
kindly provided by Reinhold Schirmbeck, Institute of Medical Microbiology and 
Immunology, University of Ulm. 
Both cell lines had been transfected with HBcAg CD8+ epitopes: P815, an 
H-2d mastocytoma cell line expressed an H-2ý epitope, while the Rauscher virus- 
transformed T lymphoma line RBL5 expressed an H-2b epitope (Kuhrober et aL 
1996); (Kuhrober et al. 1997). 
These lines were cultured in complete RPMI (cRPMI: RPMI 1640, Sigma 
R8055,10%FCS, L-glutamine, penicillin/streptomycin, 0.05mM (3-mercapto- 
ethanol) in 75cm2 vented tissue culture flasks. Cells were passaged by taking 
typically 10% of the cell culture, adding these cells to a new flask and making it up 
to the previous volume with fresh cRPMI. 
2.4.3 Lipofectamine Transfection of COS-7 Cells 
COS-7 cells were seeded into a 24 well plate at 1-5x105 cells/well, in 1ml 
cDMEM per well. The plates were incubated for 24 hours at 37°C, and 5%CO2. 
The cRPMI was removed from the wells and replaced, following a wash with lml 
Hanks solution, with lml cDMEM minus antibiotics. 
DNA was added to lipofectamine at a ratio to ensure that for each 2p1 of 
lipofectamine delivered per well, the complexes contained up to 19g DNA. These 
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complexes were prepared by admixing 50µl of the DNA, resuspended in 
incomplete RPMI, with 5Oµ1 of lipofectamine solution. The mixture was then 
incubated for 20 minutes to allow DNA/lipofectamine complexes to form. To 
transfect the cells, the media above the cells was removed and replaced with 1O0µ1 
of DNA/lipofectamine mixture per well. After 4 hours at 37°C, an additional 900µl 
of cDMEM was added to each well and the plates returned to the incubator for up 
to 72 hours. 
To measure the level of protein produced from the DNA vaccine, cells were 
recovered from the wells using trypsin 72 hours after transfection. The cells were 
then lysed using high speed centrifugation (14krpm for 10 minutes) and the 
resultant material was concentrated at least 5 fold by allowing evaporation of the 
water. Samples were then assayed for the presence of the protein by dot-blot as 
described earlier. 
2.4.4 Salmonella Invasion Assays 
Adherent, confluent monolayers of J774 mouse macrophages were prepared 
in 24-well plates by seeding at 1x105 cells/well 24 hours before starting an infection 
assay. To ensure antibiotics used in the media during routine passage of the cells 
did not affect bacterial viability, cells were washed with incomplete RPMI 1 hour 
prior to the start of the experiment. 
10µ1 of Salmonella from an overnight culture were added per well (the precise 
number of bacteria was subsequently determined by preparation of viable counts), 
giving an initial dose of approximately 1x10' bacteria per well. To bring the bacteria 
into close proximity to the cell monolayer, the plates were centrifuged at 450g for 5 
minutes. Bacteria were then allowed to interact with the cells for 2 hours before 
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free bacteria were removed by washing with sterile PBS. Extracellular bacteria were 
killed by the addition of incomplete RPMI containing 100µg/ml gentamycin for a 
minimum of 1 hour. At various time points following this treatment, monolayers 
were washed and cells lysed with 1% triton X 100. Serial dilutions of the contents 
of each well were prepared and plated out to quantify the number of viable 
intracellular bacteria. These are expressed as colony forming units (CFU)/ml. 
2.5 In Vitro Immunoassays 
2.5.1 Enzyme Linked ImmunoSorbent Assays (ELISAs) 
2.5.1.1 ELISA to Determine Serum Antibody Levels 
Sera were prepared from blood samples taken from mice by hypodermic 
needle from the tail vein or from cardiac bleeds. Serum was routinely separated 
from the red blood cell component by centrifugation at 14,000rpm for 5 minutes. 
96 well ELISA plates (Corning Costar 96 well ELISA plates 3590) were 
coated with the appropriate antigen (e. g. HBcAg; Biodesign international R3B601, 
at 0.5µg/4 in sodium carbonate coating buffer (O. 1M Na2HCO3 in distilled water 
at pH 8.2) in a final volume of 50µ1/well. The plates were then incubated for a 
minimum of 2 hours at 37°C before being washed with PBST. Wells were then 
blocked with 150µ1/well 10% newborn calf serum (NCS; Gibco 16010-159) in PBS 
and incubated for another hour at 37°C. Plates were washed as before and dilutions 
of mouse sera prepared in 10% newborn calf sera. Samples were tested from 1: 50 
for sera (neat for mucosal washes) in the top well and serially diluted by 5 fold 
increments. This gave a range of dilutions from 1/50 to '1/3.9x106. In addition, 
on each plate, a standard positive and negative control sera was added at the same 
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dilutions. This allowed direct comparison of data from different samples tested on 
the same day or samples tested on different days. 
Following addition of the sera, plates were returned to the incubator for a 
minimum of 1 hour. Following careful washing of the plates (using PBST) 50µl 
detecting antibody was added (e. g. rabbit anti-mouse HRP conjugated antibody; 
Dako P0260, diluted to 1: 1000 in 10% NCS/PBS'1) to each well. The plates were 
again incubated for a minimum of 1 hour before being washed and developed using 
50µ1 of substrate solution (0.051 citric acid, 0.125M Na2HPO4,0.006% H2021 1 
tablet O-phenyldiamine-dichloride (OPD; Sigma P-8287) per 50m1). Once the 
maximum colour change had been completed (5-15 minutes), the reaction was 
stopped by the addition of 50µ1 of 3M HC1 per well, which inactivates the enzyme. 
The colour change in the wells was then measured and the absorbance recorded. 
Plates were read on an Elx 808 Ultramicroplate reader (Bio-tek instruments 
inc. ) at a wavelength of 490nm. The data were analysed using the program 
Kineticalc 4 (Bio-tek instruments) and Microsoft Excel. Endpoint titres were 
calculated as the reciprocal of the highest dilution, which gave an absorbance of 
0.3U above the background absorbance observed in the negative control wells. All 
titres were standardised against the same positive control sera. 
25.1.2 ELISA to Measure Immunoglobulin A at Mucosal Surfaces 
These ELISAs were carried out in a similar manner to those for serum 
antibody with the following exceptions. Firstly, mucosal washes were added neat to 
the top row of the ELISA plate (and then diluted using 5 fold serial dilutions down 
the plate, as with serum samples). Secondly, the detection antibody used in these 
assays was an a-chain specific goat anti-mouse biotinylated antibody (Sigma B- 
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2766) diluted at 1: 500. Binding of this antibody was subsequently detected using 
streptavidin-horse radish peroxidase conjugate (Dako P0397) added to the wells at a 
concentration of 1: 1000. 
2.5.1.3 ELISA to Determine Lip opolysaccharide-SpecifcAntibodyLenels 
The coating antigen used in these ELISAs was S. typhimurium LPS (Sigma L- 
6511). This was prepared by dissolving 500µg of LPS in 1m1 5x Reggiardo's buffer 
(0.25M glycine, 0.5M NaCl, 0.005M EDTA, 0.25M NaF) and then adding 4m1 
distilled water, providing antigen sufficient to coat a single ELISA plate at 
50µ1/well. The remainder of the assay for detection of LPS specific antibodies is 
otherwise identical to that described above. 
2.5.2 Preparation and Culture of Murine Lymphocytes 
Mice were killed by cardiac bleed under terminal anaesthesia followed by 
cranial dislocation. Spleens and lymph nodes were then recovered and stored in ice- 
cold RPMI media until required. To generate single cell suspensions, tissues were 
placed in sterile petri dishes and were crushed using the blunt end of a sterile 
disposable syringe with the rubber cap removed. Cells were then recovered in 
approximately 5ml of sterile RPMI. To purify single cell suspensions from spleen 
tissues, the crushed tissue was additionally subject to a brief centrifugation step (to 
remove large masses of debris and connective tissue) and the supernatants were 
decanted into fresh tubes. The cells were then pelleted by centrifugation and 
erythrocytes removed by the addition of iml ACK red blood cell lysis buffer 
(160mM NH3,100mM KHCO3,100mM EDTA) for 2 minutes. This reaction 
was then stopped by addition of 5 volumes of RPMI and unlysed white cells 
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recovered by centrifugation at 200g for 10 minutes. In contrast, cells from the 
lymph nodes were passed through sterile 100µm nylon mesh, (`nytex' Cadlish) to 
remove any remaining debris and adipose tissue, and then cells pelleted by 
centrifugation. 
Once single cell suspensions were prepared they were counted using a 
haemocytometer before being used in further applications. 
2.5.3 Magnetic Cell Separation (MACS) 
In order to isolate a particular cell type from a population (either to be used 
as the sole cell type in an assay or to be specifically excluded from an assay) cells 
were sorted using a magnetic cell separation system. To label the cells with the 
appropriate magnetically tagged antibody, cells were initially resuspended in MACS 
buffer (0.5%BSA, 2mM EDTA in sterile PBS) at 1x10' cells per 9Oµ1 buffer. l0µ1 
of MACS beads bound to antibody of the appropriate specificity (Miltenyi Biotec) 
were added to every 10' cells. The cells and beads were incubated together at 4°C 
for 15 minutes. The cells were then washed to remove any unbound antibody and 
the cells finally resuspended in lml MACS buffer. 
A washed magnetic column (LS 130-041-306) was then placed in the MACS 
magnet and the labelled cell suspension added. A collection tube was placed under 
the column and the column washed through with a minimum volume of 5m1 of 
MACS buffer. This ensured the removal of any unbound cells. 
For positive selection, e. g. T cell selection, the flow through was discarded 
and the T cells collected by removing the column from the magnet, adding 5m1 
more MACS buffer and expelling the cells into a new collection tube. 
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For positive deletion, e. g. B cell depletion, the flow through was retained 
and the column, containing bound B cells, was discarded. 
The selected cells were counted, washed and resuspended in cRPMI for 
further applications. 
2.5.4 Preparation of APCs for Proliferation Assays 
25.4.1 Irradiation ofAPCs 
Spleen cells were separated into a single cell-suspension and irradiated with 
2500 rads from a Cobalt-60 source. 
25.4.2 Mitomycin C Treatment ofAPCs 
Cells were treated with 50µg mitomycin C (Sigma) per 10' APCs and 
incubated for 75 minutes. The cells were washed in a large volume of culture 
medium four times to remove all traces of mitomycin C prior to use in cultures. 
25.4.3 Culture ofMurine DCs 
DCs were prepared from culture of bone marrow cells prior to the 
proliferation assay (Lutz et al. 1999). The femur was removed from recently killed 
mice of the same strain to be examined in the proliferation assay. The marrow was 
removed by washing with sterile PBS and a single cell suspension prepared. The 
cells were incubated in 75m1 flasks in 20m1 of complete RPMI containing 2m1 GM- 
CSF solution. The GM-CSF was a kind gift of Dr. J. Brewer (University of 
Glasgow) and was obtained from transgenic cell line supernatants (Zal et aL 1994). 
Cells were incubated and fed with fresh media containing GM-CSF (9m1 cRPMI 
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plus 1ml GM-CSF) 3 and 6 days later. On the 7' day cells were harvested and used 
as mature APCs in the proliferation assay. 
2.5.5 Proliferation of Restimulated Lymphocytes Measured by 
Tritiated Thymidine Incorporation 
Following preparation of a single cell suspension of the appropriate 
lymphocyte population, cells were added to the wells of a round-bottomed 96 well 
plate (Corning/Costar L6950) at a concentration of 105 cells/well in a final volume 
of 100µL Cells from each experimental group of mice were added to 12 wells, to 
give four sets of triplicate wells, which were then tested using 3 different 
concentrations of restimulating antigen. Following addition of antigen, cells were 
incubated for 72 hours and then pulsed with 1 tCi 3H-thymidine (Amersham) per 
well. The plates were incubated for a further 12-16 hours before harvesting. 
Cells were harvested onto a glass fibre filtermat using an automated MACH 
III cell Harvester (TomTec, USA). These mats were then dried before being placed 
in a plastic sample bag with 4m1 scintillant and analysed using a Trilux 
MicroBetacounter (PerkinElmer). Measured counts per minute (cpm) were 
generated for each well and mean data and standard deviations calculated using 
Microsoft Excel. 
2.5.6 Cytotoxic T lymphocyte Killing Assay 
25.61 SDayRestimulation 
The appropriate target cells (ie. RBL5/c or P815/c, see tissue culture 
protocols) were grown up in bulk prior to recovery of CTLs from immunised 
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animals. The target cells were centrifuged and resuspended in an appropriate 
volume of cRPMI. To prevent proliferation of these cells, 50µg mitomycin C was 
added per 10' cells. The cells were incubated for 75 minutes (37°C, 5%CO) and 
then washed 4 times in cRPMI. 
Single cell suspensions of spleen cells were added to the target cells in 25cm2 
tissue culture flasks at a final concentration of 1.5x106 target cells and 
3x107splenocytes. To ensure the generation of sufficient effector cells, 4 or 5 flasks 
were prepared per experimental group and amplification was allowed to proceed by 
incubation of the two populations for 5 days at 37°C, 5%CO2. 
25.6.2 S'Chtom! um Release Assay 
To label the target cells, 2x10' fresh target cells and the same number of 
control cells, were incubated separately with 5MBq sodium chromate (51Cr) each, 
for 120 minutes. 
Restimulated cells from 5-day incubation were washed, counted and 
resuspended at 1x108/ml. These cells were plated out in four rows of 6 wells 
containing two-fold dilutions from 10' cells/well to 1.25x106 cells/well. To half of 
these wells 105 target cells were added whilst the equivalent numbers of control cells 
were added to the remaining wells. This gives effector : target cell ratios ranging 
from 100: 1 to 12.5: 1. As controls, six wells were prepared which contained either 
no antigen or effector cells. To allow estimation of the uptake of Cr" by the cells, 
three of these wells were treated with 10% Triton-X100. This completely lyses the 
cells and releases the radioactivity into the surrounding media. 
The target and effector cells were allowed to interact for 4 hours before 25µ1 
of media from above the cells was carefully removed and transferred to a flexiplate 
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where it was mixed with 150µl scintillation fluid. The amount of radioactivity 
present in each well was analysed using a Trilux Microbeta plate reader. Percentage 
lysis was calculated as: 
" 2.5.7 Cytotoxic T lymphocyte IFN-y Secretion Assay (ELISPOT) 
T cells were isolated using the pan T cell MACS beads as described 
previously and restimulated with target cells for 5 days. 
To allow detection of IFN-y release, a 96 well multiscreen plate (Millipore) 
was coated with 5Oµ1 of anti mouse IFN-y antibody (Phamiingen, UK. 5µg/ml) 
overnight at 4°C. The plates were the washed and blocked for 1 hour in cRPMI 
before addition of the restimulated cells. The isolated T cells were added in 
duplicate wells to APCs that had previously been treated with antigen or CD8+ 
peptide and the volume of media in each well made up to 2O0µ1 using cRPMI. The 
cells were then co-incubated for 20 hours before removal by vigorous washing. 
IFN-y released and captured was then detected using a biotinylated anti-IFN-y 
antibody (Pharmingen, UK; 1µg/4, which was added in cRPMI for 1 hour at 
37°C. 
To detect the bound biotinylated antibody the plates were treated with 
100µ1 extravadin alkaline phosphatase at 1: 1000 of a 1.5mg/ml solution and 
incubated for 1 hour. The plate was then washed and 5Oµ1 of insoluble developing 
solution added (30mg tablet of BCIP/NBT in 10ml distilled water) to each well. 
Spots then developed on the base of the wells and were counted using a low 
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powered microscope at 32x magnification. Mean counts of triplicate wells were 
calculated. 
Finally, the number of antigen specific IFN-y producing cells was 
determined by subtracting the number of spots observed in wells containing 
unstimulated cells from those which had been stimulated with peptide or protein. 
2.6 In Vivo Protocols - Vaccinations and Acquisition of 
Samples 
2.6.1 Intra-muscular (i. m. ) Protein and DNA Vaccination 
Mice were immunised in the hind quadricep by hypodermic injection. 
Vaccine DNA or protein was delivered in a volume of l00µ1 sterile, LPS-free PBS, 
50µl to each leg. 
2.6.2 Gene Gun DNA Vaccination 
24 hours prior to vaccination the region of the skin to be immunised was 
shaved. When vaccinating, the gene gun was positioned against the mouse skin, 
separated by a 2.5cm spacer, and the coated gold particles driven into the skin using 
helium pressurised to 40psi 
2.6.3 Intra-Gastric Immunisation with Salmonella 
S. typhimurium BRD 509 were grown statically overnight at 37°C. They were 
harvested by centrifugation in a Sorval SS34 rotor, washed in LPS-free PBS and 
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resuspended to 5x101° bacteria/mL Bacteria were delivered to anaesthetised mice 
using a gavage needle in a final volume of 2O0µ1. 
2.6.4 Collection of Blood Samples 
Sample bleeds were taken from mice at stages throughout experiments. 
Hypodermic needles were used to extract approximately 50µ1 of blood from the tail 
vein of restrained mice. Samples were allowed to clot for approximately 3 hours at 
room temperature or overnight at 4°C. The samples were then centrifuged at 
10,000g for 5 minutes and the supernatant collected. This serum was then further 
cleaned by centrifugation for a further 10 minutes and removal of the supernatant 
to a fresh tube. Samples were stored at -80°C. 
If serum samples were required at the end of the experiment, mice were 
terminally anaesthetised with halothane and exsanguinated by cardiac puncture. 
2.6.5 Collection of Mucosal Washes 
26.5.1 Nasal and Pulmonary Washes 
Following exsanguination, the trachea of the mouse was exposed and 
punctured. A sharpened, fine tipped pastette was used to infiltrate the lungs with 
up to 1.5m1 of 0.1% BSA in PBS. Following 3-4 flushings, as much of the fluid as 
possible was recovered and used in subsequent analysis. 
Nasal washes were obtained by separating the head of the mouse from the 
body and removing the lower jaw. A fine-tipped pastette was used to introduce 1ml 
of 0.1% BSA in PBS via the Eustachian tube through the nasal passages of the 
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mouse. Samples were collected as this wash emerged from the nostrils of the 
animal. Samples were stored at -20°C prior to analysis. 
2.6.5.2 Intestinal Washes 
The upper intestine was dissected from the body and separated into -5cm 
sections. Digested material was gently removed from each section and the tissue 
was washed through twice with 1.5m1 of PBS containing 0.1% BSA and 1mM 
Phenyl-methane-sulphonyl-fluoride (PMSF). Samples were stored at -20°C prior to 
analysis. 
2.7 Statistics 
Data were analysed with Student's two-sample t test using Microsoft Excel. 
Differences in variation were calculated and taken into account when deciding 
whether to use the test for equal or unequal variance. The p values shown in the 
text indicate the probability of the two samples analysed being different. Values 
over 0.95 were considered significant. 
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3 RESULTS - VACCINE DEVELOPMENT 
3.1 Chapter Aims 
The aim of work described in this chapter was to characterise the different 
vaccine formulations used in the course of this project. This includes their 
preparation prior to their testing in the. 
3.2 Introduction 
Investigations carried out during the course of this project were based on 
the presentation of one antigen, HBcAg, to the immune system using different 
vaccination techniques. Whilst some of these vaccines were prepared from 
commercially available material, others were synthesised in the laboratory. 
Following production, each vaccine type required characterisation in vitm, to 
demonstrate the suitability of the formulation for vaccine delivery. 
3.3 Routes and Types of Vaccine 
Although based on the delivery of the same antigen, this study aimed to 
consider the type of immune response generated when the antigen is delivered in 
three very different forms: 
" as a purified recombinant protein, 
" encoded on purified plasmid DNA vaccine 
" expressed from a plasmid DNA carried by an attenuated strain of 
Salmonella. 
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In addition, the antigens were delivered either parenterally or mucosally. 
The different methods of vaccination used are described in Table 3-1. 
3.4 Vaccine Formulations 
3.4.1 Purified HBcAg Vaccinations 
Purified HBcAg obtained from a commercial source was used for both 
parenteral and mucosal vaccinations. This recombinant protein, obtained from 
Biodesign International, (product number R3B601), was expressed in P. pastoris 
from an expression vector encoding the entire 183 amino acids of the antigen. The 
resultant 21kDa protein was described as having purity of >95% and required only 
dilution in PBS prior to vaccination. However, to ensure the protein was as 
described in the certificate of analysis, it was additionally analysed prior to use by 
PAGE, Western blot and by electron microscopy (conducted as described in 
Materials and Methods sections 2.3.2,2.3.3 and 2.3.5). Figure 3-1A shows that 
under denaturing conditions, the protein can be seen as a monomer of 
approximately 21KDa. Figure 3-1B shows that by Western blot this protein reacts 
strongly with polyclonal anti-HBcAg sera. In addition, the same blot shows two 
additional bands of approximately 42 and 64KDa. It is believed that these bands 
represent dimers and triiners of the protein. This indicates the strength of binding 
between monomers, which treatment with P-mercaptoethanol failed to reduce 
entirely to the monomeric form. 
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Route of Vaccination Vaccine Formulation 
Parenteral Intra-muscular DNA expressing HBcAg 
Gene gun DNA expressing HBcAg 
Intra-muscular Purified HBcAg protein 
Mucosal Intra-nasal Purified HBcAg protein 
Intra-gastric Attenuated Salmonella expressing HBcAg 
Table 3-1: Vaccination strategies examined throughout this project 
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Figure 3-1: Characterisation of commercial HBcAg under denaturing 
conditions by SDS PAGE and Western blot analysis 
I, 'igurc 3-1 A shows different quantities of I IBcA g visualised by Coomassie blue 
stain. Lanes I-5 contain 1). 25µg, O. Sµg, 0.75µg, 1.0µg and 1.5µg of protein. Lane 
M contains standard markers. 
Figure 3-113 shows the binding of anti-HBcAg antibody to the protein. Lanes 1-3 
contain I. 5µ1;, 1.0µ1; and 0.5µ1; of protein. 
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To confirm that the purified material was particulate in nature at the time of 
vaccination, the material was also analysed by transmission electron microscopy. A 
negatively stained sample of the HBcAg is shown in Figure 3-2. This clearly shows 
assembled core particles of the expected size; approximately 350 Angstrom (see 
Introduction section 1.6.3, Structure and Immunogenicity of the Core Antigen). 
3.4.2 Generation of a Naked DNA Vaccine Encoding HBcAg 
A DNA vaccine containing the cloned HBcAg sequence under the control 
of the CMV promoter was generated using the Invitrogen plasmid pcDNA3.1+ as 
the backbone of the construct (see Figure 2-1). 
3.4.2.1 Plasmid Construction 
The sequence of hepatitis B virus core antigen (HBcAg) used for cloning 
was obtained from the plasmid ptrr/core, a kind gift from MedevaPharama PLC. In 
this plasmid, the HBcAg is expressed under the control of a prokaryotic promoter, 
which allows the production of this protein in bacteria. 
In order to create a plasmid that could be used in DNA vaccination, the 
sequence was cloned into the plasmid pcDNA3.1 (Invitrogen P790-20) using the 
strategy outlined in Figure 3-3. In brief, primers were designed (BJS 1 and BJS 2, 
see Table 2-3) that would amplify the HBcAg DNA and introduce restriction 
enzyme cutting sites close to the 5' (Hind III) and the 3' (BamH I) ends of the PCR 
product. After removal of the enzyme and buffer salts using the Qiagen PCR 
purification kit, the PCR product was subjected to digestion with Hind III and 
BamH I (see Materials and Methods section 2.2.5). The digested DNA was then run 
on a 0.8% agarose gel and the DNA fragment cut and purified from the gel (Qiagen 
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gel extraction kit). Simultaneously, the vector pcDNA3.1 was digested with the 
same enzymes and purified using the same method. The purified HBcAg sequence 
and pcDNA3.1 fragments were combined and ligated to give a new plasmid, 
designated pcDNA3.1/core, which was transformed into competent E. coli XL10. 
Ampicillin resistant colonies were then screened by PCR for the presence of the 
HBcAg sequence using specific primers (BJS4 and 5), see Figure 3-4. Insertion of 
the HBcAg sequence was additionally confirmed by digest of plasmid isolated from 
PCR positive colonies. Figure 3-5 shows single and double digests of both the 
original plasmid (pcDNA3.1) and the cloned plasmid pcDNA3.1/core. Whilst it is 
difficult to observe a difference of 500bp between the plasmids following 
linearisation with a single enzyme (lanes 2 and 5), a fragment of approximately 
550bp is visible when pcDNA3.1/core is digested with both enzymes (lane 6). This 
corresponds to the size of the HBcAg gene. This band is absent when pcDNA3.1 
is similarly digested (lane 3). To verify the sequence of the cloned DNA, the 
isolated plasmid was sequenced. The data in Table 3-2 confirms the expected 
sequence of the inserted DNA. 
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Figure 3-2: Electron micrograph showing assembled HBcAg particles 
Transmission electron microscopy of a negatively stained sample of commercially 
obtained I McAg expressed in P. pastonc, viewed at 8O, 000x magnification. 
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Figure 3-3: Schematic showing the cloning steps involved in the generation 
of pcDNA3.1/core 
The HBV core sequence was amplified from ptrc/core by PCR with modified 
primers encoding the restriction enzyme recognition sites Hind III and BamH I 
flanking the HBcAg reading frame. The PCR product was digested with Hind III 
and BamH I and ligated to the similarly digested plasmid pcDNA3.1. The resulting 
construct, designated pcDNA3.1/core, expresses the HBV core sequence under the 
control of a eukaryotic promoter. 
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Figure 3-4: Screening of E. coli XL-10 bacteria for the presence of HBcAg 
DNA following transformation with pcDNA3.1/core 
Following the transformation of V. ro/i with the pcDNA3.1/core plasmid, the 
presence of the core sequence was confirmed by PCR using primers internal to the 
FIBV core sequence. "These primers were expected to amplify a band of 
approximately 450hp, which was observed in all ampicillin resistant colonies 
screened (lanes 1-6). No such band was present when PCR was conducted using 
untransformed, ampicillin sensitive I;. co/i (lane 7). 
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Figure 3-5: Confirmation of insertion of HBcAg sequence by restriction 
digest of pcDNA3.1 and pcDNA3.1/core plasmids 
Lanes 1,2 and 3 contain undigested, singly digested (I lind III) and doubly digested 
(Rawl I I) pcl)N; A3.1 respectively. Lanes 4-6 contain the same digests of 
pcl)N A3.1 /core. 
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Position Sequence: top row pcDNA3.1 core 
bottom row ptrc/core 
1 ATGGACATTGACCCTTATAAAGAATTTGGAGCTACTGTGGAGTTACTCTC 
ATGGACATTGACCCTTATAAAGAATTTGGAGCTACTGTGGAGTTACTCTC 
51 GTTTTTGCCTTCTGACTTCTTTCCTTCCGTCAGAGATCTTCTAGACACCG 
GTTTTTGCCTTCTGACTTCTTTCCTTCCGTCAGAGATCTTCTAGACACCG 
101 CCTCAGCTCTGTATCGAGAAGCCTTAGAGTCTCCTGAGCATTGCTCACCT 
CCTCAGCTCTGTATCGAGAAGCCTTAGAGTCTCCTGAGCATTGCTCACCT 
151 CACCATACTGCACTCAGGCAAGCCATTCTCTGCTGGGGGGAATTGATGAC 
CACCATACTGCACTCAGGCAAGCCATTCTCTGCTGGGGGGAATTGATGAC 
201 TCTAGCTACCTGGGTGGGTAATAATTTGGAAGATCCAGCTAGCAGGGATC 
TCTAGCTACCTGGGTGGGTAATAATTTGGAAGATCCAGCTAGCAGGGATC 
251 TAGTAGTCAATTATGTTAATACTAACATGGGTTTAAAGATCAGGCAACTA 
TAGTAGTCAATTATGTTAATACTAACATGGGTTTAAAGATCAGGCAACTA 
301 TTGTGGTTTCATATATCTTGCCTTACTTTTGGAAGAGAGACTGTACTTGA 
TTGTGGTTTCATATATCTTGCCTTACTTTTGGAAGAGAGACTGTACTTGA 
351 ATATTTGGTCTCTTTCGGAGTGTGGATTCGCACTCCTCCAGCCTATAGAC 
ATATTTGGTCTCTTTCGGAGTGTGGATTCGCACTCCTCCAGCCTATAGAC 
401 CACCAAATGCCCCTATCTTATCAACACTTCCGGAAACTACTGTTGTTAGA 
CACCAAATGCCCCTATCTTATCAACACTTCCGGAAACTACTGTTGTTAGA 
451 CGACGGGGCCGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAG 
CGACGGGGCCGAGGCAGGTCCCCTAGAAGAGAACTCCCTCGCCTCGCAAG 
501 ACGCAGATCTCAATCGCCGCGTCGCAGAAGATCTCAATCTAGGGAATCTC 
ACGCAGATCTCAATCGCCGCGTCGCAGAAGATCTCAATCTAGGGAATCTC 
551 AATGTTAG 
AATGTTAG 
Table 3-2: Sequence analysis of cloned HBcAg in pcDNA3.1/core 
This table shows a comparison of the cloned sequence with that of the known 
sequence from the ptrr/core plasmid. The sequence shown in the top row is that of 
pcDNA3.1/core and that in the bottom row is ptn? /core. The sequences are 
identical. 
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3.4.22 Expression ofHBcAg from pc)NA3.1/core in Eukaryotic Cells 
As expression of the core antigen in eukaryotic cells is a prerequisite for the 
vaccine to function, it was necessary to determine whether the newly synthesised 
pCDNA3.1/core plasmid was able to express antigen in vita. This was 
demonstrated by transformation of COS-7 cells with pcDNA3.1/core using 
lipofectamine (see Materials and Methods section 2.4.3). Initially, cellular samples 
were subject to standard PAGE gel and Western blot analysis. However, these 
experiments failed to reveal any expression of the antigen. To improve the 
sensitivity of the assay, lysed cellular debris was dotted directly onto nitrocellulose 
membranes and a chemiluminescent secondary antibody used in the staining 
procedure (section 2.3.4). Using this method, the sensitivity could be improved 
from a lower limit of approximately 500ng using standard Western blot to between 
1-10ng using the dotblot. Comparison with samples of the commercial HBcAg 
showed that cells transfected with pcDNA3.1/core were able to express around 5ng 
of protein per 104 transfected COS-7 cells (Figure 3-6). 
Confirmation that this plasmid could direct the expression of antigen in 
eukaryotic cells suggested that the DNA generated could function as an effective 
DNA vaccine. Immune responses to DNA vaccination via two routes of 
immunisation were to be considered; i. m. and by particle bombardment with a gene 
gun- 
3.4.2.3 Large Scale Preparation ofDNA 
Large quantities of pcDNA3.1/core were required for use in vaccination 
experiments. Following confirmation of eukaryotic expression, a large-scale 
preparation of the plasmid was undertaken. Using a Qiagen Megaprep Kit plasmid 
was isolated and then characterised by digestion with Hind III and BamH I to 
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confirm the presence of the core sequence. The DNA isolated quantified by UV 
spectrophotometry. Table 3-3 shows typical values recorded for the purity and 
concentration of the DNA sample by W spectrophotometry. From a culture of 
500ml, approximately 1-2mg of DNA was generated. This procedure was carried 
out on several occasions and each batch was characterised as described above. 
3.4.24 Measurement ofLPS Contamination ofDNA 
To determine the level of LPS present in the purified plasmid 
pcDNA3.1 /core, LAL assays was performed on each batch of DNA prepared (see 
Materials and Methods section 2.2.13). Results of these tests showed that the 
plasmid produced was clean and uncontaminated (less than O. lIU/100ug of DNA). 
3.4.25 Preparation of Gene Gun Cartridges 
In brief, purified DNA was bound to l pm-diameter gold particles, which 
were then attached to the inside of a hollow plastic tube (external diameter 
approximately 2mm) using a special rotating apparatus to ensure an even coating of 
particles. Following attachment, the tubing was cut into 8mm-long sections, which 
could then be used as cartridges in the gene gun. The method is more fully 
described in Materials and Methods section 2.2.1.1. 
The DNA attached to the cartridges was quantified by soaking the prepared 
cartridges in Tris/HC1 overnight. The resultant supernatant was analysed by UV 
spectrophotometry. Typical results of this analysis are shown in Table 3-4 and 
confirm that approximately 1 µg of each vector was bound per cartridge. 
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Figure 3-6: Expression of HBcAg in COS 7 cells 
1, 'xpressi<on of antigen in cells transfected with either pclNA3.1/core (sample a), 
pclNA3. l (sample b) or untransformed cells (sample c). I? xpression detected by 
polyclonal mouse anti- Ii BcAg and rabbit anti-mouse HRP detected with chemi- 
luminescent substrate. V ach sample represents _104 hosed cells. The standard 
represents different quantities of commercial I IBcAg dotted onto the membrane. 
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Sample OD260 OD2so OD2601280 Concentration 
(of 100x dilution) (of 100x dilution) of neat sample 
(mg/ml) 
pcDNA3.1 0.354 0.187 1.893 1.77 
pcDNA3.1/core 0.468 0.252 1.857 2.34 
Table 3-3: Spectrophotometric analysis of DNA samples prepared by Qiagen 
Megaprep 
Two typical examples of calculated concentrations of DNA purified from a 500ml 
overnight culture of bacteria are given here. Values were calculated using the 
following formula: 
Concentration (ng) = 5OxOD2. 
The level of protein contamination of the sample is calculated by: OD,, = OD. o. 
Protein contamination of the sample leads to significantly reduced values and 
renders the concentration calculation invalid. A value of 1.8 in a DNA sample is 
considered to be uncontaminated (Sambrook et aL 1989). This shows the DNA 
produced was of high quality. 
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Sample Test 
cartridge 
number 
OD260 ODsso DNA 
recovered 
Group mean 
(µg), standard 
deviation 
pcDNA3.1/core 1 0.206 0.161 1.03 1.102,0.174 
2 0.297 0.126 0.985 
3 0.185 0.126 0.925 
4 0.266 0.171 1.33 
5 0.248 0.181 1.24 
pcDNA3.1 1 0.264 0.192 1.32 0.975,0.179 
2 0.222 0.174 1.11 
3 0.193 0.139 0.965 
4 0.220 0.166 1.1 
5 0.145 0.131 0.725 
Table 3-4: Measurement of DNA from gene gun cartridges 
DNA was recovered from cartridges by overnight treatment with Tris/HCL DNA 
recovered was calculated as [ODo]x50 = [DNA concentration] tg/mL Samples 
were 1 O0µ1 volume. 
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3.4.2.6 Attenuated Salmonella Vaccine Expressing HBcAg 
The S. typhimurium strain used in these studies contained two attenuating 
deletions in the aroA and aroD genes (strain designated as BRD509). Expression of 
HBcAg was driven from the plasmid pGA-1, which encodes the protein under the 
control of an anaerobically induced promoter (nirB). As pGA-1 was provided in the 
first instance in E. coli, the first part of this work involved the transfer of the 
plasmid into the Salmonella strain. 
3.4.2.7 Generation of the Salmonella typhhnurium Vaccine Strain 
Two considerations rendered the transformation strategy somewhat 
complex. The first involved the need to avoid degradation of the plasmid by the 
Salmonella due to inappropriate methylation. To achieve this, the plasmid was 
initially transformed into an intermediate strain; S. typhimurium LB5010 (Bullas and 
Ryu 1983), a recA" strain that is unable to degrade the plasmid, but is able to 
methylate progeny plasmids appropriately for Salmonella. This has been described 
previously as a successful method for the production of Salmonella vaccine strains 
(Londono et al. 1996). This transformation was achieved by heat-shock of S. 
pphimurium LB5010, followed by selection of the transformed strain on agar 
containing ampicillin. 
The second problem was the maintenance of the LPS phenotype of S. 
typhimurium BRD509 during transformation. Straightforward heat-shock 
transformation can occasionally result in the loss of the O-antigen region of the LPS 
in the recipient bacterial strain. This gives the bacteria a `rough' phenotype and 
allows antibodies and complement to bind to the bacteria enabling rapid clearance 
and reduced exposure of the antigen, rendering the vaccine less effective (Ernst et al. 
2001; Freudenberg et ah 2001). Therefore an alternative method of transformation 
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was employed; the Salmonella specific bacteriophage P22 was used as a transfer 
vector between the two strains (as previously described by (Miller et al. 1989). 
Transformed S. fy imurium LB 5010 were infected with the phage. Due to the 
random nature of the packaging of DNA into virus particles, some of the resultant 
phage particles contain the plasmid instead of the P22 genome. The packaged 
DNA was then used to infect BRD 509 and any infectious particles were prevented 
from replication by addition of EGTA to the medium. Those bacteria in which 
plasmid had been successfully injected were then identified by their ability to grow 
on plates containing ampicillin. The presence of the plasmid within these clones 
was confirmed by PCR 
3.4.2.8 Characterisation of S. typhimurium BRD509 PGA-1 
To verify that this transformed strain (designated BRD509 PGA-1) was able 
to express HBcAg, the recombinant bacteria were grown under anaerobic 
conditions and antigen expression confirmed by Western blot (Figure 3-7). The 
band identified by HBcAg specific sera was approximately 28kDa in size. This is 
larger than previously observed HBcAg from P. pastorir (see Figure 3-1) and reflects 
the addition of a number of amino acids upstream of the start codon of the protein. 
These codons do not affect particle formation but have been shown to enhance the 
level of expression of the recombinant protein in E. coli (D. Rowlands, personal 
communication). 
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Figure 3-7: Expression of HBcAg from S. typhimurium BRD509 pGA-1 
Anaerobic overnight cultures of S. lyphimuri»m BRll509 pGA-1 were grown and a 
volume of culture that would give an ()D5 reading of 0.5 was centrifuged and the 
pellet resuspended in protein sample buffer. 't'hese samples were run on a 30°% 
acrylamide gel, transferred to nitrocellulose and visualised using polyclonal mouse 
anti-H13cAg antibody and II RP- conjugated rabbit anti-mouse antibody. Samples 1 
-5 are S. /yphimurinm 1381)5O9 pGA 1. Sample 6 is ß8D509 without the plasmid. 
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To ensure that the LPS profile of the transformed bacteria was intact, the 
bacteria were treated with proteinase K to remove the protein component and the 
remaining material was subject to SDS PAGE. The resultant gel was silver stained 
and the results shown in Figure 3-8. This figure shows the banding pattern 
associated with smooth LPS structure of S. t)phimurium with typical core and 0 
antigen sugars visualised. Comparison of the market lanes (LPS samples lacking 0 
antigen) with lane 1 (the original vaccine strain BRD509) illustrates the typical 
ladder feature associated with 0 antigen expression. From this figure, it would 
appear that no differences exist between the LPS profiles of BRD509 and LPS from 
the transformed strain BRD509 pGA-1 (lanes 2 and 3). Therefore S. typhimurium 
BRD509 pGA-1 has not lost the 0 antigen and has maintained the smooth 
phenotype of BRD509. 
To show that the transformed bacteria were still able to invade and persist in 
eukaryotic cells, an invasion assay in a macrophage cell line, J774, was conducted 
using a similar protocol to that described previously (Jones et al. 1993). Over a 
period of 72 hours, the number of viable bacteria recovered from infected J774 
macrophages was recorded. These data are shown in Figure 3-9 and indicates that 
the presence of the pGA-1 plasmid within the Salmonella strain does not affect the 
ability to both invade and persist in this cell line. Invasion of around 1% of the 
original inoculum occurs with both strains within the first 2 hours (and is in line 
with similar studies using this strain in the literature (Carlson et al. 2000)) and this 
level was maintained during the remaining 72 hours. 
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Figure 3-8: Silver-stained polyacrylamide gel comparing LPS from samples of 
S. typhimurium BRD509 and S. typhimurium BRD509 pGA-1 
This gel confirmed that the I. PS profile is unchanged in V. typhinrurium BR1)509 
following transformation with bacteriophage P22 containing the plasmid pGA-1. 
Lane 1 contains ITS from BR1)509, lanes 2 and 3 contain BRD509 pGA-1 ITS. NI 
arc markers containing I, PS without 0 antigen. 
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Figure 3-9: Number of bacteria recovered from infected J774 cells over time. 
Following infection of J774 cells with the S. typhimurium BRD 509 strains, non- 
infecting bacteria were killed with the addition of gentamycin. At 2,24,48 and 72 
hours after infection, cells were taken and lysed, the lysates plated out after serial 
dilution to give the number of infecting bacteria. 0 represents BRD509 and 
represents BRD509 pGA-1. 
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Characterisation of S. typhimurium BRD509 pGA-1 clearly demonstrates that 
the bacteria are able to express HBcAg and possesses a smooth LPS phenotype. 
The vaccine is therefore judged as being suitable for in vivo vaccination experiments. 
3.5 Summary 
The work described in this chapter describes the characterisation of each 
vaccine type in vitro. It shows that each vaccine behaved as expected and could 
subsequently be used with some confidence for in vivo experiments. 
132 
4 RESULTS - ASSAY DEVELOPMENT 
4.1 Chapter Aims 
The aim of the work described in this chapter was to develop 
immunological assays capable of measuring both humoral and cellular immune 
responses to HBcAg following vaccination of mice. Optimisation of the procedures 
used ensured the reproducibility and sensitivity of the assays. 
4.2 Introduction 
As the overall objective of this thesis was to determine the influence of 
route and form of immunisation on the magnitude and quality of the immune 
response induced, it was necessary from the outset to define which aspects of the 
immune response should be measured. As the emphasis was on vaccine design, it 
was felt that such measurements be limited to aspects of the acquired immune 
response, in particular, to aspects of both the cellular and humoral response. The 
work outlined in this chapter describes the assays chosen for measurement of these 
responses and the modifications made in order to maximise the sensitivity and 
reproducibility of each method. 
4.3 Humoral Immune Responses 
Antibodies generated by B cells have a vital role in combating infection and 
protecting the host, through a number of functions including neutralisation and 
opsonisation of pathogens, activating complement and inducing NK-mediated 
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killing of infected cells. Antibody responses are important in the control of 
pathogens and toxins in the extracellular spaces of the body, including the mucosal 
surfaces, but through NK-mediated killing can also attack intracellular pathogens 
(see Introduction section 1.4.3). 
One of the oldest and simplest forms of measuring an immune response is 
to assay the quantity of serum antibody against a particular antigen. The assay used 
to measure serum antibody levels was an ELISA. 
4.3.1 Development of an HBcAg-Specific ELISA 
The sensitivity and reproducibility of an antigen specific ELISA can be 
affected by a number of factors, which were considered when optimising this assay. 
These include: 
a) The initial concentration of coating antigen added to the wells of the assay 
plate. Insufficient antigen bound to the surface of the well will reduce the 
upper detection limit of the assay, even when the quantity of antibody in the 
sample is still increasing. 
b) The coating buffer, in which the coating antigen is suspended, can affect the 
quantity of antigen bound to the plate; some antigens fail to bind effectively 
to plastic at neutral pH's, binding more effectively in alkaline conditions. 
c) The selection of blocking agent. This prevents the non-specific binding of 
unrelated antigens to the surface of the well. An inappropriate choice of 
blocking buffer can allow other antigens to bind, potentially increasing the 
background levels of substrate colour change and decreasing the overall 
sensitivity of the assay. 
134 
d) Concentration of horseradish peroxidase (HRP) conjugated secondary 
antibody. HRP is the enzyme that catalyses the change of colour when the 
reaction substrate (0-phenyl diamine - OPD) is added. Since the colour 
change is proportional to the quantity of HRP present, it is essential to use 
sufficient to allow full detection of antigen-specific antibody bound to the 
wells. 
These variables were examined to determine the optimal conditions that 
would allow clear and consistent assessment of antibody concentrations in different 
samples. In these optimisation experiments, a polyclonal mouse anti-HBcAg 
antibody raised by i. m. vaccination of mice with HBc-Ag in alum was used. This 
was known to contain a high concentration of antigen specific antibody and was 
therefore easy to detect. 
For all experiments, the ELISA was performed as described in Materials and 
Methods section 3.5.1.1, with variations outlined below. 
4.3.1.1 Coating Antigen Concentration 
Wells were coated with a range from 0 to 1µg/ml of the coating antigen, 
HBcAg. As the concentration of the coating antigen bound to the well is also 
dependent on the buffer in which the antigen is added, the antigen was coated 
independently into different plates, the first using carbonate buffer as the diluent 
and the second using PBS. The plates were blocked in 10% NCS and polyclonal 
mouse anti-HBcAg was added at 2µl/well. After incubation, a secondary antibody 
(rabbit anti-mouse HRP conjugated antibody) was added at a 1: 1000 dilution. 
Following addition of the substrate, colour was allowed to develop before the 
addition of acid to stop the enzyme activity. The colour change in the wells was 
then measured at a wavelength of 490nm and the absorbance recorded. 
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From this experiment, it appears that 0.5µg HBcAg saturated the wells of 
the plate. Figure 4-1 shows the effect of coating the wells of the ELISA plate with 
different concentrations of HBcAg. Figure 4-1A shows the absorbance from wells 
coated with antigen in carbonate buffer and 4-1B shows that of wells coated using 
PBS. The choice of buffer had a small impact on the assay sensitivity, with those 
wells coated with HBcAg in carbonate buffer showing a higher OD 
4.3.1.2 Selection of BlockingBui7er 
For blocking of non-specific binding to the wells, two buffers were 
considered; Newborn Calf Serum (NCS) and BSA. Wells were coated with 0. 
5 tg/ml HBcAg in carbonate buffer. Two plates were then blocked; one with 10% 
NCS and one with 1% BSA, for 1 hour at 37°C. The results are shown in Figure 4- 
2A (NCS) and 4-2B (BSA). These indicate that the buffers function similarly well. 
Since the NCS was relatively inexpensive compared to BSA, 10% NCS was used as 
the blocking agent in all subsequent work. 
4.3.1.3 Concentration ofAnti Mouse HRP Conjugated Antibody 
To determine the effect of varying the concentration of the conjugated 
antibody, various concentrations ranging from 1: 250 to 1: 5000 were used to detect 
the mouse antibody bound to HBcAg on the plates. Over the range of dilutions 
examined, a dilution of 1: 1000 was shown to provide greatest sensitivity. 
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Figure 4-1: Impact of coating antigen concentration and buffer on HBcAg- 
specific ELISA 
Wells were coated with different concentrations of coating antigen (HBcAg) in 
carbonate buffer (Figure 4-1A) or PBS (Figure 4-1B) and blocked with NCS. 
HBcAg was bound with polyclonal anti-HBcAg sera and detected with a 1: 1000 
dilution of HRP conjugated secondary antibody. " represent ODs from reactions 
containing secondary antibody at a 1: 1000 dilution. o represent ODs from 
reactions without secondary antibody. 
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Figure 4-2: Impact of blocking agent on HBcAg-specific ELISA 
Wells were coated with different concentrations of HBcAg in carbonate buffer, 
blocked with 10% NCS (Figure 4-2A) or 1% BSA (Figure 4-2B). HBcAg was 
bound with polyclonal anti-HBcAg sera and detected with a 1: 1000 dilution of 
HRP-conjugated secondary antibody. Negative control values (no anti-HBcAg sera 
added) were subtracted from the values shown. " represent ODs from reactions 
containing secondary antibody at a 1: 1000 dilution. o represent ODs from 
reactions without secondary antibody. 
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4.3.1.4 Optimised HBcAg-Specific ELISA 
To summarise, the final ELISA assay consisted of plates coated with 50µ1 of 
0.5µg/ml HBcAg in sodium carbonate buffer. Plates were blocked with 10% NCS. 
After the test antibody samples had been added, secondary antibody was added to 
wells at a dilution of 1: 1000. The plates were developed with OPD substrate and 
the OD 490 was measured. Between each step plates were incubated for 2 hours at 
37°C and washed thoroughly in PBST. The full protocol is detailed in Materials and 
Methods section 2.5.1. Data were analysed using Microsoft Excel and variations 
between separate ELISA plates were corrected using the titres of a standard positive 
controL 
4.3.2 ELISA Subtype Assay 
The method for measuring titres of individual IgG subtypes was similar to 
that of the total immunoglobulin ELISA. The main difference was the use of 
subtype-specific secondary antibodies: anti-IgGl and anti-IgG2a. These antibodies 
were biotinylated, so the plates were additionally incubated with 1: 1000 dilution of 
streptavadin-HRP for an hour at 37°C prior to the final wash. The anti-isotype 
antibodies were added to wells at dilutions of 1: 5000 for IgG1, and 1: 2500 for 
IgG2a, as these antibodies had been shown in previous studies performed in this 
laboratory to have a slightly different avidity for each isotype. The dilutions used 
have been calculated as capable of detecting the equivalent amount of each of the 
respective IgG isotypes in a mixed population. 
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4.3.3 Measurement of HBcAg-Specific IgA 
Immunoglobulin A (IgA) is a class of antibody important in protecting 
against infection and pathology at mucosal surfaces, as described in the 
Introduction, section 1.4.3. In order to develop an ELISA that could be used to 
determine the IgA levels in different samples, it was necessary to a) employ a 
method that would discriminate between IgA and other immunoglobulins and b) 
obtain a positive control IgA sample that would allow comparison between ELISA 
plates. In order to generate a positive control for IgA-specific ELISAs, mice were 
immunised in. with 2µg HBcAg and 2µg E. coli labile toxin (LT) in a volume of 
30µl PBS. They received an identical boost 10 days later. After a further 10 days, 
the mice were sacrificed and washes of the lungs and nasal cavity were made, using 
sterile PBS containing 1% BSA. These mucosal washings were pooled and used as 
positive control for these assays. The IgA ELISA was conducted in the same way as 
that described for total antibody (section 4.3.1.4), except for the use of IgA specific 
secondary antibody. The assay is described in full in Materials and Methods sections 
2.5.1.2). 
4.4 T Cell Responses 
T lymphocytes (T cells) fall into two main functional classes that can be 
distinguished by their cell-surface markers; cytotoxic T lymphocytes (CTLs) bear a 
cell surface molecule called CD8+ and helper T (Th) cells carry the CD4+ molecule. 
The activation of these cells is an important indicator of the immune response. 
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4.4.1 Ex Vivo Measurement of HBcAg-Specific CD4+ T Cell 
Proliferation 
CD4+ Th cells enhance antibody function, phagocytosis by macrophages 
and CTL activation (see Introduction section 1.4.2.2). The presence of a Th cell 
population able to proliferate in response to an antigen is an indicator of effective 
vaccination, and is therefore an important aspect of the response to be measured. 
Following successful vaccination, antigen-specific CD4+ T cells differentiate 
and proliferate. The higher the number of these cells present in the animal tissue, 
the greater the level of ex vivo proliferation seen upon restimulation of cells from the 
lymphoid tissue with antigen. The proliferation of cells can be measured by the 
addition of radioactively labelled nucleotides to the media. These molecules are 
taken up by cells and used in the synthesis of DNA when they divide, therefore the 
level of radioactive uptake is proportional to the level of proliferation in the culture. 
The level of uptake is measured by harvesting the cells, washing off free radioactive 
nucleotides still in the media and assaying the cells for (3-particle emission. This 
forms the basis of the proliferation assay. The sensitivity of the assay depends on a 
variety of factors outlined below. 
a) Culture media selection, specifically foetal calf serum (FCS). FCS is an 
essential component of tissue culture media used to maintain the immune 
cells during the course of the proliferation assay. Different batches of FCS 
can contain different levels of mitogenic components. These compounds 
can cause the non-specific proliferation of cells in the culture. Since any cell 
synthesising DNA will take up radioactive nucleotides, regardless of the 
initial stimulus for proliferation, the assay does not differentiate between 
specific and non-specific proliferation. Therefore to ensure the assay 
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measures antigen-specific proliferation only, it is essential to select a batch of 
FCS with minimal mitogenicity. 
b) Selection of restimulating antigen. A complication of using HBcAg as the 
model antigen in these experiments, is the fact that it can act as aT cell 
independent B cell mitogen (Nilich and McLachlan 1986). This can be 
another cause of non-specific proliferation of B-cells in the assay culture, 
making measurement of CD4+ antigen-specific proliferation impossible. 
One way around this problem is to use a suitable CD4+ peptide on the 
HBcAg as the restimulating antigen. This will be appropriate for the 
restimulation of existing HBcAg specific CD4+ cells without causing non- 
specific proliferation of B-cells. 
c) Cell population selection. Another means of avoiding non-specific 
proliferation of B cells is to remove these cells from the proliferation culture. 
This can be done using MACS separation (see Materials and Methods 
section 2.5.3) in one of two ways: by selectively removing the B cells from 
the population, or by selecting only the CD4+ cells for inclusion in the 
proliferation assay. The second choice requires the addition of an APC 
population to the culture. 
The aim of the following experiments was to determine the impact of the 
factors described above on the execution of an antigen-specific T cell proliferation 
assay. The results were used to develop an optimised assay that would be able to 
reproducibly demonstrate quantitative differences in the responses generated by the 
different vaccine regimes examined later in this thesis. 
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4.4.1.1 Generation of Immune Cells for Development of the HBc. Ag- 
Specific CD4} T Cell Proliferation Assay 
To generate populations of HBcAg-specific T cells, mice were immunised 
i. m. with 5µg of HBcAg in alum or s. c. with 3µg of HBcAg in CFA (actual doses 
and adjuvants are described in each figure legend). Ten days after vaccination, the 
spleens of immunised animals were removed and single cell suspensions' prepared 
(as described in Materials and Methods section 2.5.2). The cells were then used 
either directly in the proliferation assay or separated by MACS (Materials and 
Methods section 2.5.3) prior to inclusion in the assay cultures. The mouse strain 
used in these experiments was C57/B16. 
4.4.1.2 Media Selection 
To identify an appropriate source of FCS for use throughout the entire 
project, two batches of FCS, obtained from different companies (Gibco 
LifeSciences and Harlan Serolabs), were compared. Media was prepared containing 
10% FCS and used to set up proliferation assays using cells taken from immunised 
and naive mice. For both groups of animals four spleens were initially pooled and 
single cell suspensions prepared. As purified HBcAg was to be used as a 
restimulating antigen in this assay, B-cells were removed from the population using 
the MACS system. The resultant cell suspension was divided into two equal 
volumes of cells and the assay was performed in parallel using media containing the 
different batches of FCS. Apart from the media used, the assay was performed as 
described (Materials and Methods 2.5.4). 
The impact of using different batches of FCS is shown in Figure 4-3. This 
figure shows the proliferation of B cell depleted spleen cells from mice immunised 
with HBcAg and CFA compared to non-immunised controls. For these 
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experiments cells were resuspended in media containing Gibco FCS (Figure 4-3A) 
or media containing Harlan FCS (Figure 4-3B). This shows that proliferation 
occurs at similar levels whichever source of FCS is used and suggests that use of 
one particular sera does not provides a significant advantage. However, when the 
proliferation from non-immunised animals is considered, the nonspecific response 
is seen to be lower and less varied when the Harlan FCS was used. 
Therefore, to minimise the level of non antigen-specific proliferation in the 
assay, and to decrease variation within groups, a large batch of Harlan FCS was 
purchased and used in all subsequent experiments described in this thesis. 
4.4.1.3 Peptide Versus Protein as RestirnulatingAntigen 
To determine whether HBcAg or a small CD4+ specific peptide from 
HBcAg acts as a more effective restimulation antigen, the two antigens were 
compared in parallel. For this assay, the splenocytes from immunised and non- 
immunised animals were isolated and the B cells removed by MACS (Materials and 
Methods 2.5.2). The cells restimulated with titrating concentrations of either the 
whole protein or a previously described HBcAg CD4+ peptide for H2-b mice 
(Milich et al. 1987). The sequence for this peptide is given in Materials and Methods 
Table 2-3. The cells were restimulated with concentrations of peptide that had 
previously been shown to be effective in this paper. The results of this experiment 
are shown in Figure 4-4. 
The three major points of interest about these data are: 
1) Both the HBcAg and CD4+ peptide are able to stimulate antigen 
specific T-cells in the spleen cell population to proliferate in a 
concentration dependent manner. 
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2) The thymidine incorporation is approximately 3 fold higher in the 
peptide-stimulated cultures than in the equivalent HBcAg cultures, 
in both immunised and naive groups. 
3) The immunised cells in the peptide cultures respond much more 
strongly to an increase in antigen concentration than the cells in the 
equivalent HBcAg culture, over the range of concentrations 
examined. 
From initial consideration of the data, it is not obvious whether protein or 
peptide restimulation better provides a sensitive and consistent proliferation assay. 
In terms of counts measured, the ratio of immunised to naive counts was the same 
for both peptide and protein. The only important difference between the two was 
that small increases in the peptide concentration had a greater effect on the level of 
proliferation than the equivalent changes in HBcAg concentration. However, in 
terms of practical application, use of the peptide has another advantage in that it 
does not require the removal of B-cells. 
For these reasons, it was decided that the CD4+ peptide is a more effective 
restimulation antigen than the entire HBcAg, and therefore restimulation using this 
peptide was adopted in all future experiments. 
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Figure 4-3: Impact of different sources of FCS on the proliferation of HBcAg- 
specific T cell responses. 
C57/Bl6 mice were immunised s. c. with 3µg HBcAg in CFA. The proliferation of a 
pool of B cell depleted spleen cells from 4 mice was measured by [3-emission of 
cells after DNA incorporation of ['H] thymidine over 16 hours following 3 day 
restimulation with a range of HBcAg concentrations. Mean CPM of triplicate 
cultures of pooled cells are shown ± 1SD. The two cultures were restimulated with 
media containing HBcAg with FCS sourced from Gibco life sciences (Figure 4-3A) 
or from Harlan serolabs (Figure 4-3B). CPM from cells of immunised mice are 
represented by ". CPM from the cells of naive mice are represented by o. 
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Figure 4-4: Impact of using purified protein versus HBcAg p120-140 on 
proliferation of HBcAg specific T cells 
9 C57/B16 mice were immunised im. with 5µg HBcAg in alum on day 1 and day 8. 
Mice were sacrificed and splenocytes recovered on day 15. Proliferation of spleen 
cells from pooled mice was measured by ß-emission from cells after DNA 
incorporation of [3H] thymidine over 16 hours following 3 day restimulation with a 
range of antigen concentrations. Mean CPM from triplicate cultures of pooled cells 
are shown ± 1SD. Figure 4-4A shows cells cultured with HBcAg as the 
restimulating antigen, whereas Figure 4-5B shows cells restimulated with peptide 
HBcAg p120-140. CPM from cells of immunised mice are represented by ". CPM 
from cells of naive mice are represented by o. 
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4.4.1.4 Cell Population Selection 
As the T cell proliferation assay measures proliferation of all cells in the 
culture, irrespective of the stimulus or cell type, it is vital to the accuracy of the assay 
to prevent both non-specific T cell proliferation, and proliferation of other cell 
types. 
One approach employed to avoid the problem of B cell mitogenicity 
involves the removal of these cells from the rest of the lymphocyte population. 
This can be accomplished using the MACS separation system (Materials and 
Methods section 2.5.3). The choice of antibody used in the system determines 
which cells are removed and which remain in the population. Two different 
methods were considered. 
In the first method, the B cells alone were removed using a magnetic anti- 
CD19 antibody. As CD19 is aB cell marker, use of this antibody causes B cells to 
become stuck to the magnetic column whilst the remaining splenocyte population is 
able to pass through uninhibited. The advantage of this method is that it does not 
remove the majority of APCs present in the spleen that are required for efficient 
presentation of the antigen ex vivo. 
In contrast, a second method makes use of a CD4+ specific antibody 
attached to a magnetic bead, which binds the CD4+ T-cells to the column. The 
resulting, highly pure, population of CD4+ T cells can then be eluted by removal of 
the magnet and should not be contaminated with B cells. However, to be effective 
in the proliferation assay, the HBcAg specific T cells require presentation of the 
antigen by a suitable APC. For these experiments, 3 different types of APC were 
considered. These were: 
1. Irradiated splenocytes. Spleen cells were taken from a naive mouse and 
irradiated. These cells are still able to take up and present antigen but 
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are unable to proliferate due to the damage caused to their DNA by 
irradiation. Cells were used at a ratio of 1: 3 irradiated splenocytes :T 
cells in the proliferation assay. 
2. Mitomycin C treated splenocytes. Mitomycin C treatment causes DNA 
alterations to the cell that again prevents proliferation without inhibiting 
antigen presentation. Cells were treated with 50µg mitomycin C per 10' 
splenocytes for 75 minutes and washed thoroughly to remove the 
mitomycin C before being added to cultures at a ratio of 1: APCs :T 
cells (see Materials and Methods section 2.5.4.2). 
3. Irradiated naive DCs. DCs are potent specialist antigen presenters, and 
can be cultured from the bone marrow cells of mice stimulated with 
granulocyte-monocyte colony stimulating factor (GM-CSF) (Materials 
and Methods section 2.5.4.3). The process of irradiation was the same 
as that used for splenocytes. Cells were added at 1: 3 APCs :T cells. 
To find the optimal cell population to use in the proliferation assay, C57b1/6 
mice were immunised with HBcAg in alum, as described above in section 4.4.1.2. 
Cells were recovered from the spleens of vaccinated animals and split into four 
populations of equal number. One volume of cells was depleted of B cells using 
anti-CD19 beads. The remaining populations were treated with anti-CD4+ beads 
and the CD4' cell population isolated. These were then used to set up three 
proliferation assays, each provided with one of the APC types described above. All 
four cultures were then restimulated with the CD4+ peptide as the restimulating 
antigen. 
The results of these experiments are shown in Figure 4-5. In all cases, 
HBcAg specific CD4+ proliferation was induced with higher counts in wells 
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containing cells from immunised animals than those from naive animals. The 
proliferation observed was also shown to be antigen-concentration dependent. 
However, the greatest proliferation was observed when only the B cells were 
depleted from the cell suspension; Figure 4-5A. This is despite the higher level of 
emission from naive groups in this experiment compared to those using non- 
proliferating splenocytes; both the absolute and proportionate increase of the 
immunised group over the naives is greater than in any other group. Also, the 
immunised B cell depleted cultures were more sensitive to increases in antigen 
concentration than any other group. 
One factor that might explain the high level of proliferation in this system 
may be that the APCs in the B cell depleted culture (Figure 4-5A) have not suffered 
significant DNA damage. Irradiation and mitomycin C treatment both result in 
significant damage to chromosomal DNA and prevent the cells replicating. Protein 
expression from damaged genes will also be impaired, and although the cells are 
able to survive and present antigen, this may be less efficient than in non-treated 
cells (Figure 4-5B and C). 
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Figure 4-5: Comparison of proliferation of T cells with different APC 
populations. 
9 C57/B16 mice were immunised i. m. with 5µg HBcAg in alum. The proliferation of 
a pool of spleen cells from 9 mice was measured by n-emission from cells after 
DNA incorporation of ['H] thymidine over 16 hours following 3 day restimulation 
with a range of antigen concentrations. Mean CPM from triplicate cultures of 
pooled cells are shown ± 1SD. Figure 4-5A shows B cell depleted splenocytes, 
while B, C and D show CD4+ T cells with added APCs. Figure 4-5B shows T cells 
plus naive irradiated splenocytes, Figure 4-5C shows T cells with naive, mitomycin 
C treated splenocytes and Figure 4-5D shows T cells with naive, mitomycin treated 
DCs as APCs. CPM from cells of immunised mice are represented by ". CPM 
from cells of naive mice are represented by o. 
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After the B cell depleted group, the next highest level of proliferation was 
measured in wells in which purified CD4+ T cells had been admixed with irradiated 
DCs (Figure 4-5D). DCs are potent APCs, capable of efficiently presenting antigen 
to T cells, which probably explains their success when compared to the mixed 
populations of naive non-proliferating splenocytes present in the two remaining 
cultures. 
A problem with the cultures containing DCs as APCs is the high level of 
proliferation seen in the naive group. This indicates that either the DCs are causing 
T cells to proliferate non-specifically, or that the DCs were insufficiently treated 
with Mitomycin C to prevent their own replication during the proliferation assay. 
Whichever theory is correct, it means that these cells are not suitable for use in the 
proliferation assay. 
As a result of these data, all further experiments looldng at antigen specific 
CD4+ T cell proliferation were performed using CD-19 B cell deleted lymphocyte 
populations. 
4.4.1.5 Optimised Assay for Measuring HBcAg-Specific CD4'Responses 
As a result of these experiments, CD4+ T-cell responses were subsequently 
measured by isolation of a splenocyte population whose B-cells were removed using 
CD19 beads. To each well of a microtitre plate, 2x105 cells were added and were 
restimulated with the HBcAg CD4+ peptide (HBcAg p120-140). All RPMI media 
used in culturing of these cells contained FCS sourced from Harlan Serolabs. 
Cultures were incubated for 72 hours at 37°C, 5% COZ, then pulsed with tritiated 
thymidine. 
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4.4.2 CD8+ CTL Responses 
CTLs are a second type of T lymphocyte, generally characterised by the 
presence of CD8+ molecules on the cell surface, rather than CD4+ as on T helper 
cells. Functionally, they are quite different from T helper cells. Although they also 
recognise antigen in a specific manner, antigen can be presented to CD8+ T cells by 
almost any cell (not just specialist APCs), since they recognise antigen bound to 
MHC class I molecules, expressed by nearly every cell type in the body. On 
recognition of antigen and following a secondary signal, a naive CD8+ T cell is 
activated and differentiates into a CTL that can kill cells presenting its specific 
antigen by inducing apoptosis. This mechanism is used to control intracellular 
pathogens, such as viruses and invasive bacteria. Activated CTLs also secrete IFN-y 
a molecule whose functions include the inhibition of virus replication within cells 
and the activation of macrophages (see Introduction section 1.4.2.1). Both CTL 
killing and IFN-y secretion have been assayed for as part of this project. 
4.4.21 CTL KillingAssay 
In order to determine whether different formulations of vaccine could 
stimulate HBcAg-specific CD8+ killing responses, a chromium release assay was 
developed. This CTL killing assay is based on the ability of antigen specific CD8' 
cells to recognise and destroy target cells which express the HBcAg specific CD8+ 
peptide on their surface. The assay itself involves the isolation of splenocytes from 
vaccinated animals, which are incubated with the target cell population in vitro for 5 
days. This is necessary to restimulate and amplify the number of specific CTLs 
generated. After 5 days, the amplified cell population is re-exposed to a fresh set of 
target cells that have been previously incubated with radioactive sodium chromate 
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[51Cr]. After co-incubating radioactive cells with the CTLs for 4 hours, the culture 
supernatants are removed and measured for ß-emission. As target cells that have 
been destroyed by CTL activity release [51Cr] into the supernatant, the level of 
radioactivity in the supernatants can be correlated to the number of cells destroyed. 
This is calculated as a percentage by comparing the emission to populations of 
target cells lysed with a detergent, triton X, which gives 100% lysis, and unlysed 
target cells. 
Optimisation of [s'Cr] Sodium Chromate Labelling of Target Cells 
HBcAg specific target cells, P815/c and the equivalent P815 control cells 
were a kind gift from R Schirmbeck, University of Ulm, Germany. To optimise the 
assay the uptake of radioactive sodium chromate [s'Cr] by these cells was examined. 
Different numbers of target cells were incubated for different lengths of time with 
radioactivity. To quantify the absorbance of radioactivity, cells were lysed with 
triton X 100 and the (3 emissions of the supernatants measured. The results are 
shown in Figure 4-6. The data shows that the a-emission increases with the 
number of cells labelled, but is not directly proportional, with a greater increase 
between 1x104 and 1x105 cells than between 1x103 and 1x104. The greatest increase 
in counts due to incubation time was between 30 minutes and 1 hour, with a longer 
incubation period giving less of an increase. 
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Figure 4-6: Effect of incubation time and target cell number on CrS1 
absorbance 
The amount of radioactivity absorbed by either P815 (hollow symbols) or P815/c 
cells (filled symbols) was measured by lysis of these cells with detergent after 30 
minutes (2), 60 minutes (A) or 120 minutes(*). Mean CPM of triplicate cultures are 
shown ±1 SD. 
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The results from this experiment show that 1x105 target cells generate a 
strong ß-emission signal, i. e. in the order of 10,000cpm. The counts were directly 
proportional to the number of cells present, and both target (P815c) and control 
(P815) cells gave similar counts. Therefore it was considered that 1x105 target cells 
per well was the optimal number for use in these assays and cells should be labelled 
for a minimum of 1 hour prior to use. 
Optimisation of the Chromium Release Killing Assay 
To determine whether antigen specific CD8+ responses could be measured 
in vivo, BALB/c mice were vaccinated with 100µg pcDNA3.1/core im. and 
sacrificed after 10 days. Splenocytes were isolated and restimulated with target cells 
for 5 days, as described above. They were then incubated for 4 hours with sodium 
[51Cr] chromate labelled target cells and the ß emission measured. 
Figure 4-7 shows the percentage of specific killing by cells from BALB/c 
mice immunised with pcDNA3.1/core, pcDNA3.1 and in untreated animals. 
These data show that the assay is able to measure antigen-specific killing, which 
occurs effectively in animals immunised with the pcDNA3.1/core vaccine. Such 
induction is in agreement with similar observations in the literature (Kuhrober et aL 
1996). This assay appears discriminatory with little killing observed in control 
groups. It was therefore decided that this assay was sufficiently sensitive and 
discriminating to be used for measuring CTL activity. 
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Figure 4-7: HBcAg-specific CTL killing by mice immunised with 
pcDNA3.1/core 
Percentage of specific killing of target cells by spleen cells restimulated in vitm for 5 
days, following harvesting from BALB/c mice 10 days after immunisation with 
pcDNA3.1/core. 50: 1 effector : target cell ratio. 
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4.4.2.2 Interferon-y Release -an Indirect Measurement of CTL Activation 
One feature of CTL activation that can be used as an indirect measurement 
of CTL activity is secretion of IFN-y. To assess whether CTLs could be quantified 
using this method, 5 BALB/c mice were vaccinated with 100µg pcDNA3.1/core 
im. and sacrificed after 10 days. Using the protocol described in the materials and 
methods 2.5.7, adapted from (Culshaw et aL 1997), no spots were detectable on the 
filter, suggesting that no activated CTLs were present. However, considering that 
the CTL killing described in section 4.4.2.1 was so high, it was felt that the HBcAg 
specific CTLs were present, but that assay lacked discrimination. In order to 
emulate the method and level of response indicated by the killing assay, it was 
decided to restimulate the isolated T cells with target cells prior to their use in the 
ELISPOT (see above). 
Therefore the isolated T cells were restimulated for 5 days in vitro at a ratio 
of 10 :1 effector : target cells. Using this method clear, antigen specific IFN-'y 
production was observed. The numbers of Spot Forming Cells (SFC) are shown in 
Figure 4-8. The data in this figure confirms that immunisation of mice with 
pcDNA3.1/core results in the generation of IFN-y producing T-cells. Although it 
is likely that the production of this cytokine is from antigen specific CD8+ cells 
(given the use of the CD8; specific peptide), this could have been further confirmed 
by intracellular cytokine staining of these cells and measurement by FACSort 
analysis. This assay appeared to be discriminating as the number of spots generated 
following vaccination with pcDNA3.1/core was approximately twice the number 
observed in equivalent control wells. 
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Figure 4-8: Numbers of IFN-y secreting T cells following i. m. 
pcDNA3.1/core vaccination 
The number of spots per well produced by IFN-y secreting T cells are shown. Cells 
from BALB/c mice immunised with pcDNA3.1/core (0), pcDNA3.1 alone (o) and 
from naive animals (C) are shown. T cells were recovered 10 days after vaccination 
and restimulated for 5 days prior to the ELISPOT assay. SFC represent the mean 
number of spots counted in duplicate wells containing 50µ/ml HBcAg peptide 
CD8+ p87-95. 
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4.5 Conclusion 
As a result of work described in this chapter, it was felt that appropriately 
sensitive and discriminating methods had been developed for studying the cellular 
and humoral immune response to HBcAg. These assays therefore form the 
foundation for subsequent studies, which were carried out to compare the relative 
response to different vaccination strategies described in the remainder of this thesis. 
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5 RESULTS - GENERATION OF AN IMMUNE RESPONSE 
FOLLOWING SYSTEMIC DELIVERY OF A DNA VACCINE 
ENCODING THE HBcAG 
5.1 Chapter Aims 
The aim of this chapter was to examine the humoral and cellular HBcAg- 
specific responses generated following vaccination with the naked plasmid vaccine 
pcDNA3.1/core. The effects of delivering this vaccine either directly into the skin 
using a gene gun or into the muscle by injection were observed. In addition, 
consideration is given to the subsequent enhancement of these responses by im. 
delivery of a purified protein boost. 
5.2 Introduction 
It has previously been shown that the route of immunisation for DNA 
vaccines can significantly affect the magnitude and quality of the immune response 
generated (see Introduction section 1.5.4.3). In general, DNA vaccines delivered 
intramuscularly (im. ) require high amounts of DNA to stimulate measurable 
antibody and cellular responses. In the literature, these appear to be dominated by 
the stimulation of helper CD4+ T cells of the Thl phenotype. In contrast, when 
DNA is given intradermally using a gene gun, relatively low doses of the vaccine are 
required to generate equivalent levels of immunity, and the response is dominated 
by CD4+ T cells of the Th2 phenotype. However, most studies to date have 
examined soluble, non-particulate antigens. This chapter describes the impact of a 
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DNA vaccine based on a large particulate antigen. This work provides a strong 
foundation on which the subsequent impact of additional heterologous boost 
vaccinations can be considered. 
To determine the effect of the HBcAg-encoding DNA vaccine 
pcDNA3.1/core in stimulating various aspects of the immune response, mice were 
initially given 2 doses of the vaccine either by intramuscular (i. m) injection or via 
the skin using a gene gun. To avoid any bias of the inbred mouse strains towards a 
particular type of immune response, experiments were carried out in both BALB/c 
and C57/B16 mice. The subsequent humoral and cellular responses that were 
measured are described below and are considered based on the route of 
immunisation, with immunity to im. vaccination examined in the first instance. 
5.3 Humoral Responses to pcDNA3.1/core Following 
Intramuscular Vaccination 
In these experiments, C57/B16 mice (H2-b MHC haplotype) were 
immunised on days 1 and 8 with 100µg of pcDNA3.1/core im. Control animals 
were similarly immunised with 100µg of pcDNA3.1 vector alone to differentiate 
between responses due to the expressed vaccine antigen and the plasmid backbone. 
A third group of mice were given two doses of 1µg HBcAg protein im. at the same 
times, to act as a positive control To monitor the generation of HBcAg specific 
antibodies, sample bleeds were taken 14 and 31 days following the second 
vaccination (see Figure 5-1). 
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Day 0 Day I Day 8 Day 21 Day 33 
Sample bleed DNA vaccinations Sample bleed Sample bleed 
Figure 5-1: Immunisation regimen for mice vaccinated i. m. with the DNA 
and protein vaccine formulations. 
This figure shows the timing of vaccine delivery to the mice and quantification of 
anti-HBcAg response by assessment of tail sample bleeds taken from each mouse. 
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HBcAg specific humoral responses were measured by ELISA and are 
shown in Figure 5-2. In brief, this figure shows that although no detectable 
responses were observed prior to immunisation (Figure 5-2A), 14 days after the 
second vaccination, all mice immunised with pcDNA3.1 /core had developed low 
but detectable antibody responses in the sera (Figure 5-2B). The titres generated are 
approximately ten times lower than those observed in mice immunised with the 
purified protein. These data indicate the strong immunogenicity of the HBcAg and 
are consistent with results described elsewhere (Bohm et aL 1996). These responses 
do not appear to improve with time as calculated titres of HBcAg specific antibody 
had not changed significantly in any group by 39 days following immunisation 
(Figure 5-2C). 
To confirm that the MHC haplotype of the mice does not affect the 
humoral response generated, the experiments were repeated in BALB/c mice (H2-d 
haplotype). The results from these experiments are given in Figure 5-3. These 
confirmed the previous data generated in the C57/B16 mice and show that low 
levels of HBcAg specific antibodies are detectable in all mice immunised with 
pcDNA3.1/core 14 days after immunisation. No such responses are observed in 
animals immunised with the vector alone. These responses are lower than those 
observed in mice immunised with the purified HBcAg material and do not improve 
over time (Figure 5-3C). These data demonstrated that the DNA vaccine construct 
was able to stimulate equivalent humoral HBcAg specific responses in two mouse 
strains of different MHC haplotype. 
In order to more fully define the nature of the immune response generated 
by the DNA vaccine, the pattern of antigen specific IgG isotypes in the sera was 
also analysed. T helper cell responses can be broadly divided into Thl or Th2, 
depending on the cytokines secreted by individual 11i cells. These cytokines drive 
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the production of specific sub-types of immunoglobulin G (IgG), therefore the 
nature of the T helper cell response can be determined by examining the levels these 
subtypes. In mice, IgG1 is indicative of a Th2 CD4* response and IgG2a indicates 
Thl (Abbas el at 1996), see Introduction section 1.4.2.2, CD4+ T cell Responses). 
Figure 5-4 show the titres of HBcAg-specific IgG subtypes in the sera of the 
two mouse strains at day 39, after immunisation on days 1 and 8 with 
pcDNA3. l /core, control DNA or 1µg purified HBcAg. Interestingly, none of the 
mice immunised with either protein or pcDNA3. l/core show any specific IgGl 
production, instead the dominant antibody was IgG2a, although the titres measured 
varied considerably. This indicates the development of a'I'hl response to HBcAg 
whether vaccination is DNA or protein based. 
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Figure 5-2: i. m. DNA vaccination in C57/B16 mice; development of HBcAg- 
specific serum antibody 
Groups of 5 C57/Bl6 mice were immunised im. with either 100µg DNA 
(pcDNA3.1/core and DNA control groups) or 1pg HBcAg protein alone (HBcAg 
x2 group), on days I and 8 of the experiment. Figure S-2A shows the titres of 
HBcAg specific immunoglobulin from all mice prior to vaccination, Figure 5-2B at 
14 days after the second vaccination and Figure 5-2C shows titres at 31 days after 
vaccination. HBcAg specific titres are represented by 4, groups means by 
horizontal bars. 
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Figure 5-3: i. m. DNA vaccination in BALB/c mice; development of HBcAg- 
specific serum antibody 
Groups of 5 BALB/c mice were immunised i. m with either 100µg DNA 
(pcDNA3.1/core and DNA control groups) or lpg HBcAg protein alone (HBcAg 
x2 group) on days 1 and 8 of the experiment. Figure 5-3A shows the titres of 
HBcAg specific immunoglobulin from all mice prior to vaccination, Figure 5-3B at 
14 days after the second vaccination and Figure 5-3C shows titres at 31 days after 
vaccination. HBcAg-specific titres are represented by 4, groups means by 
horizontal bars. 
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Figure 5-4: Measurement of antibody subtypes in, the sera of mice vaccinated 
with pcDNA3.1/core i. m. or purified HBcAg 
BALB/c (Figure 5-4A) and C57/B16 (Figure 5-4B) mice were immunised with 
100µg pcDNA3.1 /core or 1µg HBcAg im. on day 1 and day 8. Immunoglobulin 
subtypes were examined on day 39. Calculated specific anti-HBcAg titres are 
shown. A represent IgGl titres for individual mice, 11 represent IgG2a titres. 
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5.4 Cellular Responses to pcDNA3.1/core Following 
Intramuscular Vaccination of C57/B16 mice 
5.4.1 CD4+ T Cell Responses 
To determine the impact of vaccination on HBcAg specific CD4; cells, mice 
were immunised as described in Figure 5-1 and CD4f T cells purified from spleens 
and draining lymph nodes (popliteal and inguinan 14 days after the second vaccine 
dose. Proliferation was measured by ß-emission of these cells following 
incorporation of'H-thymidine in culture (Materials and Methods section 2.5.4 - 
2.5.5). Unfortunately, despite several attempts using optimised protocols no 
HBcAg-specific proliferation could be measured in any of the mice. This may have 
been due to a genuine lack of response in the animals, or problems with sensitivity 
of the assay (see Chapter 4 for details of the assay development). Another 
possibility was that there were only low numbers of primed cells at the time point 
studied. To see if this was the case, CD4* responses were measured using an 
alternative vaccination protocol In this experiment, mice were immunised on days 
1 and 28 and T cell proliferation examined on day 56 of the experiment. It was 
thought that the greater time interval between immunisations and killing would 
allow a longer period of antigen expression by the cells leading to stimulation of a 
greater number of naive T cells. 
The results of this experiment are shown in Figure 5-5 and confirm that 
antigen-specific T cell proliferation can be observed in the spleens of these mice. 
These responses were dramatically higher than those observed in cells from naüve 
mice. In contrast no detectable response was observed in the cells taken from the 
popliteal lymph nodes (Figure 5-5B). This suggests that the antigen specific cells 
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have matured and trafficked to the spleen at this time point This longer-term 
vaccination regime was not adopted for general use since these experiments were 
conducted toward the end of the experimental work for this thesis and too late to 
be incorporated into the general scheme of work. 
5.4.2 CD8+ T Cell Responses 
To measure HBcAg specific CD8ý T cell responses, mice were given a single 
dose of 100µg pcDNA3.1/core and killed 10 days later. Splenic cells from these 
mice were isolated and restimulated ex vivo for 5 days with P815/c target cells, as 
described in Materials and Methods section 2.5.6. The killing capacity of these 
restimulated cells is shown in Figure 5-6. These data dearly demonstrate the 
induction of antigen-specific CTZs following vaccination with a single 100µg im. 
dose of the pcDNA3.1/core vector. At effector : target cell ratios of 50: 1 and 25: 1 
this killing response is approximately 25% greater than that observed with the 
equivalent number of cells taken from naive animals or those immunised with the 
vector alone. 
An alternative method of evaluating the CIL response is to measure the 
number of IFN-'y secreting cells in an ELISPOT assay (Materials and Methods 
section 2.5.7). Cells taken from mice immunised twice with pcDNA3.1/core, as 
before, yielded the results shown in Figure 5-7. 
The number of spot forming cells (SFC) are higher in the pcDNA3.1/core 
group than the DNA control and naive groups, at both the 10: 1 and 5: 1 E APC 
ratios, irrespective of the quantity of restimulation antigen used in the assay (the 
results shown are from cultures stimulated with 50µg/ml HBcAg peptide (p93-100). 
This confirms that vaccination with pcDNA3.1/core activated CD8+ T cells and 
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shows that CD8* T cells from naive animals were not activated to produce IFN-y 
during the assay. 
These results are in line with and expand upon previous findings showing 
that im. DNA vaccination can induce an anti-HBcAg specific CTL killing 
(Kuhroben et aL 1996). 
5.5 Summary of Results 
From these initial in sire experiments, it was clear that the plasmid 
pcDNA3.1/core was able to stimulate humoral and cellular immune responses 
following im. administration. The results shown here represent typical data from 
several experiments and did not appear to be affected by the haplotype of the 
mouse strain used. Therefore unless stated, all later experiments were carried out in 
C57/BI6 mice only. These data confirm similar observations in the literature that 
im. DNA immunisation induces strong antigen specific CD8* responses and low 
but detectable humoral responses. It was not possible to detect a measurable 
antigen specific CD4* response without increasing the time between immunisations 
and the measurement of proliferation. This may be due to the limit of sensitivity of 
the assay employed or an only gradual activation of such cells because of long-term, 
low level antigen expression. 
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Figure 5-5: Measurement of CD4' T cell proliferation in vitro using cells from 
mice immunised i. m. with pcDNA3.1/core 
C57/Bl6 mice were immunised with 100µg of DNA i. m. on days 1 and 8 of the 
experiment, or 1µg HBcAg alone on day 8, and sacrificed on day 56. Spleen (Figure 
5-5A) and popliteal and inguinal lymph node cells (Figure 5-5B) were recovered 
from mice immunised with pcDNA3.1 /core (0) or naive mice (0). Control mice 
received only the 1µg dose of HBcAg im. ("). The proliferation of cells from 
pooled mice was measured by ß-emission from cells after DNA incorporation of 
['H] thymidine over 16 hours following 3 day restimulation with a range of peptide 
concentrations. Assay described in full in materials and methods sections 2.5.2 - 
Z5.4. Mean CPM from triplicate culture wells are shown ± ISD. 
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Figure 5-6: Specific killing by spleen cells of DNA immunised mice 
Percentage specific killing of p815/c target cells by spleen cells of C57/B16 mice 
immunised im. with 100µg pcDNA3.1/core. Groups of 5 mice were immunised 
with 100µg pcDNA3.1/core (") or pcDNA3.1 (0) or were left unimmunised (1k) 
and were sacrificed 10 days after the final vaccination. The spleen cells were 
restimulated ex vivo for 5 days with p815c target cells (5 target cells per 100 
splenocytes) at 37°C, 5% CO2. The cells were then added to fresh, "Cr labelled 
target cells at different ratios for a4 hour killing assay, as described in full in section 
2.5.5. 
173 
150 
100 
Co 
50 
10: 1 5: 1 1: 1 
E: APC 
Figure 5-7: CD8* T cell activation in DNA vaccinated mice measured by 
IFN-y ELISPOT 
C57/B16 mice were immunised on day 1 and 8 with 100µg of pcDNA3.1/core ("), 
pcDNA3.1 (o) or remained naive (Cfj, and sacrificed on day 15. Cells were 
incubated in a5 day restimulation assay and IFN-y secreting cells quantified by 
ELISPOT at different effector : APC ratios. Cells were incubated with 50µg/ml 
HBcAg p93-100 peptide during the assay. Error bars represent the standard 
deviation of three SFC counts for each well. 
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5.6 Enhancement of Immunity Through Prime-Boost 
Vaccination Strategies 
For a DNA vaccine candidate to be of maximal potential use, strong cellular 
and humoral responses should be activated following immunisation. Therefore in 
an attempt to augment the CD4+ and antibody responses to HBcAg (and to provide 
both types of response simultaneously) the potential for combining 
pcDNA3.1 /core vaccination with different boosts was investigated. The remainder 
of this chapter describes the investigations into whether immunity to the HBcAg 
generated by the im. DNA vaccine could be enhanced by boosting with a small 
quantity of purified HBcAg protein, also administered by the i. m. route. Figure 5-8 
shows the revised vaccination schedule and the timing of this boost immunisation. 
5.7 Humoral Responses Following i. m. DNA Prime and 
Purified i. m. HBcAg Boost 
For these experiments, animals were primed with pcDNA3.1 /core, as 
described previously, on days 1 and 8, and then boosted with Ipg HBcAg on day 40 
of the experiment (Figure 5-8). As before, to determine the response to the DNA 
vector backbone, control mice were immunised with the vector alone and then 
boosted with purified HBcAg as described above. To allow comparison with mice 
given the purified protein alone, some mice were injected with the purified protein 
rather than DNA (HBcAg x3), at the same timepoints. Finally, to determine the 
impact of the boost alone, previously naive mice were given a single lµg dose of 
HBcAg (xl) on day 40. To confirm no differences were observed using mice of 
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different haplotype, these experiments were performed in both BALB/c and 
C57/B16 mice. 
The effect of the boost is shown in Figure 5-9 (C57/B16 mice) and Figure 5- 
10 (BALB/c mice). In both strains, those animals primed with pcDNA3.1/core 
show a greater than ten-fold increase in mean titres. The increase in the BALB/c 
mice pcDNA3.1/core group following the boost is significant (Student's t-test, 
p=0.042), however that observed in the equivalent C57/B16 group is not (p=0.079), 
although it is consistent between experiments. 
It is clear that there is a much greater increase in HBcAg-specific antibody 
titres in these groups than is observed in either the mice primed with the vector 
alone or those animals receiving the boost immunisation alone. In contrast, there 
was little change in the antibody titres observed in mice previously immunised with 
2 doses of HBcAg. This is possibly because the maximal antibody response had 
already been achieved in these animals. Interestingly, the mean titre of the group 
immunised with pcDNA3.1/core HBcAg and boosted with protein was 
approximately equivalent to that observed at the final time-point of those given the 
purified antigen alone, despite low titres measured prior to the boost. 
5.7.1 Subtype Responses 
To determine the impact of the boost on the nature of the CD4+ Th 
response in these animals, the presence of different IgG isotypes within the HBcAg- 
specific serum antibody response were examined. The titres are shown in Figure 5- 
11. On boosting, titres of IgG2a increased in all mice primed with 
pcDNA3.1 /core, although there was still a broad range of titres in identically 
immunised animals. As before, in C57/B16 mice, there was no measurable IgG1 
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production. In the BALB/c mice, one out of 5 animals showed a low level of IgGI 
production, whilst the others showed no response. This combination of responses 
indicates the maintenance of the Thl dominated response seen following DNA 
vaccination alone. 
5.8 Cellular Responses Following i. m. DNA Prime and 
Purified i. m. HBcAg Boost Vaccination 
5.8.1 CD4+ T Cell Proliferation 
Splenocytes taken from mice immunised with two doses of pcDNA3.1 /core 
and boosted with HBcAg protein were cultured in proliferation assays, the results of 
which are shown in Figure 5-12. In contrast to earlier experiments when no 
detectable CD4+ responses could be observed in animals immunised with 
pcDNA3.1/core alone (in a short-term vaccination regime), animals primed with 
pcDNA3.1/core and boosted with purified HBcAg showed strong antigen specific 
proliferation. These responses were equivalent in magnitude to those observed in 
animals that received three doses of the protein. Interestingly, a single dose of the 
HBcAg was not sufficient to cause proliferation in previously naive mice, but did 
result in low level proliferation in control DNA-primed mice. This may have been 
due to the non-specific immuno-potentiating activity of the CpG motifs in the 
control DNA. 
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Figure 5-8: Revised vaccination regime for pcDNA3.1/core immunisation 
including a subsequent heterologous boost with i. m. recombinant HBc. Ag 
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C57/B16 mice were immunised as described in Figure 5-8. The graph shows the 
mean titres of HBcAg-specific antibody calculated from 5 individual animals. 
Sample bleeds were taken 1 day prior to the boost immunisation (D) or 10 days 
following the boost (M). Error bars represent the standard deviation from the mean 
titre of each group. 
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Figure 5-9: Impact of i. m. boost with purified HBcAg on HBcAg-specific 
serum antibody titres 
Figure 5-10: Impact of i. m. boost with purified HBcAg on HBcAg-specific 
serum antibody titres 
BALB/c mice were immunised as described in Figure 5-& The graph shows the 
mean titres of HBcAg-specific antibody calculated from 5 individual animals. 
Sample bleeds were taken 1 day prior to the boost immunisation (0) or 10 days 
following the boost (1). Error bars represent the standard deviation from the mean 
titre of each group. * indicates a significant difference between titres in the 
pcDNA3.1 /core group following the HBcAg boost. 
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Figure 5-11: Measurement of antibody subtypes in the sera of mice 
vaccinated with pcDNA3.1/core and boosted with purified HBcAg 
BALB/c (Figure 5-11A) and C57/B16 (Figure 5-11B) mice were immunised with 
100µg pcDNA3.1/core or control DNA on days 1 and 8, and boosted with 1µg 
HBcAg im. on day 40 (as described in Figure 5-8). Immunoglobulin subtypes were 
examined on day 50. Calculated specific anti-HBcAg titres are shown. A represent 
IgGi titres for individual mice, 0 represent IgG2a titres. 
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Figure 5-12: Impact of i. m. boost with purified HBcAg on specific 
proliferation of CD4; T cells from mice primed with pcDNA3.1/core 
C57/B16 mice were immunised according to the schedule described in Figure 5-8. 
100µg pcDNA3.1 /core (0) or control DNA (O)was delivered im. on days I and 8, 
and mice were boosted on day 40 with 1µg purified HBcAg im. Control groups 
were given three doses of lpg purified HBcAg at the same timepoints () or a 
single dose on day 40 A. One group remained untreated (A). All mice were 
sacrificed and splenocytes recovered on day 50. Pooled splenic populations were 
stimulated in vitro and the level of proliferation measured by incorporation of 
tritiated thymidine. The counts shown are the mean values calculated from 
triplicate wells of pooled cells stimulated with different concentration of protein. 
Error bars represent the standard deviation from the mean. 
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5.8.2 CD8+ T Cell Responses 
CD8+ T cell activation was measured by ELISPOT assay, as shown in 
Figure 5-13. As with DNA vaccination alone, the prime-boost strategy was able to 
activate greater numbers of cells than when a single dose of HBcAg was given. 
5.9 Comparison of the Route of Administration of the 
DNA Vaccines on Immunity: i. m. Vaccination 
Versus Gene Gun Delivery 
Based on the impressive results achieved by boosting the DNA primed mice 
with purified antigen, we looked to improve the overall prime boost strategy 
employed. As i. m. vaccination requires very high amounts of DNA per dose, it is 
unlikely to be ever considered as suitable for use in humans. Alternative methods 
such as use of gene gun have therefore been used clinically. However, previous 
experiments have shown that the use of gene gun can alter significantly the type of 
immune response primed. The impact of priming animals with DNA by gene gun 
on subsequent responses following boosting with purified protein was therefore 
considered. 
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Figure 5-13: Measurement of CD8+ T cell activation in DNA primed, purified 
HBcAg boosted mice by IFN-y ELISPOT 
Mice were immunised twice with 100µg of pcDNA3.1 /core (. ) or psDNA3.1 alone 
(/) and boosted with 1µg HBcAg im. before sacrifice 10 days later. One group 
remained untreated (Q. Cells were incubated in a5 day restimulation assay and 
IFN-y secreting cells quantified by ELISPOT at different effector : target cell ratios. 
Cells were incubated with 200pg/ml HBcAg p93-100. 
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5.9.1 Humoral Responses 
DNA vaccination using a gene gun is fully described in the Introduction 
(section 1.5.4). 
For these experiments, animals were again immunised using the schedule 
shown in Figure 5-8. Animals given im. immunisations were given 100µg of DNA 
per dose whilst in parallel, animals immunised using the gene gun were given with 
between 1-2µg per dose (Figure 5-14). Despite the lower dosage, the anti-HBcAg 
antibody titres calculated were not significantly different to those observed in 
animals immunised im. with pcDNA3.1 /core (Figure 5.14B, C). Control DNA did 
not elicit an antibody response by either route. 
5.9.2 Impact of Purified Protein Boost on Gene Gun-Primed 
Mice Compared to i. m. -Primed Mice 
5.9.2.1 Impact ofBoost on Humoral Responses 
Following boosting of these primed animals with purified protein, titres of 
antibodies were again enhanced to an approximately equivalent level (Figure 5-15). 
In contrast, the mice immunised with the control vector im. and the naive animals 
failed to respond to the antigen alone. Interestingly, the mice given the vector alone 
by gene gun and then boosted showed a low but measurable response to the 
antigen. It is unclear why this occurred but may reflect the sensitivity of the 
immune system to CpG motifs delivered using the intradermal route. Indeed, this 
may also explain why slightly stronger responses were observed in the gene gun 
group compared to i. m. vaccinated DNA control mice, (although not statistically 
significant). Interestingly, animals vaccinated with the gene gun responded more 
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consistently; with less variation between individual titres observed in this group. 
For this reason the increase in titres following the boost are highly statistically 
significant (p<0.001) and the more varied titres in the im. group following 
vaccination do not constitute a significant increase, although the observation of an 
increase was consistent between experiments. 
The titres of IgG subtypes 1 and 2a in the serum of mice on day 50 are 
shown in Figure 5-16. Both gene gun and im. immunisation led to the 
development of HBcAg-specific IgG2a titres. As before, the i. m. DNA 
immunisation followed by purified HBcAg boost resulted in an IgG2a dominated 
response, as was the case with animals given control DNA by either gene gun or 
im. routes followed by the im. protein boost. In contrast, as well as strong IgG2a 
titres, immunisation with the gene gun resulted in strong IgG1 titres in most mice. 
This is indicative of a more Th2-like immune response (Abbas et aL 1996) and is 
consistent with other observations that have indicated that immunisation with gene 
gun induces a greater Th2 response. 
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Figure 5-14: Development of antibody titres following DNA vaccination by 
gene gun or i. m. injection 
Groups of C57/Bl6 mice were immunised either i. m. with 100µg pcDNA3.1 /core 
or by gene gun (10 mice by gene gun, 5 in all others) with 1µg of the same plasmid, 
on days 1 and 8 of the experiment. Anti-HBcAg specific antibodies were measured 
in blood samples taken prior to the first immunisation (Figure 5-14A), 14 days after 
the second vaccination (Figure 5-14B) or 31 days after the second vaccination 
(Figure 5-14C). Titres of individual mice are represented as f, the mean value of 
each group as horizontal bars and the threshold of sensitivity of the assay by the 
horizontal line. 
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Figure 5-15: effect of boost on anti-HBcAg titres in gene gun and i. m. DNA 
vaccinated C57/B16 mice 
Mice were immunised as described in Figure 5-8, with either 100µg DNA i. m. or 
1µg DNA delivered by gene gun, on days 1 and 8. In addition, they were 
subsequently boosted with 1µg recombinant HBcAg protein im. on day 40 of the 
experiment, and the final sample taken on day 50. Sample bleeds were taken 1 day 
prior to the boost immunisation (0) or 10 days following the boost ( ). mean 
titres of groups of 5 mice (excepting pcDNA3.1/core gene gun group, which 
consisted of 10 mice) ±1 standard deviation. * indicates a highly significant 
difference (p>0.9999) between titres in the gene gun group following the HBcAg 
boost. 
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5.9.2.2 CD e proliferation in Gene Gun Primed and HBcAg Boosted Mice 
To compare the effect of gene gun priming on T cell responses, splenic 
CD4+ cells from mice vaccinated with pcDNA3.1/core and boosted with protein. 
Again in contrast to the DNA alone experiments described at the start of this 
chapter, measurable proliferative responses were observed in cells from animals 
boosted with purified protein (Figure 5-17). The level of proliferation was 
considerably greater in the group primed with pcDNA3.1 /core than that observed 
in either the naive or vector alone control mice. Interestingly, although the highest 
specific responses were observed in inguinal lymph nodes from animals primed with 
pcDNA3.1 /core (Figure 5-17B), the highest responses in the spleen were observed 
in animals immunised with the purified antigen alone. This may indicate a 
difference in the rate of trafficking of DNA- or protein-primed activated CD4+ T 
cells to the spleen. As only one time point was considered in these experiments it is 
unclear whether the results reflect differences in timing or efficiency of trafficking 
to the spleens of these animals. 
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Figure 5-16: Antibody subtype titres following i. m. and gene gun vaccination. 
C57/B16 mice were immunised with 100µg pcDNA3.1/core or control DNA on 
days 1 and 8, and boosted with 1 µg HBcAg im. on day 40 (as described in Figure 5- 
8). Immunoglobulin subtypes were examined on day 50. Calculated specific anti- 
HBcAg titres are shown. A represent IgGI titres for individual mice, O represent 
IgG2a titres. 
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Figure 5-17: Gene gun DNA immunisation; spleen and lymph node CD4* T 
cell proliferation 
C57/B16 mice were immunised on days 1 and 8 with 1-2ig pcDNA3.1/core (A) or 
control DNA (A) by gene gun vaccination. One group was given 1 Vg purified 
HBcAg in alum im. on days 1 and 8 as a positive control (0). All three of these 
groups were given a boost of lµg of purified HBcAg on day 34. One group 
remained untreated (0). Mice were sacrificed, splenocytes and draining lymph node 
cells recovered on day 45. The proliferation of spleen (Figure 5-17A) and lymph 
node (Figure 5-17B) cells from pooled mice was measured by ß-emission from cells 
after DNA incorporation of ('H] thymidine over 16 hours following 3 day 
restimulation with a range of peptide concentrations. Assay described in full in 
materials and methods sections 2.5.2 - 25.4. Mean CPM from triplicate cultures of 
pooled cells are shown ± 1SD. Note the difference in scale between spleen and 
lymph node graphs. 
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5.10 Summary of Responses to DNA Prime, Protein Boost 
Vaccination 
5.10.1 Humoral Responses 
The experiments described in this chapter show that pcDNA3.1/core is able 
to induce an antibody response in both C57 b1/6 and BALB/c mice, when delivered 
by im. or gene gun vaccination. This response can be significantly enhanced 
following boosting with the purified antigen. This shows that vaccinated animals 
have seen sufficient antigen as a result of the DNA vaccine to be specifically primed 
against this antigen. Responses to pcDNA3.1/core with an im. HBcAg boost 
appear equivalent and are unaffected by the route of delivery, despite 50 to 100 fold 
less plasmid delivered when the gene gun method is employed. These results show 
that both im. and gene gun DNA vaccination are effective at inducing HBcAg- 
specific humoral responses, especially when coupled with a purified protein boost. 
However, despite the similarity in magnitude of the antibody response, im. 
DNA vaccination leads to an IgG2a dominated response, whilst gene gun 
immunisation results in a more mixed IgGl/IgG2a response. It has been shown 
that the structural nature of HBcAg is crucial to the nature of the T helper response 
developed: mice injected with purified HBcAg developed IgG2a but no IgG1 anti- 
HBcAg antibodies. In contrast, mice immunised with HBeAg, (an HBV protein 
with near identical sequence but which does not polymerise into a particulate form) 
exhibited a response dominated by IgG1 (Milich et aL 1997). This suggests that Th 
cells with the same specificity can develop into different Th subsets depending on 
the structural nature of the antigen. 
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The work in this chapter echoes these findings, with particulate antigen 
stimulating IgG2a production. Immunisation im. with the plasmid also stimulates a 
IgG2a dominated response suggesting that sufficient levels of antigen are being 
produced to form a particle. In contrast, gene gun vaccination results in a mixed 
response including both subtypes. It is unclear from these data whether the route 
of immunisation or the structure of the protein generated by the transfected cells at 
each location is responsible for this difference. However, previous work conducted 
in this laboratory showing a similar pattern of results when comparing im. and gene 
gun delivered DNA vaccines expressing a soluble, non-particulate antigen (Tetanus 
toxin fragment G) (Zlei 2002), suggesting the route of immunisation has a greater 
role to play in this phenomenon. 
5.10.2 Cellular Responses 
In summary, these results show that im. DNA vaccination with 
pcDNA3.1/core is capable of eliciting CD4+ and CD8+ T cell responses. The 
strong T helper proliferative response demonstrates that many helper cells had been 
exposed to and responded to the HBcAg expressed by the DNA vaccine. These 
CD4+ T helper cells are important in co-ordinating the immune response, increasing 
the efficacy of specific humoral and mechanisms as well as encouraging non-specific 
innate immune functions. 
The vaccine has also been shown to induce C IL killing of target cells 
bearing HBcAg epitopes. This is of interest because conventional vaccination 
strategies fail to induce C TL responses to HBcAg. This is thought to be due to the 
difficulty of processing large, particulate antigen in the MHC class I antigen- 
processing pathway. Demonstration of the CTL response in mice immunised with 
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pcDNA3.1 /core confirms that the antigen is being expressed within eukaryotic cells 
where it can readily gain access to the class 1 pathway (see Introduction section 
1.4.1.1). Unfortunately time did not permit similar analysis of antigen specific CD8* 
cells following immunisation with the gene gun. 
This chapter shows that the DNA construct pcDNA3.1/core effectively 
generates specific cellular and humoral responses against the HBcAg. This is true of 
delivery by either the im. route or using a gene gun, and is especially promising 
when the effect of the combined prime-boost strategy is considered. The success of 
the prime/boost vaccination strategy, together with the knowledge that weak 
responses can be effectively increased by a heterologous boost encouraged the 
investigation of other strategies through which HBcAg-specific responses could be 
boosted. These alternative strategies are described in chapters 6 and 7. 
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6 RESULTS - DNA PRIME VACCINATION AND MUCOSAL 
BOOSTING WITH ATTENUATED SALMONELLA 
TYPHIMURIUM 
6.1 Chapter Aims 
The aim of the work described in this chapter was to examine the specific 
humoral and cellular immune responses generated when mice primed systemically 
with DNA encoding HBcAg were boosted mucosally by administration of an 
attenuated strain of S. fpbimurium expressing the same antigen. 
6.2 Introduction 
Mucosal vaccine delivery has many advantages including the fact that oral 
immunisation can induce immune responses at mucosal surfaces as well as 
systemically, thus providing protection at the site of initial entry into the body for 
many pathogens. A full description of mucosal vaccination is given in section 1.5.3. 
S. typbimurium is much studied as a vehicle for delivering heterologous 
antigens in mucosal vaccination. It is relatively simple to manipulate genetically, 
resulting in the production of a range of deletion mutants, many of which have been 
demonstrated to show an appropriate level of attenuation and immunogenicity (see 
Introduction sections 1.532 and 1.5.3.4 and Bumann et al or Darji et al for review 
(Bumann et aL 2000; Darji et aL 2000)). The strain used in these experiments, S. 
typfnmm um BRD509, is also described in the Introduction (section 1.53.3). 
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6.3 Responses to pcDNA3.1/core, S. typhrmurium 
BRD509 pGA-1 Vaccination 
Following the successful boosting of primed responses with systemically 
administered recombinant HBcAg, we wished to consider whether similar levels of 
enhancement could be achieved when different boost vaccination strategies were 
employed. One such approach made use of the attenuated Salmonella strain 
described above; S. typbimurium BRD509 pGA-1. In these studies animals were 
primed systemically as described previously and then the effects of a subsequent 
boost of Salmonella expressing the HBcAg were observed 
6.3.1 Preparation of Bacteria for Intragastric Immunisation. 
To ensure that the primed animals were boosted with an appropriate 
number of viable bacteria, a trial run of the inoculum preparation was undertaken. 
Bacteria were grown for 12-16 hours in anaerobic conditions at 37°C. The bacteria 
were harvested by centrifugation and resuspended in LB broth. As it is impossible 
to estimate the number of viable bacteria prior to the inoculation of the animals, a 
curve was generated that made use of the correlation between optical density at 
650nm (ODd of the culture and viability. This was achieved by preparing the 
bacteria at various values of OD and performing viable counts (see Material and 
Methods section 2.1.6). The resultant graph is shown in Figure 6-1 and was used in 
the preparation of the inoculum for boosting the primed animals. 
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Figure 6-1: Standard curve to establish the relationship between viable 
numbers of Salmonella and optical density of cultures 
The symbol f represents the relationship between OD and viability of S. 
( biwunr im BRD509 pGA-1, whilst the symbol O represents S. typhimurium BRD509 
alone. Values were calculated from colony counts from serial dilution samples 
cultured on agar as described in section 21.6. 
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6.3.2 Immunisation of Mice 
Mice were primed im. with either 10Oµg of the HBcAg expression vector 
(pcDNA3.1/core) or the empty vector on days I and 8 of the experiment (as 
described previously). Sample bleeds taken at day 21 confirmed the previous 
observation that those animals immunised with the pcDNA3.1/core plasmid had 
generated specific anti-HBcAg antibodies. These were absent in mice immunised 
with the vector alone and naive animals (Figure 6-2). Following DNA priming, the 
ten mice in each group (pcDNA3.1/core, pcDNA3.1 alone and naive mice) were 
randomly divided into two groups of 5 animals. The first group were immunised 
intragastrically ii. ) using a gavage needle with BRD509 pGA-1, whilst the second 
group were immunised with BRD509 alone (for vaccination schedule see Figure 6- 
3). The approximate number of viable bacteria administered in each case, is given 
in Table 6-1. This shows that despite efforts to correlate OD with viability, animals 
immunised with Salmonella alone were exposed to approximately 3 times the number 
of bacteria than those given Salmonella expressing the HBcAg. The impact of this 
on the results observed will be discussed later (see section 6.4). In addition, in an 
attempt to study the impact of the Salmonella immunisation alone, naive animals 
were also inoculated with the Salmonella strain. 
Mice were sacrificed 28 days after the i. g. boost and spleens and draining 
lymph nodes recovered. The extended time period between the boost and sacrifice 
(compared to the 10 day period for other experiments in this thesis) was intended to 
allow the bacteria to be cleared by the mice prior to assessment of immunity and 
thus prevent any bacterial infection of in vitro restimulation cultures. 
198 
BRD509 + pGA-1 BRD 509 alone 
Calculated number of bacteria per dose 2.5x101° 8.1x10'0 
Mean anti-LPS titre 1393 3003 
Table 6-1: The relationship between bacteria administered and mean anti- 
LPS titre 
The number of bacteria administered per dose is shown, calculated from cultures of 
serial dilutions made from the bacterial suspension administered to mice. Also 
shown is the calculated mean anti-LPS specific titre in the sera of animals 28 days 
after administration of bacteria. 
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Figure 6-2: Titres of HBcAg-specific antibody in the sera of mice immunised 
with DNA alone 
Titres of serum antibodies from individual mice (") were measured 14 days after 
the second of two 100µg doses of DNA given im. The mean calculated titre of 
each group of 5 mice is indicated as is the threshold of sensitivity of the assay 
(1: 100, represented by horizontal line). 
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intra gastric Sacrifice by cardiac bleed 
Sample bleed DNA vaccinations Sample bleeds Sabsonella boost Recovery of immune tissues 
Figure 6-3: Vaccination regime 
This figure shows the timing of vaccine delivery to the mice and of sample bleeding 
to assess the quantity of the anti-HBcAg generated by each mouse. 
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6.3.3 Humoral Responses to i. m. DNA Prime Vaccination 
Followed by i. g. Boosting with Salmonella Expressing 
HBcAg 
Results in Figure 6-4 show the titres of antibodies in the sera of mice 
immunised im. with DNA and boosted with Salmonella. These data indicate that 
animals primed with pcDNA3.1/core and boosted with BRD509 pGA-1 show a 
mean antibody response more than 10 fold higher than those primed with 
pcDNA3.1/core and boosted with the control Salmonella However, due to the high 
variability of individual titres within this group the results are not statistically 
significant. 
Surprisingly, in contrast to the literature, no immune response was detected 
in animals given Salmonella expressing the HBcAg without DNA priming. However, 
these responses were measured following a single dose of Salmonella and may well 
have increased over time or following administration of a second dose of the 
bacteria (as was used in the described paper) (London tt aL 1996). 
Of the un-primed mice and mice primed with control DNA, only the group 
primed with control DNA exhibited a specific anti-HBcAg antibody response 
following immunisation with the HBcAg-expressing bacteria. The mean titre in this 
group was approximately half that of mice immunised with pcDNA3.1/core and 
boosted with control Salmonella Since no response was observed in un-primed 
mice, it appears that once again, the DNA alone is responsible for some non- 
specific immunostimulatory effects. This is especially impressive given the length of 
time between the second DNA vaccination and the Salmonella inoculation, and the 
physical separation of the sites of administration (i. e. peripherally with the im. 
vaccination versus the mucosal boost). 
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6.3.4 Humoral Responses in Gene Gun-Primed Mice 
In contrast to the result observed in the im. primed animals, boosting of 
animals with Salmonella in mice primed with DNA using the gene gun failed to 
enhance the antibody response generated, with no significant difference between the 
titres before and after the boost (Figure 6-5). The lack of synergy between the two 
vaccinations may be due to the different quality of the immune responses generated. 
As noted previously (see Chapter 5), the gene gun vaccination elicits a more h2- 
like immune response, whereas im. vaccination gives an IgG2a only, Thl response. 
Oral Salmonella immunisation has been described as stimulating a Thl response 
similar to that achieved by priming with DNA im. (Dunstan et at 1998) In this 
case, production of pro-Thl cytokines by Thl cells activated during the boost might 
enhance the activity of antigen specific Thl cells generated in response to the 
priming vaccination. This mechanism may be less successful in gene gun vaccinated 
animals, since Th2 cells from the DNA prime would not respond to cytoldnes 
produced by Thl cells activated by the Salmonella. 
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Groups of 5 C57/B16 mice were immunised im. with 100µg of either 
pcDNA3.1/core or control DNA. This was repeated on day 8 of the experiment. 
Mice were boosted with 10'0 S. typbimmium BRD 509 with or without the pGA-1 
plasmid (Salmonella HBcAg and Salmonella control) on day 35. Mean titres at day 34 
(prior to boost; q and day 63 (post boost, r are shown. Error bars represent I 
standard deviation. 
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Figure 6-4: Titres of HBcAg-specific antibody in the sera of C57/B16 mice 
immunised with DNA i. m. and boosted with Salmonella 
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Figure 6-5: Titres of HBcAg-specific antibody in the sera of C57/B16 mice 
inununised with DNA by gene gun and boosted with Salmonella 
Groups of 5 C57/B16 mice were immunised by gene gun with 1-2µg of either 
pcDNA3.1/core or control DNA. This was repeated on day 8 of the experiment. 
Mice were boosted with 10'0 S. tyßhimmium BRD 509 with or without the pGA-1 
plasmid on day 35. Mean titres at day 34 (prior to boost; Cl} and day 63 (post boost, 
0) are shown. Error bars represent I standard deviation from the mean titre 
calculated from 5 mice. 
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6.3.5 Generation of Mucosal IgA Antibody 
An obvious advantage of combining a systemic and mucosal vaccination 
strategy would be the induction of mucosal as well as systemic immune responses. 
To determine whether the prime boost strategies used above could stimulate the 
production of HBcAg specific mucosal IgA, ELISAs were performed on faecal 
samples and intestinal washes taken from the mice of both gene gun and i. m. prime 
experiments on day 63. Unfortunately, none of the samples showed the presence of 
any HBcAg specific IgA. This was disappointing; especially in the groups given 
Salmonella expressing the antigen alone, which according to the literature should 
have generated these detectable responses. The implication of this poor response 
will be discussed in greater detail later in the chapter. 
6.3.6 Anti-Salmonella Responses 
6.3.6.1 Anti-Salmonella Serum Antibodies 
Serum samples taken at the end of the experiment were examined for the 
presence of anti-S. typbimurium LPS antibodies by ELISA (described in section 
2.5.1.3). The results of this assay (shown in Figure 6-6) show that the mice 
immunised with either strain of Salmonella develop a low but specific anti-LPS 
response. In addition there is a good correlation between the calculated bacterial 
dose and the mean anti-LPS titre with animals immunised, with 3 times more 
Salmonella showing approximately 3 times higher titres of antibodies to LPS in the 
sera (see Table 6-1). These titres indicate that the BRD509 strain is immunogenic 
with or without the plasmid pGA-1, and that the bacteria persist for sufficient time 
for a serum antibody response to develop. 
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Figure 6-6: Anti-S. typhimurium LPS titres in serum 28 days after 
administration 
Mice were immunised with S. typbimurium BRD509 pGA-1 (n=13), S. typhimurium 
BRD509 alone (n=12), or remained naive (n=5). The calculated inoculation doses 
are shown in 'f'able 6-1. Titres of LPS-specific antibodies in the sera of individual 
mice (") and calculated mean titres (horizontal bars) are shown. 
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6.3.62 Anti Salmonella Mucosal Antibodies 
Figure 6-7 shows the and S. typhimurium LPS titres of individual mice 
measured from intestinal washes (P and faecal pellets (FP). In the intestinal wash 
samples, the majority of mice from both groups (those immunised with BRD509 
pGA-1 and those with the control bacteria) display LPS specific IgA responses. 
These responses are about three times stronger in the control group (Salmonella 
alone) than the group immunised with Salmonella expressing the HBcAg. This result 
is in agreement with that observed in the serum titres (Figure 6-6) and probably 
reflects differences in the number of bacteria initially administered (see Table 6-1). 
This result indicates that the Salmonella strains used are capable of generating both a 
mucosal and serum immune response even if this response is limited the carrier. 
6.3.7 Cellular Responses to HBcAg in DNA-Primed Animals 
Following Mucosal Boosting with Salmonella. 
To measure the cellular responses following vaccination, tissues from all 
groups of mice were isolated and single cell suspensions prepared. These were 
either used to measure CD4+ responses using the optimised method described 
(Materials and Methods section 2.5.5) or cultured with RBL5 target cells for the 
CD8+ IFN-y ELISPOT assay (Materials and Methods section 2.5.7). Unfortunately, 
despite the presence of antibiotics in the tissue culture medium in both assays, 
contamination was observed in the cultures of cells taken from mice immunised 
with the Salmonella expressing the HBcAg protein. This contamination prevented 
any measurement of the cellular responses. Interestingly, bacterial growth was 
restricted to cultures taken from those mice immunised with BRD509 pGA-1. In 
order to determine whether the contaminants were the Salmonella used for 
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vaccination persisting in the tissues, an HBcAg-sequence specific PCR was 
conducted. This confirmed the presence of the HBcAg gene in the contaminating 
bacteria, suggesting that the contamination due to the presence of the vaccine strain, 
which was able to persist in vivo for at least 28 days following immunisation. 
Although many experiments using Salmonella as a delivery system have been 
performed successfully at 28 days following vaccination, the study which most 
closely resembles this one (Londono et aL 1996) studied cellular responses 42 days 
after vaccination. It is likely that by this time point the bacteria would be cleared 
from the organs, allowing measurement of cellular responses. 
6.4 Study of Tissue Colonisation by BRD509 
The anti-HBcAg titres generated following im. and gene gun vaccination 
were generally disappointing, especially as this approach has been apparently 
successful previously (Londono et aL 1996). However, on further consideration of 
the literature, it became clear that most of the studies described used BALB/c (H2- 
d) (Schodel et aL 1994); (Huang et aL 2001) rather than C57/B16 mice (H2-b). 
Although am mutants of S. tt phinrurium have been observed to be attenuated in this 
strain of mice (Khan et aL 2003), it has also been shown that inbred mouse strains 
display varying levels of natural resistance to Salmonella infection (Hormaeche 1979). 
It was therefore unclear whether the lack of response reflected differences in the 
ability of the two strains of mice to dear the bacteria. 
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Figure 6-7: Anti-Salmonella LPS antibody detected in intestinal washes from 
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Specific antibody titres from individual mice (") were determined as the reciprocal 
of the highest serum dilution which gave a value of 0.4 above the background. The 
mean calculated titre of groups of mice is indicated as is the threshold of sensitivity 
of the assay (1: 100 - represented by the horizontal line). 
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In an attempt to determine whether colonisation of organs varied in 
BALB/c and C57/B16 mice, parallel experiments were performed in which mice of 
both haplotypes were immunised with the two Salmonella strains used in this 
experiment. Twenty four days after immunisation, animals were culled and Peyer's 
patches, mesenteric lymph nodes, livers and spleens were removed. These tissues 
were homogenised and viable bacterial counts prepared on L-agar plates with and 
without ampicillin. Results of the experiment are shown in Figures 6-8 and 6-9. 
Figure 6-8 shows the number of viable bacteria (CFU/tissue) recovered 
from various tissues and grown on 1-agar plates containing no antibiotics. These 
data dearly show that more bacteria (from animals immunised with bacteria both 
with and without pGA-1) could be recovered from C57/B16 mice than from the 
BALB/c strain. This suggests that the Salmonella strains were being more readily 
cleared from the organs of the BALB/c animals. This may explain why, in contrast 
to the literature, our cultures were contaminated with bacteria 28 days post 
vaccination. Interestingly, when plated on agar in the absence of antibiotic, the total 
number of bacteria from animals immunised with Salmonella or Salmonella containing 
the plasmid did not appear to vary significantly within each mouse strain. This 
suggests that the presence of the plasmid does not result in any additional metabolic 
burden on the strain. However, if the number of viable, ampicillin-resistant bacteria 
recovered from the same animals are calculated (Figure 6-9), it is clear that the 
presence of the plasmid has some effect, as a high percentage of the total bacteria 
have managed to effectively lose this construct. This means the number of bacteria 
capable of re-stimulating the DNA primed response to HBcAg will be fairly low. 
This lack of stability is surprising, given the previous use of the plasmid in Salmonella 
inoculation studies that resulted in the development of specific anti-HBcAg titres 
(Londono et aL 1996). The explanation could be expression of the antigen occurs 
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over an initial period shortly after administration of the bacteria, and although the 
plasmid was lost at some stage, expression up to that point was sufficient to 
enhance the existing systemic antibody response to HBcAg. 
Interestingly, the majority of bacteria were recovered from the Peyer's 
patches and mesenteric lymph nodes in both strains of mice. This result probably 
reflects the relatively low numbers of bacteria that survive and are able to traffic to 
deeper tissues, compared to much larger numbers able to colonise the epithelium 
and M cells of the Pet'er's patches. The high counts in the mesenterics may indicate 
the presence of macrophages recently infected via the nearby GALT but which have 
not yet migrated to other sites. 
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Figure 6-8: Number of viable Salmonella recovered from various tissues of 
BALB/c and C57/B16 mice 24 days after i. g. vaccination 
BALB/c and C57/B16 mice were immunised i. g. with 2.3x101° S. tjphimurium BRD 
509 with or without the pGA-1 plasmid. Mice were sacrificed and Peyer's patches, 
mesenteric lymph nodes (MIN), spleens and livers were recovered. Tissues were 
homogenised and serial dilutions made in PBS. Dilutions were plated on LB agar 
and incubated overnight at 37°C. CFU per organ were calculated from colony 
counts. Figures 6-8A -D show the number of bacteria recovered from C57/B16 
mice whilst Figures 6-8E -H show the number recovered from BALB/c mice. A 
and E are counts from the Peyer's patches, B and F from the mesenteric lymph 
nodes, C and G from the spleen and D and H from the liver. 
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Figure 6-9: Number of viable, ampicillin resistant bacteria recovered form 
the tissues of BALB/c and C57/B16 mice 24 days after i. g. vaccination 
Samples from the same mice as described in Figure 6-8 were cultured on LB plates 
containing ampicillin. This allows growth of only S. typhimurium BRD509 carrying 
the pGA-1 plasmid. A shows counts from the Peyer's patches, B from the 
mesenteric lymph nodes, C from the spleen and D from the liver. 
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6.5 Summary of Results 
In these experiments, priming of a humoral response was only boosted by 
ig. vaccination with S. typhimurium BRD509 pGA-1 when DNA was delivered im. 
Such an enhancement was not observed when the animals were primed 
intradermally using the gene gun (Figure 6-4). 
Obviously the efficacy of the prime-boost strategies described in this 
chapter cannot be fully assessed without consideration of the T helper cell and CTL 
activation. This could be addressed by extending the period between Salmonella 
vaccination and harvesting cells for T cell assays to 42 days (Londono et at 1996). 
Alternatively, different antibiotics could be used in the in vitm cultures that would 
more effectively prevent bacterial growth. CD4+ T cell proliferation data would 
give a much dearer understanding of the role of the mechanisms driving the anti- 
HBcAg antibody response, as well as clarifying the presence and magnitude of a 
CD8+ T cell response. 
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7 RESULTS - SYSTEMIC DNA AND INTRANASAL PROTEIN 
VACCINATION 
7.1 Chapter aims 
The aim of the work described in this chapter was to determine the impact 
of mucosal boosting with purified protein on the magnitude and type of immune 
response generated in mice that had been previously vaccinated systemically with 
pcDNA3.1 /core. 
7.2 Introduction 
Work described in Chapter 5 examined the effect of systemic boosting, 
using purified protein, on the immune response generated following systemic 
priming of the animals with the DNA vaccine pcDNA3.1/core. In this chapter, 
experiments were designed to determine to what extent mucosal boosting using 
purified protein could affect the nature and magnitude of the primed responses 
generated. 
These experiments aimed to answer the following questions: 
1. Is the HBcAg particle an effective mucosal antigen, or does it require 
the presence of a mucosal adjuvant to trigger the mucosal response? 
For a description of the mucosal adjuvants used in this project, see 
sections 1.3.1 and 1.5.4.3. 
2. Does priming with systemic DNA vaccination prior to mucosal 
boosting with the particulate HBcAg enhance the subsequent immune 
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response? If so, what effect does the route (that is, im. or id) of the 
priming vaccination have on the final immunological readout? 
7.3 Efficacy of HBcAg as a Mucosal Immunogen 
7.3.1 Humoral Responses to i. n. Delivered Purified HBcAg 
In initial experiments mice were immunised intranasally with purified 
HBcAg in the presence or absence of the mucosal adjuvant LT. In addition, as a 
positive control, a third group of animals were immunised im with 1µg of HBcAg, 
without adjuvant. Ten days later the HBcAg specific serum antibody response was 
measured by ELISA. The data shown in Figure 7-1 indicates that even after this 
relatively short period of time, mice that received HBcAg in. with LT developed a 
low but detectable anti-HBcAg response in the sera. These responses were of a 
similar order of magnitude to those observed when the same amount of protein was 
delivered parenterally without adjuvant. In contrast, mice immunised with the same 
dose of HBcAg in. in the absence of an adjuvant, only a very low antigen specific 
response was observed. Therefore the immunogenicity of the protein is dependent 
on the route of delivery. Nose and lung washes were also examined for the 
presence of anti-HBcAg antibody, but no specific responses were observed in any 
of the samples tested. 
7.3.2 CD4+ T Cell Proliferation 
In addition to humoral responses, proliferation of HBcAg specific CD4+ T 
was also measured in these mice. For these experiments cells were isolated from the 
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spleens and cervical lymph nodes (CLN) and restimulated in in with HBcAg 
specific peptide (Materials and Methods section 2.5.2 - 2.5.5). 
The results of these experiments are shown in Figure 7-2. Following in. 
delivery of HBcAg with IT, strong proliferation of antigen specific CD4* T cells 
can be observed in both the spleens and CLN. Interestingly, the proliferation 
appears greater in the local draining lymph nodes than the spleen, with the average 
count at the highest concentration of restimulating antigen more than 20,000 higher 
than that in the spleen. In contrast, when the antigen was delivered without LT, 
there was no detectable response in the lymph nodes and only a moderate response 
in the spleen. This demonstrated that the presence of the LT adjuvant is very 
effective at stimulating a long-lasting antigen specific CD4* response in the local 
tissues. 
The CD4; proliferation in response to HBcAg delivered im. also appears to 
be different from the situation with LT as in this case, like the antigen alone 
mucosally, low responses are seen in spleens but not in the local draining lymph 
nodes (popliteal and inguinal), as shown in Figure 5-5, for example. This 
demonstrates that the localisation and magnitude of immune responses may be 
dependent on both the route of immunisation and the adjuvant used to enhance this 
response. 
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Figure 7-1 Serum anti-HBcAg titres following in. or i. m. HBcAg vaccination 
in C57/B16 mice 
Groups of 10 C57/B16 mice were immunised in. with 1µg HBcAg with or without 
LT, or with 1 µg of HBcAg im. The mean serum anti-HBcAg titres are shown prior 
to immunisation Q or 10 days post immunisation (W, ± 1S. D. Results are 
representative of two experiments. 
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Figure 7-2: i. n. HBcAg vaccination; effect of LT adjuvant on CD4+ 
proliferation 
Groups of 5 C57/B16 mice were immunised with 1Etg of HBcAg in with (0) or 
without LT (ti). One group remained untreatedol. Ten days later mice were 
sacrificed and the proliferation of pools of B cell depleted cervical lymph node 
(Figure 7-2A) or spleen (Figure 7-2B) cells was measured by [i-emission of cells 
after DNA incorporation of [ l1] thymidine over 16 hours following 3 day 
restimulation with a range of HBcAg peptide [aa 120-1401 concentrations. Mean 
CPM of triplicate cultures of pooled cells are shown ± 1SD. 
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7.4 Intramuscular DNA Prime, Intranasal HBcAg Boost 
Vaccination 
In line with the previous chapters, we aimed to determine the effect on 
DNA primed animals of boosting these same animals mucosally with purified 
HBcAg delivered in. An outline of the timings for the vaccination protocol is 
outlined in Figure 7-3. 
7.4.1 HBcAg-Specific Humoral Responses 
As observed previously, i. m. immunisation with pcDNA3.1 /core induced a 
low but measurable response to the HBcAg in the sera of vaccinated mice (Figure 7- 
4). However, following in. boosting, this response was improved by approximately 
five-fold. This increase was found to be statistically significant and in contrast to 
the previous data, appeared to be independent of whether or not LT was included 
as a mucosal adjuvant (p>0.95 for both groups). In light of these data it is not clear 
whether the protein boost is responsible for the measured increase in titres 
observed or whether these increases are the result of continued expression from the 
pcDNA3.1/core vector. Although time did not allow completion of these 
experiments, it would be relatively easy to determine whether this was the case by 
examination of HBcAg titres from animals primed with pcDNA3.1 /core only. 
In contrast, animals primed with the vector alone showed only very modest 
levels of anti-HBcAg in the serum (in line with those responses described in 7.3.1). 
Disappointingly, no antigen specific antibodies against HBcAg or LT could be 
detected in any of the mucosal washes tested. 
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Day 0 Day I Day 8 Day 21 Day 34 Day 35 Day 45 
in. ID3cAg boost Sacrifice by cardiac bleed 
Sample bleed DNA vaccinations Sample bleeds (with LT) Recovery of immune tissues 
IlBcAg i. n. 
experiments 
DNA prime 10 10 
Figure 7-3: Vaccination regime for DNA prime, i. n. boost experiments 
The timing and nature of vaccinations and sampling in the experiments described in 
this chapter. 
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Figure 7-4: HBcAg-specific titres in the sera of DNA-primed mice pre- and 
post-boost vaccination 
Groups of 10 C57/B16 mice were immunised im. with 100µg DNA 
(pcDNA3.1/core and DNA control groups), on days 1 and 8 of the experiment. 5 
mice from each group were boosted with lµg HBcAg with LT, 5 with HBcAg alone 
on day 35. The mean serum anti-HBcAg titres are shown on day 34 (CI) and day 45 
(r), ±1 SD. 
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7.4.2 CD4+ T Cell Proliferation 
In addition to humoral responses, CD4i proliferative responses were also 
measured in the local lymph nodes and spleens of the im. vaccinated mice. Figure 
7-5 shows the responses observed in the CLN of DNA-primed animals boosted 
with purified protein in the presence or absence of LT as an adjuvant. The 
responses in spleen cells are shown in Figure 7-6. 
In contrast to expectations, in both local lymph nodes and splenic tissue, 
pre-immunisation with the pcDNA3.1/core vector appears to reduce the capacity 
of the mucosal adjuvant LT to stimulate CD4; specific T cells as responses in these 
animals were shown to be lower than those observed in animals that were 
immunised with vector alone. In these animals, CD4+ cells from both local lymph 
nodes and spleens showed a very strong proliferative response following 
immunisation with LT and HBcAg (similar to that seen on immunisation with 
I-IBcAg and LT without any DNA prime, Figure 7-2). In addition, there is a 
consistency in the data with that observed previously in that proliferation was seen 
in lymph nodes when an HBcAg boost was given with IT, whilst in the spleens, 
proliferative responses were generated whether HBcAg was given alone or with LT. 
The magnitude of the humoral response generated does not appear to be 
significantly different between the two groups. This would suggest one of two 
possible explanations. Either the humoral response is unaffected by the mucosal 
boost (antibodies measured are generated by DNA alone), or the key location for 
interaction between primed T -cells for enhancement of the immune response is the 
spleen. 
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Figure 7-5: Measurement of HBcAg specific CD4+ responses in the CLN of 
DNA-primed mice boosted in. with purified HBcAg 
Groups of 5 C57/B16 mice were immunised as described in Figure 7-4: i. m. with 
100µg DNA (pcDNA3.1/core and DNA control groups), on days 1 and 8 of the 
experiment. All groups were boosted with 1µg HBcAg, either with or without LT, 
on day 35. Ten days later mice were sacrificed and the proliferation of pools of B 
cell depleted lymph node cells was measured by [3-emission of cells after DNA 
incorporation of ['H] thymidine over 16 hours following 3 day restimulation with a 
range of HBcAg peptide [aa 120-1401 concentrations. Mean CPM of triplicate 
cultures of pooled cells are shown ± 1SD. Figure 7-5A shows mice primed with 
pcDNA3.1 /core and boosted in. with HBcAg and LT (+) or HBcAg alone (O). 
Figure 7-5B shows mice primed with control DNA and boosted in. with HBcAg 
and LT U or HBcAg alone (0). 
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Figure 7-6: Measurement of HBcAg specific CD4+ responses in the spleens 
of DNA-primed mice boosted i. n. with purified HBcAg 
Mice were vaccinated and spleen cell proliferation measured in the same way as for 
lymph nodes (Figure 7-5). Figure 7-6A shows mice primed with pcDNA3.1/core 
and boosted in. with HBcAg and LT (") or HBcAg alone (O). Figure 7-6B shows 
mice primed with control DNA and boosted in. with HBcAg and LT (1) or HBcAg 
alone P. 
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7.5 Gene Gun DNA-Prime, intranasal HBcAg Boost 
Vaccination 
7.5.1 HBcAg-specific Humoral Responses 
As described previously, in response to the gene gun vaccination with 
pcDNA3.1/core a specific and detectable response to HBcAg was observed prior 
to boosting, as shown in Figure 7-7. On mucosal boosting with the purified protein 
and LT, the magnitude of this response was significantly enhanced over that 
observed prior to the boost (p=0.00722). There was also an increase in the group 
boosted with HBcAg alone, but this was increase was not statistically significant due 
to variation in individual titres within the group. As with the i. m. prime and 
boosted experiment, the inclusion of LT as the adjuvant did enhance the humoral 
response over that observed when the antigen was used alone. Once again, no IgA 
specific responses to HBcAg or LT could be detected in nasal or pulmonary washes. 
7.5.2 CD4+ T Cell Proliferation 
The HBcAg-specific proliferations measured in response to this prime boost 
regimen are shown in Figure 7-8 (CLN) and Figure 7-9 (spleen) respectively. In the 
local lymph nodes, gene gun administration of pcDNA3.1 /core followed by an in. 
boost of HBcAg alone resulted in proliferation of the same level as that induced by 
vaccination with control DNA boosted by HBcAg with LT. When animals were 
primed with pcDNA3.1 /core and boosted with HBcAg with LT the response was 
higher still. This situation is the reverse of the observed following im. vaccination, 
where priming the animals with pcDNA3.1/core and boosting with LT + HBcAg 
appeared to reduce the proliferative response. Once more, the magnitude of spIcnic 
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responses did not appear to be affected by the inclusion of LT as a mucosal 
adjuvant 
These data are of particular interest in that the pattern of the response being 
enhanced at the local (lymph node) rather than the systemic (spleen) level following 
gene gun vaccination corresponds to that observed following systemic boosting of 
DNA primed animals as shown in Chapter 5. 
7.6 Comparison of IgG Subtype Titres 
Figure 7-10 shows a comparison of the IgGl and IgG2a titres measured in 
response to the prime-boost vaccination regime with and without LT. In line with 
the total IgG titres, the IgG2a titres are higher in the im. group than the gene gun 
group. As previously noted in chapter 5, gene gun, but not im. vaccination, 
induced low levels of IgG1 antibody, indicating a more Th2 like response in the 
gene gun group. Inclusion of LT as a mucosal adjuvant in these experiments did 
not appear to influence the IgG1: IgG2a generated. 
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Groups of 10 C57/B16 mice were immunised by gene gun with 100µg DNA 
(pcDNA3.1/core and DNA control groups), on days 1 and 8 of the experiment. 5 
mice from each group were boosted with lµg HBcAg with LT, 5 with HBcAg alone 
on day 35. The mean serum anti-HBcAg titres are shown on day 34 (q and day 45 
(0), ± 1S. D. 
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Figure 7-7: HBcAg-specific titres in the sera of gene gun DNA-primed mice 
pre- and post-i. n. HBcAg boost vaccination 
Groups of 5 C57/B16 mice were immunised as described in Figure 7-4: by gene gun 
with 100µg DNA (pcDNA3.1/core and DNA control groups), on days 1 and 8 of 
the experiment. All groups were boosted with 1µg HBcAg, either with or without 
LT, on day 35. Ten days later mice were sacrificed and the proliferation of pools of 
B cell depleted cervical lymph node cells was measured by n-emission of cells after 
DNA incorporation of ['H] thymidine over 16 hours following 3 day restimulation 
with a range of HBcAg peptide [aa 120-140] concentrations. Mean CPM of 
triplicate cultures of pooled cells are shown ± 1SD. Figure 7-8A shows mice primed 
with pcDNA3.1/core and boosted in. with HBcAg and LT (/) or HBcAg alone 
(0). Figure 7-8B shows mice primed with control DNA and boosted i. n. with 
HBcAg and LT (") or HBcAg alone (O). 
230 
Figure 7-8: Measurement of HBcAg specific CD4* responses in the CLN of 
gene gun DNA-primed mice boosted i. n. with purified HBcAg 
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Figure 7-9: Measurement of HBcAg specific CD4+ responses in the spleens 
of gene gun DNA-primed mice boosted i. n. with purified HBcAg 
Groups of 5 C57/B16 mice were immunised as described in Figure 7-4: by gene gun 
with 100µg DNA (pcDNA3.1 /core and DNA control groups), on days 1 and 8 of 
the experiment. All groups were boosted with 1µg HBcAg, either with or without 
LT, on day 35. Ten days later mice were sacrificed and the proliferation of pools of 
B cell depleted spleen cells was measured by ß-emission of cells after DNA 
incorporation of ['H] thymidine over 16 hours following 3 day restimulation with a 
range of HBcAg peptide [aa 120-140] concentrations. Mean CPM of triplicate 
cultures of pooled cells are shown ± 1SD. Figure 7-9A shows mice primed with 
pcDNA3.1/core and boosted in. with HBcAg and LT (0) or HBcAg alone (1). 
Figure 7-9B shows mice primed with control DNA and boosted in. with HBcAg 
and LT (+) or HBcAg alone (O). 
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Figure 7-10: Antibody subtype titres following i. m. and gene gun vaccination. 
C57/B16 mice were immunised with 100µg pcDNA3.1 /core or control DNA on 
days 1 and 8, either im. (Figure 7-10A) or by gene gun (Figure 7-10B). Animals 
were boosted with 1µg HBcAg in., with or without LT on day 35. 
Immunglobulin subtypes were examined on day 45. Calculated specific anti- 
HBcAg titres are shown. A represent IgG1 titres for individual mice, 11 represent 
IgG2a titres. 
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7.7 Mucosal Antibody Production 
Given the strong CD4+ proliferation observed in these experiments in local 
lymph nodes, it was hoped that a mucosal antibody response would develop. 
However, this promise was not borne out by ELISAs using nasal and pulmonary 
washes; no HBcAg specific IgA responses could be detected in any samples. To 
determine if a secretory antibody response had developed against the adjuvant, LT- 
specific ELISAs of these samples were also conducted, but again, no specific 
responses could be detected. 
This was disappointing, and upon reflection, it may be that either a greater 
length of time is required between the delivery of the protein boost and the 
examination of the mucosal tissues, or that multiple doses of LT and HBcAg are 
required to maximise this response. In previous studies, antigen specific IgA has 
been observed in nasal and lung washes following at least three immunisations with 
a similar toxin (Douce et aL 1997). 
7.8 Summary of Results 
7.8.1 Humoral Responses 
Overall, the magnitude of the humoral responses generated when animals 
are primed im. or by gene gun and boosted mucosally are remarkably similar. Final 
titres, after the boost, are slightly higher in the gene gun experiments when 
equivalent groups are examined, but these differences are small and not statistically 
significant. Disappointingly, neither vaccination strategy resulted in measurable IgA 
specific antibodies against either HBcAg or against LT. 
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7.8.2 CD4+ T Cell Responses 
The experiments described in this chapter demonstrate that there are 
differences in the localisation of CD4' specific T -cells following priming with DNA 
either by im. or gene gun delivery. As seen before in Chapter 5, following boosting 
of gene gun immunised animals, the majority of proliferation occurs in the lymph 
nodes, whilst in animals vaccinated im., the greater responses were found in the 
spleen following the boost. However, the use of LT appears to introduce a second 
location-specific response. Since it is a mucosal adjuvant, it is unsurprising that the 
toxin enhanced the responses observed in the CLN, however, more interesting is 
the fact that these responses were enhanced in these lymph nodes if the animals 
were primed using pcDNA3.1/core using the gene gun. In contrast use of LT in 
mice primed using the im. route generated less proliferation in the local lymph 
nodes than those immunised with the vector backbone. The implications for these 
observations on use of prime boost strategies are given in the Discussion. 
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8 DISCUSSION 
Although there has been a large volume of work conducted on the efficacy 
of DNA vaccination, there have been few studies systematically comparing the 
delivery of one antigen by different vaccination strategies. Likewise, although 
prime-boost vaccination has been studied in depth, parallel studies comparing 
delivery of a particulate antigen by different prime-boost vaccination strategies have 
rarely been conducted, in fact, only one study (based on a regime of DNA-prime, 
protein boost (Schirmbeck and Reimann 2001)), could be found. The results 
presented in this thesis directly compare the immune response to im. and gene gun 
HBcAg DNA vaccination in three prime-boost vaccination strategies. The 
strategies studied were: systemic DNA vaccination boosted either systemically with 
(Lm. ) recombinant protein, or mucosally using purified protein or attenuated 
Salmonella strain as a delivery vehicle. 
8.1 Intramuscular DNA Vaccination 
In order to examine the impact of vaccinating with the DNA vaccine 
pcDNA3.1/core alone, the response to im. delivery of the plasmid was studied in 
isolation. These experiments are described in Chapter 5. Several experiments 
consistently showed the ability of the plasmid to induce a limited humoral response. 
The magnitude of this response was found to be independent of whether DNA was 
delivered im. or by gene gun. The generally low level of antibody produced by 
DNA vaccination when unaccompanied by a heterologous boost is probably a 
consequence of too low a concentration of protein in the extracellular environment 
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for the activation of significant numbers of B cells. This is consistent with work 
described in the literature describing variable humoral responses to DNA 
vaccination (Davis and McCluskie 1999). 
CD4' T cell proliferation was not observed over the short time-scale initially 
examined, when DNA was given on days 1 and 8 and cells recovered on day 21. 
However, an alternate protocol in which mice were immunised with two doses of 
DNA on days 1 and 28, and cells were examined on day 56, revealed strong 
proliferation. This shows the importance of selecting the most appropriate time- 
scale for vaccination and examination of responses. 
In contrast, a strong CD8' response could be measured relatively quickly 
(10 days) after a single vaccination. These could be restimulated in vitm with an 
HBcAg specific peptide to secrete IFN-y and were also shown to be capable of 
killing target cells expressing an HBcAg epitope in an antigen-specific manner. 
These results are in agreement with a body of work in the literature, regarding 
activation of CD8'' T cells following DNA vaccination, as measured by IFN-y 
secretion (Sedegah et aL 1998), (not previously shown for HBcAg), and antigen- 
specific cytotoxicity in the same cells (which has been shown in HBcAg studies: 
(Bohm et aL 1996; Kuhrober et aL 1996). The relatively early time point at which 
these can be measured suggests that expression of antigen in the context of MHC 
class I occurs more rapidly than in the context of MHC class II. 
Although vaccination with pcDNA3.1 /core alone demonstrated that this 
vaccine has the potential to induce powerful cellular responses, the low humoral 
response generated reduces the applicability of these type of vaccines over a greater 
number of diseases in which both cellular and humoral responses are important. 
Therefore the challenge remained of strengthening humoral responses and perhaps 
of enhancing the existing cellular responses. The experiments discussed below (and 
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detailed in the remainder of Chapter 5, and Chapters 6 and 7), examined the 
heterologous prime-boost strategies that were studied in order to achieve these 
aims. 
8.2 DNA Prime, Recombinant Protein Boost Vaccination 
Animals that had been primed with the pcDNA3.2/core construct were 
boosted with small amounts of purified antigen alone (as outlined in the latter part 
of Chapter 5). These experiments consistently showed that the humoral responses 
primed by pcDNA3.1 /core could be enhanced by boosting the animals with 
purified protein. These responses were significantly higher than those titres 
observed in animals which were only given the purified protein boost or were pre- 
immunised with the vector backbone alone. In addition, cellular responses did not 
appear to be affected following im. boosting with recombinant protein. The CD4+ 
Th proliferations induced were equivalent to those seen following multiple 
vaccinations with the protein, in line with observations in the literature (Böcher et aL 
2001). 
Unfortunately, results from later experiments, in which DNA alone was 
administered and responses were measured after a longer time period, did not 
determine whether the strong CD4' response measured following prime-boost 
vaccination results from the boost effect. It could also be due to continual exposure 
of the antigen from the DNA vaccine over a long period of time, as seen in the 
extended time-scale DNA alone experiment. It seems likely, though, that both the 
prime and booster vaccinations contribute to the CD4t response, since the purified 
HBcAg protein has been shown to elicit such responses following im. injection of 
the purified antigen alone (Milich and McLachlan 1986). 
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The responses to im. and gene gun vaccination appeared superficially 
similar, but two main differences were observed. These were: firstly, the localisation 
of the CD4* cells that exhibited the strongest HBcAg-specific proliferation and 
secondly, the pattern of antigen-specific IgG subtype production. Intramuscular 
vaccination with DNA and recombinant protein induced strong CD4+ proliferative 
responses in cells isolated from the spleen, but weaker responses in draining lymph 
nodes close to the site of vaccination, at the time-point examined. Interestingly, this 
observation is reversed with epidermal gene gun vaccination; higher CD4+ 
proliferation was observed in the lymph nodes than in the spleen. This may be 
linked to the timing of the experiments; it has been shown that T cell responses 
initiate in draining lymph nodes and are not observed until later in the spleen 
(Akbari tt aL 1999). Alternatively it may suggest that less antigen is being generated 
using this route of immunisation and may reflect the lower dose of DNA used for 
this form of vaccination. 
It has been suggested that activation of native CD4+ cells depends solely 
upon antigen presentation by DCs (Akbari et aL 1999; Jenkins et aL 2001). In the 
case of gene gun vaccination, the main group of cells involved would be LCs, a 
subset of DCs that form an almost continuous layer in the dermis, and which are 
directly transfected during gene gun vaccination (Tighe et aL 1998). These cells 
become migratory due to inflammatory signals caused by tissue damage associated 
with vaccination and express chemokines, which direct migration to the secondary 
lymphoid tissues. Within these tissues they are able to activate CD4' T cells 
following specific recognition of the presented antigen by the TCR (see 
Introduction section 1.4.1.2). The occurrence of a stronger CD4; proliferation in 
the lymph nodes following gene gun vaccination could therefore also be due to the 
238 
preferential initial migration of the DCs transfected during vaccination to the lymph 
nodes prior to the spleen Qenkins et aL 2001). 
Following im. DNA vaccination, on the other hand, myeloid DCs (from 
other sites within the body) rather than DCs will be involved in the processing and 
presentation of antigen to CD4+ cells. These DCs will be attracted to the site of 
vaccination due to inflammation caused by tissue damage. They could process and 
present HBcAg epitopes as MHC class II-peptide complexes by one of two 
mechanisms. Firstly by taking up HBcAg, expressed by myocytes, as exogenous 
antigen (which is the same mechanism by which purified HBcAg from the boost 
vaccination is processed and presented). A perhaps less likely mechanism, would be 
that the DCs internalise the pcDNA3.1/core plasmid and express the HBcAg 
themselves. As well as the MHC class I presentation that would follow expression, 
it is possible that some peptide would be presented by MHC class II through cross- 
priming mechanisms (see Introduction section 1.4.1.3). Whichever mechanism is 
responsible, the DCs may then migrate directly to the spleen rather than to 
peripheral draining lymph nodes, which could explain the higher CD4' proliferation 
observed in the spleen following im. DNA immunisation (Akbari et aL 1999; 
Bajenoff and Guerder 2003). Further details of the localisation of the T cell 
response are discussed below in section 8.6. 
Another difference between the responses following im. and gene gun 
vaccination is nature of the humoral response. These results indicate that both im. 
DNA vaccination with a plasmid encoding HBcAg and vaccination with purified 
protein, generate a strong IgG2a response, with little or no IgGI. In contrast, gene 
gun vaccination results in response that includes both subtypes of antibody. This 
mixed response is in contrast to previous work conducted in this laboratory and 
elsewhere (Zlei 2002; Zhou et aL 2003), showing a more definitive shift to a Th2 
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phenotype when DNA vaccines encoding non-particulate antigens (Tetanus toxin 
fragment C) are delivered by gene gun. It is therefore possible that the differences 
observed reflect the impact of the structure of the particle on the response induced. 
For example, it has previously been shown that the HBcAg preferentially induces 
Thl responses when delivered im., as indicated by the presence of IgG2a, but no 
IgG1 anti-HBcAg antibodies. This response is believed to reflect the particulate 
nature of the antigen, as mice immunised with HBeAg, (an HBV protein with near 
identical sequence but which does not polymerise into a particulate form) exhibited 
a response dominated by IgGl (Milich et aL 1997). 
This result suggests that the antigen is being expressed following im. 
vaccination that it is being generated in sufficient quantities to generate particulate 
structures, (although there is no direct evidence of this). In contrast, the mixed 
response observed following gene gun vaccination (which usually induces Th2 
responses (Zhu et aL 2004) suggest that that some particle structure is also being 
generated. However, due to the relatively low amount of DNA delivered and 
therefore protein expressed, the concentration maybe insufficient for generation of 
high numbers of complete particles leading to the mixed response observed. 
Therefore, gene gun delivery of pcDNA3.1 /core may still have potential for 
immunomodulation of existing Th2 responses to Thi, unlike delivery of other 
antigens by gene gun (see Introduction section 1.5.4.3) and section 8.6 on 
therapeutic vaccination, below. 
Trans-dermal protein vaccination, like gene gun vaccination, induces Th2 
biased responses, as determined by cytokine production and antibody subtype 
analysis (Strid et aL 2004), whereas im. DNA vaccination gives Ill responses 
(Fcltquate et aL 1997). This suggests that it is the route of vaccination that results in 
the induction of 112 cells rather than the nature of the vaccine (DNA or protein). 
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It is likely that LCs are the most important APCs involved in generation of the 
responses in these cases, given the presence of large numbers of LCs in the dermis. 
Myeloid derived DCs (MDC) in mice express TLR-9 and can therefore their antigen 
presenting and T cell activating capabilities can be enhanced by CpG motifs (Cella et 
aL 1999; Krug et aL 2001). Most MDCs, such as those derived from peripheral 
blood monocytes, preferentially induce CD4' differentiation into Thi cells (Rissoan 
et aL 1999). However, the LCs that reside in the dermis, although derived from the 
same lineage, have been shown to differ in several aspects from other MDC, 
including a lack in IL-12 production (a pro-Thi cytokine) following stimulation 
(Peiser ct aL 2004). Since vaccine antigen is more likely to encounter other MDCs 
capable of producing IL-12, this could explain the resultant Th2 bias of gene gun 
vaccination compared to im. vaccination. 
Another potential factor in the bias of the CD4+ response is the level of 
CpG motifs present in the two forms of vaccination. Although both methods 
produce sufficient antigen to stimulate cellular and humoral responses, im. 
vaccination uses greater quantities of DNA, and therefore contains more CpG 
motifs. Since these motifs preferentially generate Thl immunity (see Introduction 
section 1.5.4.3) this provides a simple potential explanation for the results, backed 
up by observations that addition of CpGs to gene gun delivered DNA overcomes 
the usual Th2 bias of this strategy (Schirmbeck and Reimann 2001; Zhou et al 
2003). 
8.3 DNA Prime, Oral Salmonella Boost Vaccination 
Several prime-boost studies involving delivery of attenuated Salmonella 
expressing vaccine antigens have been performed to date. In one such experiment 
241 
Salmonella expressing a 1l ycobacterium tuberculosis antigen were delivered by i. v. 
injection to animals that had been primed by gene gun with DNA expressing the 
same antigen (Mollenkopf et al 2001). Interestingly, whilst the Salmonella expressing 
the antigen offered some protection against M. tuberculosis challenge, the animals 
which had been primed with DNA did not experience enhanced protection. 
Unfortunately this study failed to characterise specific immunological readouts and 
it is therefore unclear why the DNA prime appeared ineffective. Other prime-boost 
vaccine strategies involving Salmonella have in general used the bacteria as the prime 
immunisation (Devico et aL 2002; Londono-Arcila et aL 2002). In these studies, 
Salmonella prime was followed by a heterologous boost using purified protein. As 
such it is difficult to directly compare the results with the work in this thesis, 
although these experiments show that the prime-boost strategies offer improved 
immune responses over single vaccinations. 
One recent study found that boosting gene gun primed BALB/c mice with 
Salmonella gave a much more Thl-like response than mice given the gene gun prime 
alone (Lange et aL 2004). This provides some evidence that gene gun delivery might 
not preclude the use of a strategy as a therapeutic vaccine designed to initiate a type 
1 response. However, it was not clear from this study whether this response would 
have been further enhanced if the mice had been initially primed using the im. 
route of immunisation. 
The work presented in Chapter 6 explores the impact of priming the 
immune system using pcDNA3.1 /core, by either im. injection or gene gun delivery 
and boosting with subsequent oral delivery of Salmonella expressing the same 
antigen. 
The success of prime-boost strategies is dependent on both forms of 
vaccination being efficacious and synergistic. In these experiments, BRD509 pGA- 
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1 was able to generate serum antibody titres to HBcAg following im. priming with 
DNA. This indicates that there is at least some degree of positive interaction 
between the responses to two vaccines. This could take the form of restimulation 
of memory T cells from the DNA vaccination by Salmonella-expressed HBcAg 
presented by APCs either at the mucosa or elsewhere. 
Interestingly, although a strong increase in antibody titres was observed 
following the Salmonella boost in the im. experiment, this increase was not observed 
when the DNA vaccine-prime was delivered by gene gun. A possible explanation 
for the observed difference involves the restimulation of memory CD4* T cells that 
had been activated in response to the initial DNA vaccination. For this 
restimulation to occur, HBcAg must be transported (free, expressed by Salmonella or 
carried by APCs) from the mucosa to locations where primed lb cells will be found 
(e. g. the spleen or peripheral lymph nodes). Evidence discussed elsewhere in this 
thesis suggests a localisation of the Th response in the spleen following im. DNA 
vaccination. If the Salmonella response was likewise directed to the spleen, this could 
enhance the existing response. However, in the case of a gene gun prime, the 
responses to the prime and boost would occur in separate locations and might not 
enhance antibody production. It is also possible that by using the different routes 
of DNA priming that antagonistic immune responses are produced. For example it 
is possible that the M2 cells activated by the gene gun prime immunisation (Creusot 
et aL 2001) down-regulate responses to HBcAg expressed by Salmonella, which is 
known to generate a more Thl-like response (Medina and Guzman 2000). 
Another interesting observation in the im. experiment was the complete 
lack of antibody response when previously naive mice were immunised with 
BRD509 pGA-1, compared to a response in the group of mice primed with the 
control plasmid before boosting with the same bacteria. This result may reflect the 
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impact of unmethylated CpG motifs on the immune system. Pre-immunisation 
with pcDNA3.1 may have activated the immune system via interaction with cells 
bearing TLR-9, resulting in the upregulation of co-stimulatory molecules by APCs 
and providing the secondary signal needed in addition to specific antigen- 
recognition for the activation of naive lymphocytes (see Introduction section 1.4.1). 
The plasmid expressing HBcAg also contains these motifs and therefore should 
help stimulate a specific antibody response following BRD509 pGA-1 vaccination 
in the same way as the control plasmid. In the parallel experiments using the gene 
gun, there was no significant difference in titres following the boost, whether 
animals were primed with control DNA or pcDNA3.1 /core (Figure 6-5). This lack 
of response could reflect the failure of HBcAg-specific memory T cells and CpG- 
stimulated APCs to migrate to areas in which Salmonella expressing HBcAg are 
present. This theory is supported by the previous data that showed that im. DNA 
vaccination induced strong proliferative responses by cells from the spleen, whilst in 
contrast following gene gun immunisation proliferation was stronger in the lymph 
nodes than the spleen. In addition, gene gun delivery requires substantially lower 
amounts of DNA to prime a response, therefore there is less CpG DNA available 
for stimulation of Toll receptors. The impact of these motifs on the boost response 
could be further elucidated by the comparison of experiments in normal and TLR-9 
knock-out mice. It is unclear at this stage the failure of gene gun control DNA to 
enhance future responses could be overcome by more appropriate timing of the 
delivery of the prime and boost or whether one of the limitations of DNA 
vaccination using the gene gun is lack of non-specific immuno-potentiation due to 
relatively small quantities of CpG motifs. 
The inability to measure cellular responses from the vaccination experiments 
due to bacterial growth in ex tim cultures was frustrating, given the added insight 
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that the data could have provided into the nature of the overall immune response. 
As well as the information on CD4+ proliferation that would have helped to shed 
light on the development of the humoral responses, it would have been of interest 
to know the level of CD8+ T cell activation. 
The attenuated strain used in these experiments, S. typhimuiizum BRD509 has 
been studied previously with the same plasmid expressing an altered form of 
HBcAg (Londono el at 1996). In these experiments, and in contrast to ours, 
bacteria were given twice, on days 1 and 56, without any prior DNA immunisation. 
This group also found that specific serum-antibody titres were observed against 
Salmonella and low responses were also detected to the HBcAg. It is therefore 
surprising that serum anti-HBcAg antibodies could not be measured following 
vaccination with S. tyßhimarium BRD509 pGA-1 alone. However, this experiment 
varied in two aspects; the first being the fact that two doses of Salmonella were used 
prior to measurement of any immunological parameter, the second being the fact 
that these experiments were originally carried out in BALB/c mice, an inbred strain 
which is particularly sensitive to Salmonella infection. In contrast, our experiments 
were carried out in C57/BI6 mice to allow direct comparison with other 
experiments outlined in this thesis. Experiments subsequently carried out in both 
these mice strains indicated that although the Salmonella were maintained in higher 
numbers in the C57/B16 mice, the anti-LPS and anti-HBcAg titres were higher in 
the BALB/c animals. Therefore the development of the immune response- is not 
solely dependent on longevity of the bacteria in vivo, but may also reflect the ability 
of the mouse strains to effectively process the bacterial antigens. In addition, these 
experiments showed that few bacteria recovered from tissues were expressing the 
HBcAg. A consequence of this result is the limitation placed on the potential of the 
Salmonella to boost any response primed by the DNA vaccination. 
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The lack of mucosal response to HBcAg following the BRD509 pGA-1 
vaccination was also disappointing, although anti-S. tyßbimurium titres were detected. 
Again, an extended time-scale or repeat vaccinations might be of benefit under 
these circumstances. 
Maximal synergy of the prime and boost vaccinations depends on the 
enhancement of APCs and lymphocytes specifically activated by the DNA vaccine 
being stimulated in the boost vaccination. This may include upregulation of 
activation signals in previously naive cells, and the restimulation of memory T and B 
cells. One way of enhancing these effects would be to physically bring these cells 
into closer proximity. The simplest way this could be achieved would be to alter the 
sites of immunisation selected. Intra-peritoneal vaccination with DNA might result 
in stimulation of cells loser to the intestinal mucosa, however, this route has been 
shown not to generate antibody and C TL responses with viral antigens (Bohm et aL 
1998). Similarly, Salmonella can be delivered by other routes of immunisation, for 
example intravenously. However, immunisation using this route completely ablates 
the potential induction of a mucosal response. 
Despite the apparently better qualities of nirB, as a promoter in attenuated 
intracellular bacteria described in the literature (see Introduction section 1.5.3.5) 
both htrA (Roberts et at 1998) and pagC (Dunstan et aL 1999) have been shown, in 
direct comparisons with nirB, to give higher antibody titres in mvo. Therefore, 
despite in vitro and even some in vivo, evidence, switching promoters to either btrA 
or pagC may have yielded improved immune responses. 
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8.4 DNA Prime, Intranasal Protein Boost Vaccination 
Previous studies have shown that parenteral protein immunisation can 
prime mucosal immune responses, despite the fact that the sites of vaccination are 
in two separate immunological compartments (McCluskie et at 2002). The 
experiments in Chapter 7 describe a similar approach in which the prime consists of 
a DNA vaccine followed by an intranasal protein boost either with or without the 
mucosal adjuvant LT. 
The humoral responses of gene gun and im. DNA primed animals to 
mucosal boosting with purified antigen were found to be remarkably similar in these 
experiments. Although final antibody titres were slightly higher in gene gun 
experiments, these differences are small and not statistically significant. The 
important difference in the humoral response is the antibody subtype pattern, which 
shows a more MI-Eke pattern (no IgGI production) in the im. immunised mice, as 
previously observed in Chapter 5. 
One of the aims of using a mucosal boost was the potential to additionally 
induce the production of antigen-specific secretory IgA that could be measured in 
nasal or pulmonary washes. However, none of the strategies using in. delivery of 
protein resulted in measurable titres. This was disappointing, but perhaps not 
surprising given the low systemic antibody response. Repeated vaccination or 
increased doses of HBcAg might give rise to production of sIgA. Interestingly 
there was no antibody response to LT in mucosal washes, despite its known efficacy 
as a mucosal adjuvant and the impact it was observed to have on CD4' responses. 
It is unclear why this occurred and may reflect the fact that most previous studies 
have looked for these responses following more than one dose of the toxin. 
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In terms of CD4; proliferation, inclusion of LT, led to very strong 
responses in the CLN, which were absent when HBcAg was given alone. In 
contrast, responses to HBcAg were observed in the spleen and inclusion of LT 
enhanced this response. This suggests that HBcAg delivered in. is not normally 
processed by APCs and T cells in the CLN without the presence of the LT. 
When mice were primed with DNA prior to the in. administration of 
HBcAg, the pattern changes. The results shown in Chapter 5 and 7 indicate that, at 
least at the time-points examined, CD4+ proliferation following gene gun 
vaccination occurs largely in the lymph nodes whilst following im. DNA 
vaccination it is mainly restricted to the spleen. A proliferative response occurs in 
the CLN following gene gun vaccination and in. boosting, which is interesting since 
the lymph nodes here are not physically close to the site of initial vaccination. This 
suggests a migration of HBcAg presenting APCs to distant (as well as local) lymph 
nodes following gene gun vaccination, or more likely, the trafficking of activated 
HBcAg-specific CD4+ T cells through different lymph nodes. A slightly lower 
response was observed in the spleen, this may reflect the enhancement of an initial 
low level response to the gene gun vaccination by the in. boost. 
This localisation had an interesting effect on the responses of mice to a 
boost containing LT. When mice primed by gene gun vaccination were boosted in. 
with HBcAg and LT, the CLN response was increased and spleen responses were 
unaffected, as might be expected from a mucosally active adjuvant. The most 
interesting effect, however, was the nature of the response generated when an im. 
DNA prime was used in conjunction with the HBcAg and LT boost. As noted 
above, im. DNA vaccination appears to induce strong splenic CD4+ T cell 
proliferation. The presence of LT in the boost had no effect on the splenic 
proliferation, but did result in a measurable response in the CLN (compared to no 
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response without LT). However, the responses in both the spleens and CLN of 
mice primed with control DNA were much higher. It appears that priming the 
mice with pcDNA3.1 /core by the im. route reduced the ability of mice to respond 
to a boost containing LT. 
One possible explanation for this is that HBcAg-specific T cells migrate to 
(or are maintained in) the spleen following im. vaccination. These activated cells, 
would not respond to chemokine signals attracting naive T cells to the site of action 
of LT, thus preventing the development of a CLN response (Sallusto et aL 2004). 
Alternatively, hyper-stimulation of previously activated T cells could result in 
apoptosis of a proportion of the HBcAg-specific population. Whatever the 
explanation, immunisation by gene gun is dearly the more appropriate method for 
priming immunity when an intranasal boost containing LT - and possibly other 
mucosal adjuvants - is considered. 
It was interesting that strong, if localised CD4+ T cell proliferation was 
accompanied by only poor antibody responses. These observations could be 
reconciled by considering the time-scale over which responses develop following 
vaccination. Following the first exposure to an antigen, an antibody response takes 
approximately 7 days to initiate, and then increases until it reaches its maximum 
level at about 21 days post immunisation, unless subsequently boosted. Therefore 
at 10 days after immunisation the response will be far from its maximum level. On 
the other hand, CD4t T cell proliferation in response to an antigen is at its 
maximum between 9 and 15 days after immunisation. Given the strength of the 
CD4' response and the timing of the experiment, it is likely that the antibody 
response would continue to increase with time. 
The poor mucosal immunogenicity of the purified protein alone may reflect 
several factors that control the responses at mucosal surfaces. Many antigens do 
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not stimulate immune responses when presented at mucosal surfaces, instead 
inducing a state of tolerance (Eriksson and Holmgren 2002). However, particulate 
antigens have been shown to be effective mucosal adjuvants, therefore repeated or 
increased doses of HBcAg may have led to stronger humoral responses. In fact, it 
has been shown that a chimeric HBcAg particle expressing a heterologous influenza 
virus peptide inserted into the cl loop was able to generate antibody-mediated 
protection against challenge with a lethal dose of influenza virus following in. 
immunisation (Neirynck et aL 1999). 
The vaccination strategy of im. pcDNA3.1/core coupled with an in. boost 
of purified HBcAg and LT as an adjuvant was successful in enhancing the humoral 
and cellular immune responses generated by the pcDNA3.1/core alone. In 
agreement with previous experiments in this thesis the specific antibody response 
indicated that the majority of CD4' T -cell help was from cells of the Thl 
phenotype. 
8.5 Mechanisms for Localisation and Biasing of Cellular 
Immune Responses 
The results shown in Chapters 5 and 7 indicate that CD4+ T cell responses 
are at least partially localised to either the spleen or local lymph nodes following, 
respectively, im. or gene gun DNA vaccination. Whilst accepting that this may 
reflect timing of the experiments undertaken and the influence of the route of both 
priming and boosting vaccinations, these observations may have practical 
implications for the selection of prime boost combinations that are able to 
synergise. For example, it is clear that gene gun and in. vaccination with HBcAg 
and LT as an adjuvant maximise the CD4+ response generated. Conversely, the 
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same boost preceded by an im. DNA vaccination led to a reduced CD4' response 
in the local lymph nodes. 
The localisation of responses observed could be could be due to timing. It 
may be, for example, that the response progresses more rapidly following i. m. DNA 
vaccination than by gene gun, and at a later point after gene gun vaccination the 
lymph node T cells would also have migrated to the spleen. This could easily be 
investigated by a series of time course experiments. 
It is also possible that the different responses observed are due to the 
dominance of different populations of T cells in the mice at the time at which 
responses were examined. It is known that native T cells migrate through lymphoid 
tissues but memory T cells are able to recirculate through non-lymphoid tissues 
such as the mucosa and skin (Dutton et aL 1998; Mackay and von Andrian 2001). 
There are two distinct subsets of these memory T cells following vaccination or 
infection; T central memory (Tan) and T effector memory cells (rem). Tcrn are 
characterised by the ability to proliferate readily in response to antigen recognition, 
whereas Tern are more rapidly stimulated to effector function (Sallusto et aL 2004). 
As well as different functional capabilities, these populations are maintained in 
distinct areas. Tem, which are more short lived, are present in the non-lymphoid 
tissues to a greater extent, whereas the Tcm, which provide longer term memory, 
are found largely in the lymphoid tissues (Reinhardt and Jenkins 2003; Sallusto et aL 
2004). It could be that Tan and Tern are dominant in different tissues at the time 
point examined, and their relative ability to proliferate on restimulation gave rise to 
the results observed. The nature of the T cells involved could be evaluated in this 
context by FACS analysis of cell surface markers peculiar to each subset. 
The above ideas may explain the situation in terms of the recent literature. 
However, perhaps a more obvious theory is that although activated T cells migrate 
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through non-lymphoid tissues (as has been previously observed; (Sallusto et aL 
1999), the lymphoid tissues to which they home are restricted to those where they 
were first activated. This would make sense for protection against disease, since the 
locus of infection is likely to be dose to where antigen is encountered, and in the 
longer term, re-infection is also likely to occur at the same location. Such localised 
T cells might be a subset of the Tan or Tern population. 
There is some evidence for this in the literature; memory T cells isolated 
from the gut were found to migrate preferentially back to the gut following 
activation and trafficked poorly through the skin (Mackay et aL 1992). However, 
little other work to date has focussed on localisation other than lymphoid/non- 
lymphoid. The migration of antigen-specific T cells could be investigated through 
the use of peptide-MHC tetrameters bound to fluorescent markers. These can bind 
to peptide-specific T cells via the TCR and thus be used to track cells (Reinhardt 
and Jenkins 2003). 
8.6 Prophylactic and Therapeutic Vaccination 
The heterologous vaccine strategies examined in this thesis show some 
promise for further development as vaccines to prevent or treat infectious disease. 
Although this body of work has concentrated on HBcAg, this as been used as a 
model antigen, and many interesting observations on the dynamics of DNA delivery 
and in particular prime-boost vaccination regimes could offer protection against a 
wide range of infectious disease or life threatening illnesses. 
In humans and animal models, chronic HBV infection requires a powerful 
and broad Thl immune response, incorporating strong cellular and humoral 
responses, in order to dear the virus. Therapeutic agents such as ribavirin and 
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recombinant IFN are believed to function by inducing Thi responses (Hultgren et 
at 1998), but they are of limited efficacy. Therapeutic vaccination provides another 
potential method of inducing the immune response required (Michel et aL 2001). At 
this stage it is difficult to assess which of the vaccination strategies examined in this 
thesis would be most suitable to take forward into the clinic in terms of potential 
success. Intramuscular DNA vaccination followed by an intramuscular protein 
boost would probably be the most appropriate without making alterations to the 
vaccination regime; this strategy gave CD4+ and CD8' T cell responses together 
with an antibody response indicative of Thl immunity and the magnitude of 
responses was enhanced following a heterologous boost. Ian. DNA vaccination 
followed by a heterologous boost, such as im. protein, may therefore act as a 
potentially effective therapeutic vaccine. However, the problems associated with 
intramuscular delivery of a vaccine candidate (even DNA), as outlined in the 
Introduction (section *), such as dangers of contamination of hypodermic needles 
and failure of uptake in the population, would still be present. 
A possible solution to some of these problems would be the use of the 
novel gene gun technologies with intradermal delivery of DNA on gold particles. It 
has been shown in the past that gene gun vaccination results in strongly polarised 
T12 responses, and as such would not be suitable for a vaccine designed to elicit 
Thl immunity. However, results in this thesis suggest that the Th2 response is not 
as strongly biased when using a particulate antigen as in previous work with non- 
particulate antigen (see Chapter 5, Discussion section 8.2). This, coupled with other 
strategies for inducing Thl cells by gene gun vaccination, such as co-delivery of 
CpG DNA (Schirmbeck and Reimann 2001; Zhou tt at 2003), could therefore also 
provide the basis for a therapeutic vaccine. There may also be potential in gene gun 
DNA vaccination followed by an intranasal boost. Although this strategy was not 
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successful at raising a mucosal response, this is not required in a therapeutic vaccine, 
since the infection is already established. Antibody responses were also low, but 
using higher doses of antigen or adjuvant may give higher responses. 
As the majority of pathogens invade over mucosal surfaces, both im. and 
gene gun delivered DNA followed by a parenteral boost with HBcAg protein will 
not be able to generate the kind of mucosal immune responses required for 
protection. The introduction of a mucosal boost within the immunisation regime 
might produce such responses. This raises an additional problem; in the mucosal 
boosted experiments undertaken in this thesis, the mucosal adjuvant LT was used. 
Although LT is a potent mucosal adjuvant, it is highly toxic in humans and 
therefore cannot be licensed as an adjuvant. However, it may be possible that 
detoxified versions of the protein will be effective and safe (Pizza et ai 2001). Other 
strategies to incorporate a mucosal delivery of a boost in a prime-boost regime may 
offer a solution to this dilemma, such as the use of the live attenuated Salmonella 
delivering antigen utilised in this study. The Salmonella boost regime helped raise 
strong systemic antibody titres, which may indicate the presence of an effective 
CD4' T helper response. Mucosal responses were poor, and modifications to the 
vaccination regime would have to be made before this strategy could be used to 
provide protection at the mucosal surfaces. However, the antibody response in this 
case again indicated the dominance of a Th 1 phenotype after boosting, and since 
DNA vaccination alone can induce C TL responses, this strategy might also be 
effective clinically as a therapeutic vaccine. 
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